Cancer Statistics, 2002

Ca-A Cancer Journal for Clinicians 52, 23-47

DOI: 10.3322/canjclin.52.1.23

Citation Report

#	Article	IF	CITATIONS
1	Activation of Notch signaling in human colon adenocarcinoma. International Journal of Oncology, 1992, 33, 1223-9.	1.4	114
2	Knowledge about breast cancer risk factors and hereditary breast cancer among early-onset breast cancer survivors. Familial Cancer, 2001, 1, 135-141.	0.9	11
3	Validation Of Virtual Colonoscopy In The Detection Of Colorectal Polyps And Masses: Rationale For Proper Study Design. International Journal of Gastrointestinal Cancer, 2001, 30, 133-140.	0.4	21
4	Monogene and Polygene Therapy for the Treatment of Experimental Prostate Cancers by Use of Apoptotic Genes bax and bad Driven by the Prostate-Specific Promoter ARR2PB. Human Gene Therapy, 2002, 13, 2051-2064.	1.4	23
5	KIAA1096, a Gene on Chromosome 1q, is Amplified and Overexpressed in Bladder Cancer. DNA and Cell Biology, 2002, 21, 707-715.	0.9	16
6	Management of the subcentimeter pulmonary nodule. Seminars in Thoracic and Cardiovascular Surgery, 2002, 14, 281-285.	0.4	17
7	Is cisplatin still the best platinum compound in non-small-cell lung cancer?. Annals of Oncology, 2002, 13, 1515-1517.	0.6	19
8	Wine Drinking and Risk of Non-Hodgkin's Lymphoma among Men in the United States: A Population-based Case-Control Study. American Journal of Epidemiology, 2002, 156, 454-462.	1.6	48
9	Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease. Oncologist, 2002, 7, 20-28.	1.9	254
10	Surgery and the Reduction of Mortality from Prostate Cancer. New England Journal of Medicine, 2002, 347, 839-840.	13.9	63
11	Organ preservation strategies in bladder cancer. Expert Review of Anticancer Therapy, 2002, 2, 641-651.	1.1	11
12	Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. British Journal of Cancer, 2002, 87, 1287-1293.		40
	With poor progressis. Stress four fail of Carreet, 2002, 07, 1207-1203.	2.9	40
13	Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 657-669.	0.9	0
13	Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer. Expert		
	Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 657-669. Challenging Pancreatic Cancer-Prone Pedigrees: A Nosologic Dilemma. American Journal of	0.9	0
14	Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 657-669. Challenging Pancreatic Cancer-Prone Pedigrees: A Nosologic Dilemma. American Journal of Gastroenterology, 2002, 97, 3062-3070. The Treatment and Outcome of Patients With Soft Tissue Sarcomas and Synchronous Metastases.	0.9	0 2
14 15	Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 657-669. Challenging Pancreatic Cancer-Prone Pedigrees: A Nosologic Dilemma. American Journal of Gastroenterology, 2002, 97, 3062-3070. The Treatment and Outcome of Patients With Soft Tissue Sarcomas and Synchronous Metastases. Sarcoma, 2002, 6, 69-73. Computer-Aided Diagnosis of Breast Cancer in Mammography: Evidence and Potential. Technology in	0.9	0 2 45

#	Article	IF	Citations
19	Therapy of localized gastric cancer: preoperative and postoperative approaches. Annals of Oncology, 2002, 13, 7-12.	0.6	4
20	Diagnostic and Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2002, 20, 4199-4208.	0.8	282
21	Colorectal Cancer Screening for Persons at Average Risk. Journal of the National Cancer Institute, 2002, 94, 1126-1133.	3.0	71
22	Blood Transfusions and Non-Hodgkin's Lymphoma. Epidemiologic Reviews, 2002, 24, 269-279.	1.3	18
23	Is There a Preferred Combination Chemotherapy Regimen for Metastastic Nonâ€Small Cell Lung Cancer?. Oncologist, 2002, 7, 226-233.	1.9	43
24	Carcinoma Extent in Prostate Needle Biopsy Tissue in the Prediction of Whole Gland Tumor Volume in a Screening Population. American Journal of Clinical Pathology, 2002, 118, 442-450.	0.4	49
25	More Watchful (Less Waiting?) For Mismatch Repair in Prostate Cancer. Cancer Biology and Therapy, 2002, 1, 367-368.	1.5	0
26	Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2002, 2002, 193-213.	0.9	86
27	Ventilator-Associated Pneumonia and Surgical Patients. Chest, 2002, 121, 1390-1391.	0.4	4
28	Pharmacological treatments for prostate cancer. Expert Opinion on Investigational Drugs, 2002, 11, 1737-1748.	1.9	9
29	CT Screening for Colorectal Cancer. Radiographics, 2002, 22, 1525-1531.	1.4	9
30	Lung Cancer: Performance of Automated Lung Nodule Detection Applied to Cancers Missed in a CT Screening Program. Radiology, 2002, 225, 685-692.	3.6	264
31	Fish oil increases mitochondrial phospholipid unsaturation, upregulating reactive oxygen species and apoptosis in rat colonocytes. Carcinogenesis, 2002, 23, 1919-1926.	1.3	129
32	Molecular Characterization of a Metastatic Neuroendocrine Cell Cancer Arising in the Prostates of Transgenic Mice. Journal of Biological Chemistry, 2002, 277, 44462-44474.	1.6	85
33	Treatment options in hormone resistant prostate cancer. Annals of Oncology, 2002, 13, 95-102.	0.6	6
34	Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 4440-4447.	0.8	98
35	Phase II Trial of Weekly Vinorelbine and Trastuzumab as Firstâ€Line Therapy in Patients with HER2 + Metastatic Breast Cancer. Oncologist, 2002, 7, 410-417.	1.9	140
36	Novel Therapies in Ovarian Cancer Management: An Update on the Role of Topotecan. Oncologist, 2002, 7, 1-2.	1.9	2

#	ARTICLE	IF	CITATIONS
37	Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. Carcinogenesis, 2002, 23, 1455-1461.	1.3	64
38	Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer. Oncologist, 2002, 7, 3-10.	1.9	66
39	Virtual Connections: Internet Health Care. Oncologist, 2002, 7, 555-568.	1.9	28
40	Inorganic Arsenite-Induced Malignant Transformation of Human Prostate Epithelial Cells. Journal of the National Cancer Institute, 2002, 94, 1888-1891.	3.0	127
41	Post-Traumatic Stress Disorder. New England Journal of Medicine, 2002, 346, 1495-1498.	13.9	47
42	Lung cancer * 2: Screening and early diagnosis of lung cancer. Thorax, 2002, 57, 1071-1078.	2.7	25
43	Vitamin C and Vitamin E Supplement Use and Bladder Cancer Mortality in a Large Cohort of US Men and Women. American Journal of Epidemiology, 2002, 156, 1002-1010.	1.6	91
44	A Doseâ€Escalation Study of Weekly Topotecan, Cisplatin, and Gemcitabine Frontâ€Line Therapy in Patients with Inoperable Nonâ€Small Cell Lung Cancer. Oncologist, 2002, 7, 509-515.	1.9	10
45	Lung cancer * 1: Prevention of lung cancer. Thorax, 2002, 57, 994-999.	2.7	28
46	Review of Vitamin E and Selenium in the Prevention of Prostate Cancer: Implications of the Selenium and Vitamin E Chemoprevention Trial. Integrative Cancer Therapies, 2002, 1, 338-344.	0.8	26
47	Baseline Dietary Fiber Intake and Colorectal Adenoma Recurrence in the Wheat Bran Fiber Randomized Trial. Journal of the National Cancer Institute, 2002, 94, 1620-1625.	3.0	19
48	Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan. Oncologist, 2002, 7, 36-45.	1.9	18
49	Potential Pitfalls in the Frozen Section Evaluation of Parenchymal Margins in Nephron-Sparing Surgery. American Journal of Clinical Pathology, 2002, 118, 903-910.	0.4	30
50	Ovarian Cancer: Screening for Early Detection. American Journal of Nursing, 2002, 102, 46-52.	0.2	1
51	Frequency of Use of Complementary and Alternative Medicine in Women With Breast Cancer. Oncology Nursing Forum, 2002, 29, 1445-1452.	0.5	116
52	New Therapeutic Options in Colon Cancer: Focus on Oxaliplatin. Clinical Journal of Oncology Nursing, 2002, 6, 131-137.	0.3	11
53	Contrast-Enhanced Transrectal Ultrasonography of a Novel Canine Prostate Cancer Model. Journal of Ultrasound in Medicine, 2002, 21, 1003-1013.	0.8	13
54	Breast Cancer in Men. Annals of Internal Medicine, 2002, 137, 678.	2.0	379

#	Article	IF	Citations
55	Intervention to Improve Psychological Functioning for Newly Diagnosed Patients With Cancer. Oncology Nursing Forum, 2002, 29, 967-975.	0.5	100
56	Long-Term Survival of Patients With Advanced/Recurrent Carcinoma of Cervix and Vagina After Neoadjuvant Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without the Addition of Molgramostim, and Review of the Literature. American Journal of Clinical Oncology: Cancer Clinical Trials. 2002. 25. 547-551.	0.6	14
57	Reproductive Health Over the Life Phases: An Overview. Clinical Obstetrics and Gynecology, 2002, 45, 1181-1188.	0.6	1
58	Fine-needle aspiration of thyroid gland. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 407-411.	0.6	1
59	The Local Therapy for Breast Cancer as a Model for Evidence-Based Medical Care. Cancer Journal (Sudbury, Mass), 2002, 8, 288-294.	1.0	2
60	Radioiodinated (I-125) Monoclonal Antibody 425 in the Treatment of High Grade Glioma Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 541-546.	0.6	60
61	Foreword. Clinical Obstetrics and Gynecology, 2002, 45, 735-737.	0.6	0
62	Oxidative Stress, DNA Damage, and Breast Cancer. AACN Advanced Critical Care, 2002, 13, 540-549.	1.9	157
63	The Conundrum of Prostate Cancer. Cancer Journal (Sudbury, Mass), 2002, 8, 432-434.	1.0	0
65	Anaplastic Thyroid Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 442-446.	0.6	43
66	Renal Tumors in the Birt-Hogg-Dubé Syndrome. American Journal of Surgical Pathology, 2002, 26, 1542-1552.	2.1	544
67	Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes. Annals of Surgery, 2002, 236, 438-449.	2.1	137
68	Retroperitoneal sarcomas: combined modality treatment approaches. Current Opinion in Oncology, 2002, 14, 400-405.	1.1	67
69	Cancer of the Kidney. Clinical Obstetrics and Gynecology, 2002, 45, 884-891.	0.6	7
70	Liver and Hepatic Duct Cancer. Clinical Obstetrics and Gynecology, 2002, 45, 939-951.	0.6	0
71	Microsatellite instability and prostate cancer: clinical and pathological implications. Current Opinion in Urology, 2002, 12, 407-411.	0.9	11
72	PET and SPECT in the management of lung cancer. Current Opinion in Pulmonary Medicine, 2002, 8, 257-264.	1.2	10
73	P504S Immunohistochemical Detection in 405 Prostatic Specimens Including 376 18-Gauge Needle Biopsies. American Journal of Surgical Pathology, 2002, 26, 1588-1596.	2.1	170

#	ARTICLE	IF	CITATIONS
74	No effect of a high-fat diet on promotion of sex hormone-induced prostate and mammary carcinogenesis in the Noble rat model. British Journal of Nutrition, 2002, 88, 399-409.	1.2	12
75	New drugs for patients with pancreatic cancer. Current Opinion in Oncology, 2002, 14, 621-627.	1.1	12
76	Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2002, 137, 59.	2.0	94
77	Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2002, 137, 917.	2.0	298
78	Lung Cancer Screening. Chest, 2002, 121, 1388-1390.	0.4	13
79	Can Lifestyle Modification Increase Survival in Women Diagnosed with Breast Cancer?. Journal of Nutrition, 2002, 132, 3504S-3509S.	1.3	85
80	Lung Cancer Screening. Chest, 2002, 122, 1-2.	0.4	23
81	Systematic Postoperative Radiologic Follow-up in Patients With Non–Small Cell Lung Cancer for Detecting Second Primary Lung Cancer in Stage IA. Archives of Surgery, 2002, 137, 935.	2.3	53
82	Well-Being in Hispanic and Non-Hispanic White Survivors of Breast Cancer. Oncology Nursing Forum, 2002, 29, 820-826.	0.5	16
83	Impact of Age and Colony-Stimulating Factor Use on Hospital Length of Stay for Febrile Neutropenia in CHOP-Treated Non-Hodgkin's Lymphoma. Cancer Control, 2002, 9, 203-211.	0.7	78
84	Targeted Molecular Therapy for Oral Cancer With Epidermal Growth Factor Receptor Blockade. JAMA Otolaryngology, 2002, 128, 875.	1.5	21
85	Population-Based Cancer Screening. Oncology Nursing Forum, 2002, 29, 853-861.	0.5	6
86	Couples' Experiences With Prostate Cancer: Focus Group Research. Oncology Nursing Forum, 2002, 29, 701-709.	0.5	132
87	Chemotherapy-Induced Amenorrhea and Fertility in Women Undergoing Adjuvant Treatment for Breast Cancer. Cancer Control, 2002, 9, 466-472.	0.7	141
88	Efficacy of Zoledronic Acid and Pamidronate in Breast Cancer Patients: A Comparative Analysis of Randomized Phase III Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, S25-S31.	0.6	28
89	Update on pancreatic cancer. Current Opinion in Oncology, 2002, 14, 424-430.	1.1	30
90	Hereditary Cancer Syndromes of the Gastrointestinal System. AACN Advanced Critical Care, 2002, 13, 523-539.	1.9	3
91	Effect of Concurrent Radiation Therapy and Chemotherapy on Pulmonary Function in Patients with Esophageal Cancer. Cancer Journal (Sudbury, Mass), 2002, 8, 451-460.	1.0	28

#	Article	IF	CITATIONS
92	What is postmastectomy pain syndrome?. Nursing, 2002, 32, 17.	0.2	0
93	Screening for Lung Cancer With CT. Chest, 2002, 121, 1507-1514.	0.4	78
94	CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient Survival. American Journal of Pathology, 2002, 161, 1215-1221.	1.9	239
95	Office-based ultrasound-guided cryoablation of breast fibroadenomas. American Journal of Surgery, 2002, 184, 394-400.	0.9	126
96	AN IN VITRO STUDY OF INHIBITORY ACTIVITY OF GOSSYPOL, A COTTONSEED EXTRACT, IN HUMAN CARCINOMA CELL LINES. Pharmacological Research, 2002, 46, 551-555.	3.1	41
97	Male Breast Cancer: A Review of the Literature and a Case Report. Psychosomatics, 2002, 43, 326-330.	2.5	14
98	Immunohistochemical Staining for c-Kit (CD117) Is a Rare Event in Human Colorectal Carcinoma. Clinical Colorectal Cancer, 2002, 2, 119-122.	1.0	32
99	Perspectives on the Role of Sequential or Combination Chemotherapy for First-Line and Salvage Therapy in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2002, 2, 161-169.	1.0	6
100	Novel Clinical Trials in Androgen-Independent Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 51-57.	2.1	13
101	National Cancer Institute Intramural Approach to Advanced Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 153-162.	2.1	8
102	G Protein–Coupled Receptors Provide Survival Signals in Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 177-181.	2.1	16
103	The Design of a Randomized, Placebo-Controlled Trial of Celecoxib in Preprostatectomy Men with Clinically Localized Adenocarcinoma of the Prostate. Clinical Prostate Cancer, 2002, 1, 182-187.	2.1	5
104	Unfavorable Therapeutic Index of Cisplatin/Gemcitabine/Vinorelbine in Advanced non—small-Cell Lung Cancer. Clinical Lung Cancer, 2002, 4, 47-51.	1.1	6
105	Overview of Rational and Individualized Therapeutic Strategies for Non-Hodgkin's Lymphomas. Clinical Lymphoma and Myeloma, 2002, 3, S5-S11.	2.1	8
106	The Management of Localized or Locally Advanced Prostate Cancer. American Journal of Cancer, 2002, 1, 387-396.	0.4	1
107	The choice of allogeneic or autologous hematopoietic transplantation for NHL. Cytotherapy, 2002, 4, 259-269.	0.3	2
108	Colorectal cancer screening: an overview of current trends. Nursing Clinics of North America, 2002, 37, 225-245.	0.7	7
109	Anal neoplasms. Surgical Clinics of North America, 2002, 82, 1233-1251.	0.5	53

#	ARTICLE	IF	CITATIONS
110	Pharmacotherapy for male breast cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 701-708.	0.9	12
111	Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. Urology, 2002, 60, 34-39.	0.5	72
112	Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. Urology, 2002, 60, 18-23.	0.5	12
113	Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?. Urology, 2002, 60, 36-41.	0.5	11
114	PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study. Urology, 2002, 60, 464-468.	0.5	29
115	Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology, 2002, 60, 458-463.	0.5	110
116	An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology, 2002, 60, 1050-1054.	0.5	32
117	Cigarette smoking and risk of breast cancer in women. Lancet, The, 2002, 360, 1033-1034.	6.3	19
118	Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies. Annals of Thoracic Surgery, 2002, 74, 160-163.	0.7	21
119	Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochemical and Biophysical Research Communications, 2002, 298, 603-612.	1.0	134
120	EUS in rectal cancer. Gastrointestinal Endoscopy, 2002, 56, S12-S18.	0.5	45
121	EUS in lung cancer. Gastrointestinal Endoscopy, 2002, 56, S18-S21.	0.5	14
122	An Evaluation of the Man to Man Self-Help Group in Colorado and Utah. Cancer Practice, 2002, 10, 234-239.	0.8	15
124	New approaches in the treatment of non-small cell lung cancer. Lung Cancer, 2002, 38, 1-3.	0.9	10
125	Molecular biology and early diagnosis in lung cancer. Lung Cancer, 2002, 38, S5-S8.	0.9	15
126	Targeted therapy in non-small cell lung cancer. Lung Cancer, 2002, 38, 29-32.	0.9	20
127	Cancer of the cervix. Seminars in Oncology Nursing, 2002, 18, 193-199.	0.7	2
128	Legal and ethical issues confronting oncology nursing. Seminars in Oncology Nursing, 2002, 18, 86-98.	0.7	4

#	Article	IF	Citations
129	Ovarian cancer screening and prevention. Seminars in Oncology Nursing, 2002, 18, 167-173.	0.7	2
130	Ovarian cancer. Seminars in Oncology Nursing, 2002, 18, 174-183.	0.7	12
131	Preinvasive diseases of the cervix, vulva, and vagina. Seminars in Oncology Nursing, 2002, 18, 184-192.	0.7	2
132	Endometrial cancer. Seminars in Oncology Nursing, 2002, 18, 200-206.	0.7	1
133	Less common gynecologic malignancies. Seminars in Oncology Nursing, 2002, 18, 207-222.	0.7	1
134	Symptoms affecting quality of life in women with gynecologic cancer. Seminars in Oncology Nursing, 2002, 18, 223-230.	0.7	39
135	Control of cancer: The promise of the future. Seminars in Oncology Nursing, 2002, 18, 305-310.	0.7	0
136	The Environmental Protection Agency's National SunWise School Program: Sun protection education in US schools (1999-2000). Journal of the American Academy of Dermatology, 2002, 46, 683-689.	0.6	52
137	Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncology, The, 2002, 3, 461-469.	5.1	428
138	The price of anticancer intervention. Lancet Oncology, The, 2002, 3, 575-579.	5.1	4
139	MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nuclear Medicine and Biology, 2002, 29, 783-790.	0.3	54
140	Benzyl isothiocyanate: an effective inhibitor of polycyclic aromatic hydrocarbon tumorigenesis in A/J mouse lung. Cancer Letters, 2002, 187, 87-94.	3.2	79
141	Phase II Trial of Radio Frequency Ablation of Renal Cancer: Evaluation of the Kill Zone. Journal of Urology, 2002, 168, 2401-2405.	0.2	111
142	The molecular biology of laryngeal cancer. Otolaryngologic Clinics of North America, 2002, 35, 993-1012.	0.5	27
143	Current Therapy for Multiple Myeloma. Mayo Clinic Proceedings, 2002, 77, 813-822.	1.4	97
144	Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clinics of North America, 2002, 12, 525-536.	0.5	53
145	A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. Surgery, 2002, 132, 589-604.	1.0	41
146	Selective targeting of the nuclear factor-κB pathway enhances tumor necrosis factor–related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery, 2002, 132, 127-134.	1.0	67

#	Article	IF	CITATIONS
147	The effect of sunscreen on melanoma risk. Dermatologic Clinics, 2002, 20, 601-606.	1.0	56
148	Management of locally advanced adenocarcinoma of the pancreas. Hematology/Oncology Clinics of North America, 2002, 16, 95-103.	0.9	10
149	Staging and surgical management of pancreatic and biliary cancer and inflammation. Radiologic Clinics of North America, 2002, 40, 1397-1410.	0.9	6
150	Local therapy for rectal cancer. Surgical Clinics of North America, 2002, 82, 967-981.	0.5	21
151	Screening for Prostate Cancer in High Risk Populations. Journal of Urology, 2002, 168, 1980-1984.	0.2	79
152	Surgical approaches to malignant melanoma. Dermatologic Clinics, 2002, 20, 681-699.	1.0	27
153	A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate Cancer. Mayo Clinic Proceedings, 2002, 77, 219-225.	1.4	131
154	New developments in the treatment of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America, 2002, 29, 659-672.	0.7	18
155	Cancer screening. Primary Care - Clinics in Office Practice, 2002, 29, 697-725.	0.7	1
156	What do we expect from imaging?. Radiologic Clinics of North America, 2002, 40, 521-526.	0.9	8
157	Intraoperative MR Imaging. Academic Radiology, 2002, 9, 875-877.	1.3	1
158	Anaplastic Thyroid Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 442-446.	0.6	50
159	Women's Receptivity to Church-Based Mobile Mammography. Journal of Health Care for the Poor and Underserved, 2002, 13, 199-213.	0.4	27
160	Energy Imbalance and Prostate Cancer. Journal of Nutrition, 2002, 132, 3471S-3481S.	1.3	55
161	The use of Bisphosphonates in Patients with Breast Cancer. Cancer Control, 2002, 9, 480-489.	0.7	39
162	Radiotherapy and Organ Preservation in Bladder Cancer: Are We Ignoring the Evidence?. Journal of Clinical Oncology, 2002, 20, 3048-3050.	0.8	25
163	Screening for Lung Cancer: No Longer a Taboo Subject. Journal of Clinical Oncology, 2002, 20, 1959-1961.	0.8	4
164	Radiation Dose Escalation in Combined-Modality Therapy for Esophageal Cancer. Journal of Clinical Oncology, 2002, 20, 1151-1153.	0.8	20

#	Article	IF	CITATIONS
165	Compliance Rates and Predictors of Cancer Screening Recommendations Among Appalachian Women. Journal of Health Care for the Poor and Underserved, 2002, 13, 443-460.	0.4	36
166	Clinical Q&A. Clinical Journal of Oncology Nursing, 2002, 6, 232-234.	0.3	0
167	Multiple Myeloma and Its Treatment. Clinical Journal of Oncology Nursing, 2002, 6, 359-362.	0.3	2
168	Skin Cancer Screening. Physical Therapy, 2002, 82, 1232-1237.	1.1	8
169	Cutaneous Metastatic Breast Cancer. Clinical Journal of Oncology Nursing, 2002, 6, 255-260.	0.3	31
170	Clinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer. Cancer Control, 2002, 9, 457-465.	0.7	38
171	A Human Novel Gene DERPC Located on 16q22.1 Inhibits Prostate Tumor Cell Growth and Its Expression Is Decreased in Prostate and Renal Tumors. Molecular Medicine, 2002, 8, 655-663.	1.9	14
172	Prostate cancer gene therapy: Past experiences and future promise. , 2002, , 357-365.		0
173	Thalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma. Pharmacotherapy, 2002, 22, 1019-1028.	1.2	5
174	Navigating the Health Service Network: Helping Cancer Survivors Find What They Need. Ca-A Cancer Journal for Clinicians, 2002, 52, 190-194.	157.7	1
175	Novel Doublets in Extensive-Stage Small-Cell Lung Cancer: A Randomized Phase II Study of Topotecan Plus Cisplatin or Paclitaxel (CALGB 9430). Clinical Lung Cancer, 2002, 3, 205-210.	1.1	26
176	The Future of Cyclooxygenase-2 Inhibitors and Other Inhibitors of the Eicosanoid Signal Pathway in the Prevention and Therapy of Lung Cancer. Clinical Lung Cancer, 2002, 3, 271-277.	1.1	16
177	Radiotherapy Versus Chemotherapy plus Radiotherapy in Surgically Treated IIIA N2 nonâ€"small-Cell Lung Cancer, 2002, 4, 95-103.	1.1	14
178	Adjuvant Therapy in the Treatment of non–small-Cell Lung Cancer. Clinical Lung Cancer, 2002, 4, 161-167.	1.1	1
179	Pemetrexed (Alimta®): A New Antifolate for nonâ€"small-Cell Lung Cancer. Clinical Lung Cancer, 2002, 3, S22-S25.	1.1	6
180	Therapy of Advanced Non–Small-Cell Lung Cancer with Irinotecan and Gemcitabine in Combination. Clinical Lung Cancer, 2002, 4, S26-S29.	1.1	2
181	Irinotecan in Small-Cell Lung Cancer: Current Data and the Status of Ongoing Trials. Clinical Lung Cancer, 2002, 4, S30-S34.	1.1	2
182	Antibody-based vaccines for the treatment of melanoma. Seminars in Oncology, 2002, 29, 462-470.	0.8	16

#	Article	IF	Citations
183	Potential for use of amifostine in cervical cancer. Seminars in Oncology, 2002, 29, 34-37.	0.8	3
184	Increased fruit, vegetable and fiber intake and lower fat intake reported among women previously treated for invasive breast cancer. Journal of the American Dietetic Association, 2002, 102, 801-808.	1.3	107
185	Family Perspectives of Ovarian Cancer. Cancer Practice, 2002, 10, 269-276.	0.8	59
186	The parable of the proteome: cancer biomarkers. Trends in Cell Biology, 2002, 12, 358.	3.6	2
187	What's new in general surgery: endocrine surgery1 1No competing interests declared Journal of the American College of Surgeons, 2002, 195, 364-371.	0.2	14
188	Induction of Antibodies against Prostate-Specific Membrane Antigen (PSMA) by Vaccination with a PSMA DNA Vector. European Urology, 2002, 42, 67-73.	0.9	6
189	Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surgical Oncology, 2002, 11, 123-135.	0.8	52
190	Neoadjuvant and adjuvant therapy of non-small cell lung cancer. Surgical Oncology, 2002, 11, 243-253.	0.8	22
191	Current concepts in the staging of non-small cell lung cancer. Surgical Oncology, 2002, 11, 181-190.	0.8	29
192	Novel therapies for lung cancer. Surgical Oncology, 2002, 11, 229-241.	0.8	15
193	Genetic alterations associated with adult diffuse astrocytic tumors. American Journal of Medical Genetics Part A, 2002, 115, 194-201.	2.4	25
194	Cytogenetics and molecular genetics of cancer of the prostate. American Journal of Medical Genetics Part A, 2002, 115, 150-156.	2.4	29
195	Solitary metastasis from renal cell carcinoma presenting as diffuse pancreatic enlargement. Journal of Clinical Ultrasound, 2002, 30, 499-502.	0.4	19
196	Prospective analysis of quality of life after surgical resection for esophageal cancer: Preliminary results. Journal of Surgical Oncology, 2002, 81, 185-194.	0.8	71
197	Evidence for a major gene influencing risk of pancreatic cancer. Genetic Epidemiology, 2002, 23, 133-149.	0.6	123
198	A geographic analysis of prostate cancer mortality in the United States, 1970-89. International Journal of Cancer, 2002, 101, 168-174.	2.3	83
199	Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. International Journal of Cancer, 2002, 102, 244-249.	2.3	13
200	Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Cancer, 2002, 94, 2224-2231.	2.0	7

#	ARTICLE	IF	CITATIONS
201	HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer, 2002, 94, 2584-2589.	2.0	56
202	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer, 2002, 95, 340-353.	2.0	34
203	Carcinoma detection at the breast examination center of Harlem. Cancer, 2002, 95, 8-14.	2.0	18
204	Impact of undergoing prostate carcinoma screening on prostate carcinoma-related knowledge and distress. Cancer, 2002, 95, 1037-1044.	2.0	44
205	Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896). Cancer, 2002, 95, 1022-1027.	2.0	89
206	Racial differences in treatment and survival from early-stage breast carcinoma. Cancer, 2002, 95, 1759-1766.	2.0	114
207	Evaluation of HER-2/neu expression in prostatic adenocarcinoma. Cancer, 2002, 95, 1650-1655.	2.0	49
208	Strategies for improving melanoma education and screening for men age ? 50 years. Cancer, 2002, 95, 1554-1561.	2.0	86
209	Promoting early detection tests for colorectal carcinoma and adenomatous polyps. Cancer, 2002, 95, 1618-1628.	2.0	78
210	An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer, 2002, 95, 2006-2016.	2.0	252
211	Potential marker of oral squamous cell carcinoma aggressiveness detected by fluorescence in situ hybridization in fine-needle aspiration biopsies. Cancer, 2002, 95, 2152-2159.	2.0	28
212	Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Cancer, 2002, 95, 2380-2389.	2.0	91
213	Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer. Journal of Cellular Biochemistry, 2002, 86, 203-212.	1.2	9
214	Nuclear matrix proteins as biomarkers in prostate cancer. Journal of Cellular Biochemistry, 2002, 86, 213-223.	1.2	30
215	National estimates of mortality rates for radical pancreaticoduodenectomy in 25,000 patients. Annals of Surgical Oncology, 2002, 9, 847-854.	0.7	111
216	Locally advanced esophageal cancer. Current Treatment Options in Oncology, 2002, 3, 475-485.	1.3	35
217	Chemoprevention of lung cancer. Current Oncology Reports, 2002, 4, 341-346.	1.8	6
218	New developments in the treatment of esophageal cancer. Current Oncology Reports, 2002, 4, 213-221.	1.8	15

#	Article	IF	CITATIONS
219	New approaches to lung cancer prevention. Current Oncology Reports, 2002, 4, 487-494.	1.8	15
220	Permanent seed implantation for localized adenocarcinoma of the prostate. Current Urology Reports, 2002, 3, 201-206.	1.0	22
221	Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. International Journal of Clinical Oncology, 2002, 7, 219-224.	1.0	6
222	A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2459-2461.	1.0	34
223	Genetic testing for lung cancer risk. Journal of General Internal Medicine, 2002, 17, 946-951.	1.3	14
224	Screening for Lung Cancer Using Low-Radiation Dose Computed Tomography. Imaging Decisions (Berlin, Germany), 2002, 6, 4-13.	0.2	1
225	Prostate-specific antigen testing accuracy in community practice. BMC Family Practice, 2002, 3, 19.	2.9	57
226	Inguinal hernia is not a sign of colon cancer: results of a prospective screening trial. Alimentary Pharmacology and Therapeutics, 2002, 16, 1197-1201.	1.9	9
227	Interstitial brachytherapy for salvage treatment of vaginal recurrences in previously unirradiated endometrial cancer patients. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1153-1159.	0.4	59
228	Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin e1 analog misoprostol (RTOG) Tj ETQq1 1 C).7 84 814 i	gBII5/Overloc
229	Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate, 2002, 53, 109-117.	1.2	220
230	Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions. Oncogene, 2002, 21, 6949-6959.	2.6	61
231	Vasectomy and the risk of prostate cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy. Prostate Cancer and Prostatic Diseases, 2002, 5, 193-203.	2.0	52
232	Lack of Expression of the Epstein-Barr Virus (EBV) Gene Products, EBERs, EBNA1, LMP1, and LMP2A, in Breast Cancer Cells. Laboratory Investigation, 2002, 82, 1193-1199.	1.7	68
233	Chemoprevention: an essential approach to controlling cancer. Nature Reviews Cancer, 2002, 2, 537-543.	12.8	340
234	Selective anticancer drugs. Nature Reviews Cancer, 2002, 2, 645-646.	12.8	32
235	Selective anticancer drugs. Nature Reviews Drug Discovery, 2002, 1, 491-492.	21.5	81
236	Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. British Journal of Cancer, 2002, 87, 1013-1018.	2.9	85

#	ARTICLE	IF	CITATIONS
237	Prospective Evaluation of Positron Emission Tomography for the Detection of Groin Node Metastases from Vulvar Cancer. Gynecologic Oncology, 2002, 85, 179-184.	0.6	162
238	Assessment of Prognostic Factors in Stage IIIA Endometrial Cancer. Gynecologic Oncology, 2002, 86, 38-44.	0.6	119
239	Should the Presence of Lymphvascular Space Involvement Be Used to Assign Patients to Adjuvant Therapy Following Hysterectomy for Unstaged Endometrial Cancer?. Gynecologic Oncology, 2002, 87, 243-246.	0.6	113
240	Surgical Stage I Endometrial Cancer: Predictors of Distant Failure and Death. Gynecologic Oncology, 2002, 87, 274-280.	0.6	118
241	Prostate cancer gene therapy: past experiences and future promise. Cancer and Metastasis Reviews, 2002, 21, 137-145.	2.7	6
242	Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. Cancer and Metastasis Reviews, 2002, 21, 167-183.	2.7	42
243	Sexual Functioning After Treatment for Early Stage Prostate Cancer. Sexuality and Disability, 2002, 20, 239-260.	0.4	6
244	Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. Journal of Mammary Gland Biology and Neoplasia, 2002, 7, 407-413.	1.0	37
245	Treatment of Conjunctival Lymphomas by Beta-Ray Brachytherapy Using a Strontium-90–Yttrium-90 Applicator. Clinical Oncology, 2002, 14, 459-463.	0.6	19
246	Literature review and commentary. International Urology and Nephrology, 2003, 35, 581-593.	0.6	0
247	Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal Cancer. International Journal of Gastrointestinal Cancer, 2003, 32, 125-128.	0.4	56
248	Drug Development in Pancreatic Cancer: Finally, Biology Begets Therapy. International Journal of Gastrointestinal Cancer, 2003, 32, 91-106.	0.4	0
249	Chemoprevention for Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2003, 33, 27-42.	0.4	11
250	Transgenic Models of Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2003, 33, 71-78.	0.4	9
251	Novel Gene Therapy Approaches to Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2003, 33, 89-98.	0.4	4
252	Adjuvant Therapy of Colon Cancer in Idiopathic Leukopenia. Medical Oncology, 2003, 20, 185-188.	1.2	0
253	Primary Non-Hodgkin's Lymphoma of the Transverse Colon Presenting as Dermatomyositis: Case Presentation and Literature Review. Medical Oncology, 2003, 20, 413-424.	1.2	6
254	Treatment-Related Sexual Dysfunction in Male Nonprostate Pelvic Malignancies. Sexuality and Disability, 2003, 21, 3-20.	0.4	3

#	ARTICLE	IF	CITATIONS
256	Nutrition and Lifestyle Factors on the Risk of Developing Breast Cancer. Breast Cancer Research and Treatment, 2003, 79, 265-276.	1.1	60
257	A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes and Control, 2003, 14, 327-334.	0.8	141
258	Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers. Clinical and Experimental Metastasis, 2003, 20, 343-356.	1.7	27
259	The Role of Taxanes in the Adjuvant Treatment of Early Stage Breast Cancer. Breast Cancer Research and Treatment, 2003, 79, 25-34.	1.1	47
260	Lung cancer trends in young adults: an early indicator of progress in tobacco control (United) Tj ETQq0 0 0 rgB1	Oyerlock	₹ 19Jf 50 582
261	Disparities related to socioeconomic status and access to medical care remain in the United States among women who never had a mammogram. Cancer Causes and Control, 2003, 14, 419-425.	0.8	43
262	Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Investigational New Drugs, 2003, 21, 367-372.	1.2	52
263	Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Digestive Diseases and Sciences, 2003, 48, 1972-1978.	1.1	70
264	Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes and Control, 2003, 14, 721-726.	0.8	60
265	Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-tumor Immunity to the  Self' tumor-associated antigen, neu in a Rat Mammary Tumor Model. Breast Cancer Research and Treatment, 2003, 82, 169-183.	1.1	34
266	Gene Therapy of Pancreatic Cancer With Green Fluorescent Protein and Tumor Necrosis Factor?Related Apoptosis-Inducing Ligand Fusion Gene Expression Driven by a Human Telomerase Reverse Transcriptase Promoter. Annals of Surgical Oncology, 2003, 10, 762-772.	0.7	40
267	Neoadjuvant Treatment for Resectable Cancer of the Esophagus and the Gastroesophageal Junction: A Meta-Analysis of Randomized Clinical Trials. Annals of Surgical Oncology, 2003, 10, 754-761.	0.7	228
268	General Keynote: The Impact of Cancer Chemoprevention. Gynecologic Oncology, 2003, 88, S56-S58.	0.6	21
269	Characterization of C4-2 Prostate Cancer Bone Metastases and Their Response to Castration. Journal of Bone and Mineral Research, 2003, 18, 1882-1888.	3.1	40
270	Sex Hormone-Induced Mammary Carcinogenesis in Female Noble Rats: Detection of Differentially Expressed Genes. Breast Cancer Research and Treatment, 2003, 77, 49-63.	1.1	10
271	The Expression of Growth Hormone-Releasing Hormone (GHRH) and its Receptor Splice Variants in Human Breast Cancer Lines; The Evaluation of Signaling Mechanisms in the Stimulation of Cell Proliferation. Breast Cancer Research and Treatment, 2003, 77, 15-26.	1.1	57
272	Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. Digestive Diseases and Sciences, 2003, 48, 230-237.	1.1	52
273	Racial differences in lung cancer. Cancer and Metastasis Reviews, 2003, 22, 39-46.	2.7	79

#	Article	IF	CITATIONS
274	Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. Cancer and Metastasis Reviews, 2003, 22, 25-38.	2.7	122
275	Colorectal carcinoma in black and white race. Cancer and Metastasis Reviews, 2003, 22, 67-82.	2.7	54
276	Intraoperative radiotherapy in the multimodality approach to colorectal cancer. Surgical Oncology Clinics of North America, 2003, 12, 993-1013.	0.6	29
277	Coenzyme Q differentially modulates phospholipid hydroperoxide glutathione peroxidase gene expression and free radicals production in malignant and nonâ€malignant prostate cells. BioFactors, 2003, 18, 265-270.	2.6	15
278	Traitement photodynamique des cholangiocarcinomes. Acta Endoscopica, 2003, 33, 539-546.	0.0	1
279	How aggressive should we be in patients with stage iv colorectal cancer?. Diseases of the Colon and Rectum, 2003, 46, 1646-1652.	0.7	54
280	Organ preservation strategies in the treatment of laryngeal cancer. Current Treatment Options in Oncology, 2003, 4, 15-25.	1.3	5
281	Management of patients with non-small cell lung cancer and poor performance status. Current Treatment Options in Oncology, 2003, 4, 55-59.	1.3	9
282	Surgical management of esophageal malignancy. Current Gastroenterology Reports, 2003, 5, 192-197.	1.1	1
283	Small bowel tumors. Current Gastroenterology Reports, 2003, 5, 386-393.	1.1	14
284	The enormous burden of digestive diseases on our healthcare system. Current Gastroenterology Reports, 2003, 5, 93-94.	1.1	4
285	Simian virus 40 and its association with human lymphomas. Current Oncology Reports, 2003, 5, 372-379.	1.8	9
286	Molecular targets in therapy for human soft-tissue and bone sarcomas. Current Oncology Reports, 2003, 5, 295-303.	1.8	5
287	Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer. Current Oncology Reports, 2003, 5, 313-317.	1.8	6
288	Targeted therapy for lung cancer. Current Oncology Reports, 2003, 5, 326-333.	1.8	4
289	Chemoprevention of head and neck cancer. Current Oncology Reports, 2003, 5, 152-157.	1.8	6
290	New developments in therapy for colorectal cancer. Current Oncology Reports, 2003, 5, 183-191.	1.8	5
291	The evolving role of partial nephrectomy in the management of renal cell carcinoma. Current Oncology Reports, 2003, 5, 239-244.	1.8	27

#	Article	IF	CITATIONS
292	Should there be a size limit for elective nephron-sparing surgery?. Current Urology Reports, 2003, 4, 21-29.	1.0	0
293	An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis. Cancer Chemotherapy and Pharmacology, 2003, 52, 59-66.	1.1	15
294	Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemotherapy and Pharmacology, 2003, 52, 235-246.	1.1	23
295	The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemotherapy and Pharmacology, 2003, 52, 175-184.	1.1	14
298	PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, S82-S88.	3.3	102
299	High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction. World Journal of Urology, 2003, 21, 15-20.	1.2	21
300	Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. Journal of Cancer Research and Clinical Oncology, 2003, 129, 662-668.	1.2	20
301	Melanoma Metastatic to the Colon. Diseases of the Colon and Rectum, 2003, 46, 441-447.	0.7	46
302	Use of a supportive care team for screening and preemptive intervention among multiple myeloma patients receiving stem cell transplantation. Supportive Care in Cancer, 2003, 11, 568-574.	1.0	25
303	Quality of life aspects in kidney cancer patients: data from a national registry. Supportive Care in Cancer, 2003, 11, 700-706.	1.0	32
304	Isolated lung perfusion for the treatment of pulmonary metastases current mini-review of work in progress. Surgical Oncology, 2003, 12, 187-193.	0.8	19
305	Adjuvant therapy for older women with breast cancer. Breast, 2003, 12, 550-557.	0.9	12
306	Brachytherapy for recurrent prostate cancer after radiation therapy. Seminars in Radiation Oncology, 2003, 13, 158-165.	1.0	33
307	Impact of a cancer screening program on breast cancer stage at diagnosis in a medically underserved urban community. Journal of the American College of Surgeons, 2003, 196, 180-188.	0.2	125
308	Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. Journal of the American College of Surgeons, 2003, 197, 565-574.	0.2	107
309	Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell, 2003, 3, 565-576.	7.7	627
310	Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the radiation therapy oncology group C-0116 trial. Seminars in Oncology, 2003, 30, 68-71.	0.8	9
311	Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncology, 2003, 39, 610-618.	0.8	90

#	Article	IF	CITATIONS
312	The effectiveness of community-based visual screening and utility of adjunctive diagnostic aids in the early detection of oral cancer. Oral Oncology, 2003, 39, 708-723.	0.8	66
313	Symptom Concerns of Women with Ovarian Cancer. Journal of Pain and Symptom Management, 2003, 25, 528-538.	0.6	62
314	Dietary fish oil reduces oxidative DNA damage in rat colonocytes. Free Radical Biology and Medicine, 2003, 35, 149-159.	1.3	48
315	Insignificant Prostate Cancer in Radical Prostatectomy Specimen: Time Trends and Preoperative Prediction. European Urology, 2003, 43, 455-460.	0.9	76
316	Neuroendocrine Serum Tumour Markers in Hormone-Resistant Prostate Cancer. European Urology, 2003, 44, 215-221.	0.9	49
317	Early Prostate Cancer: Prevention, Treatment Modalities, and Quality of Life Issues. European Urology, 2003, 44, 283-293.	0.9	28
318	Distal gastrectomy. Operative Techniques in General Surgery, 2003, 5, 3-13.	0.0	1
319	Total gastrectomy with reconstruction options. Operative Techniques in General Surgery, 2003, 5, 23-35.	0.0	2
320	Lung cancer: The oncologist's role in smoking cessation. Seminars in Oncology, 2003, 30, 94-103.	0.8	25
321	Chemotherapy for small cell lung cancer. Seminars in Oncology, 2003, 30, 9-25.	0.8	94
322	The role of carotenoids on the risk of lung cancer. Seminars in Oncology, 2003, 30, 86-93.	0.8	22
323	Comparison of cell collection and direct visualization cervical cancer screening adjuncts. American Journal of Obstetrics and Gynecology, 2003, 188, S13-S20.	0.7	10
324	Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. American Journal of Obstetrics and Gynecology, 2003, 189, 113-117.	0.7	28
325	Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. American Journal of Obstetrics and Gynecology, 2003, 189, S17-S23.	0.7	47
326	Hepatic radiofrequency ablation with internally cooled probes: effect of coolant temperature on lesion size. IEEE Transactions on Biomedical Engineering, 2003, 50, 493-500.	2.5	136
327	Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2003, 4, S50-S55.	1.1	2
328	Selective Cyclooxygenase-2 Inhibition: A Target in Cancer Prevention and Treatment. Pharmacotherapy, 2003, 23, 9-28.	1.2	45
329	Targeted molecular therapy for cancer: The application of STI571 to gastrointestinal stromal tumor. Current Problems in Surgery, 2003, 40, 131-193.	0.6	4

#	Article	IF	Citations
330	Resection of recurrent ovarian or fallopian tube carcinoma involving the liverâ [*] †. Gynecologic Oncology, 2003, 91, 383-388.	0.6	51
331	Survival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study. Gynecologic Oncology, 2003, 91, 608-615.	0.6	68
332	Relevance of Akt phosphorylation in cell transformation induced by Jaagsiekte sheep retrovirus. Virology, 2003, 312, 95-105.	1.1	53
333	\hat{l}^2 -catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecologic Oncology, 2003, 88, 363-368.	0.6	48
334	Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecologic Oncology, 2003, 88, 266-269.	0.6	99
335	Endometrial cancer: predictors of peritoneal failurea^†a^†Supported by the Mayo Cancer Center (P30CA15083) and the Rochester Research Committee, Mayo Foundation. Presented at the 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami Beach, FL, March 16 to 20, 2002 Gynecologic Oncology, 2003, 89, 236-242.	0.6	66
336	Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecologic Oncology, 2003, 89, 281-287.	0.6	130
337	A case of chronic paclitaxel administration in ovarian cancer. Gynecologic Oncology, 2003, 89, 532-535.	0.6	12
338	Sarcomatoid carcinoma of the cervix. Gynecologic Oncology, 2003, 90, 23-28.	0.6	35
339	Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecologic Oncology, 2003, 90, 177-180.	0.6	31
341	Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecologic Oncology, 2003, 90, S39-S44.	0.6	40
342	Workshop: options for therapy in ovarian cancer. Gynecologic Oncology, 2003, 90, S45-S50.	0.6	11
343	Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma. Seminars in Oncology, 2003, 30, 369-374.	0.8	16
344	The follow-up of adult soft-tissue sarcomas. Seminars in Oncology, 2003, 30, 413-416.	0.8	39
345	The role of concurrent chemotherapy and radiation in the management of patients with squamous cell carcinomas of the head and neck. Seminars in Oncology, 2003, 30, 37-45.	0.8	4
346	Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Seminars in Oncology, 2003, 30, 616-634.	0.8	80
347	Ovarian cancer: an update. Journal of Surgical Education, 2003, 60, 7-12.	0.7	0
348	A comparative analysis of positron emission tomography and mediastinoscopy in staging non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 1900-1904.	0.4	140

#	Article	IF	Citations
349	Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless miceâ ⁻ †â ⁻ †Part of this work was conducted at the Department of Dermatology, Case Western Reserve University and the Research Institute of University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio 44106 Toxicology and Applied Pharmacology, 2003, 186, 28-37.	1.3	246
350	Small cell lung cancer: from molecular biology to novel therapeutics. Journal of Experimental Therapeutics and Oncology, 2003, 3, 305-318.	0.5	14
351	Mammography screening in African American women. Cancer, 2003, 97, 258-272.	2.0	54
352	Mammography screening matters for young women with breast carcinoma. Cancer, 2003, 97, 352-358.	2.0	54
353	Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer, 2003, 97, 561-567.	2.0	26
354	The biology of breast carcinoma. Cancer, 2003, 97, 825-833.	2.0	181
355	Prostate carcinoma. Cancer, 2003, 97, 758-771.	2.0	45
356	Mammography screening among Chinese-American women. Cancer, 2003, 97, 1293-1302.	2.0	64
357	Down-regulation of fragile histidine triad expression in prostate carcinoma. Cancer, 2003, 97, 1447-1452.	2.0	17
358	Use of quality indicators to evaluate the care of patients with localized prostate carcinoma. Cancer, 2003, 97, 1428-1435.	2.0	32
359	Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer, 2003, 97, 1663-1671.	2.0	676
360	Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck. Cancer, 2003, 97, 1701-1710.	2.0	29
361	Current understanding of the biology of advanced bladder cancer. Cancer, 2003, 97, 2064-2075.	2.0	51
362	Psychological well being and quality of life in ovarian cancer survivors. Cancer, 2003, 98, 1061-1071.	2.0	127
363	Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer, 2003, 97, 2090-2098.	2.0	33
364	Trends in leukemia incidence and survival in the United States (1973–1998). Cancer, 2003, 97, 2229-2235.	2.0	192
365	Second neoplasms after megavoltage radiation for pediatric tumors. Cancer, 2003, 97, 2588-2596.	2.0	94
366	Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer, 2003, 97, 2196-2202.	2.0	117

#	Article	IF	CITATIONS
367	Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer, 2003, 97, 2848-2852.	2.0	31
368	A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer, 2003, 97, 2988-2994.	2.0	39
369	Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer, 2003, 97, 2978-2987.	2.0	197
370	Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer, 2003, 98, 176-186.	2.0	199
371	A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer, 2003, 98, 900-907.	2.0	27
372	Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-? in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer, 2003, 98, 758-764.	2.0	104
373	Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer, 2003, 98, 798-804.	2.0	65
374	Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older. Cancer, 2003, 98, 918-925.	2.0	37
375	A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer, 2003, 98, 1918-1924.	2.0	30
376	Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma. Cancer, 2003, 98, 2192-2198.	2.0	17
377	Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer, 2003, 98, 2566-2575.	2.0	181
378	MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer, 2003, 99, 365-371.	2.0	87
379	A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer, 2003, 98, 2693-2699.	2.0	116
380	Cytology of human ovarian surface epithelial brushings. Cancer, 2003, 102, 1-10.	2.0	10
381	Effect of treatment sequence with radiotherapy and the antiestrogen EM 800 on the growth of ZR 75 1 human mammary carcinoma in nude mice. International Journal of Cancer, 2003, 103, 268-276.	2.3	6
382	Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice. International Journal of Cancer, 2003, 104, 7-11.	2.3	47
383	Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. International Journal of Cancer, 2003, 106, 605-610.	2.3	56
384	Identification of the novel role of pRB in eye cancer. Journal of Cellular Biochemistry, 2003, 88, 121-127.	1.2	8

#	Article	IF	Citations
385	Surgical considerations with lung cancer screening. Journal of Surgical Oncology, 2003, 84, 1-6.	0.8	10
386	Primary malignant melanoma of the lip. Journal of Surgical Oncology, 2003, 84, 7-9.	0.8	12
387	Tumor markers and colorectal cancer: Utility in management. Journal of Surgical Oncology, 2003, 84, 239-248.	0.8	56
388	Phased-array MRI of canine prostate using endorectal and endourethral coils. Magnetic Resonance in Medicine, 2003, 49, 710-715.	1.9	8
389	Magnetic resonance imaging of gastric cancer in Tff1 knock-out mice. Magnetic Resonance in Medicine, 2003, 49, 1033-1036.	1.9	17
390	Acute myeloid leukemia in the older patient. Critical Reviews in Oncology/Hematology, 2003, 48, S17-S26.	2.0	24
391	Molecular assay to generate expression profile of eight estrogen receptor alpha isoform mRNA copy numbers in picogram amounts of total RNA from breast cancer tissues. Analytical Biochemistry, 2003, 314, 217-226.	1.1	20
392	A fuzzy-based histogram analysis technique for skin lesion discrimination in dermatology clinical images. Computerized Medical Imaging and Graphics, 2003, 27, 387-396.	3.5	60
393	Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2003, 55, 679-687.	0.4	20
394	Outcomes and patterns of failure in bronchial carcinoid tumors. International Journal of Radiation Oncology Biology Physics, 2003, 55, 125-131.	0.4	35
395	Second primary cancers in patients with laryngeal cancer: A population-based study. International Journal of Radiation Oncology Biology Physics, 2003, 56, 427-435.	0.4	88
396	Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. International Journal of Radiation Oncology Biology Physics, 2003, 56, 611-615.	0.4	63
397	Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 98-104.	0.4	197
398	Clinical research in pancreatic cancer: The Radiation Therapy Oncology Group trials. International Journal of Radiation Oncology Biology Physics, 2003, 56, 31-37.	0.4	37
399	Effects of age on coping and psychological distress in women diagnosed with breast cancer: review of literature and analysis of two different geographical settings. Critical Reviews in Oncology/Hematology, 2003, 46, 5-16.	2.0	67
400	Epithelial cell differentiation in the human prostate epithelium: Implications for the pathogenesis and therapy of prostate cancer. Critical Reviews in Oncology/Hematology, 2003, 46, 3-10.	2.0	81
401	Follow-up care of breast cancer survivors. Critical Reviews in Oncology/Hematology, 2003, 48, 89-99.	2.0	16
402	Gemcitabine: current role and future options in the treatment of ovarian cancer. Critical Reviews in Oncology/Hematology, 2003, 48, 81-88.	2.0	22

#	Article	IF	Citations
403	Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. Journal of Gastrointestinal Surgery, 2003, 7, 766-772.	0.9	91
404	Genetic counseling for prostate cancer risk. Clinical Genetics, 2003, 63, 169-176.	1.0	16
405	Permanent Prostate Brachytherapy in Men with Clinically Localised Prostate Cancer. Clinical Oncology, 2003, 15, 301-315.	0.6	23
406	The Potential Impact on Melanoma Mortality of Reducing Rates of Suboptimal Excision Margins. Journal of Investigative Dermatology, 2003, 120, 1067-1072.	0.3	8
407	Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer. Breast Journal, 2003, 9, 208-212.	0.4	16
408	Global Summit Consensus Conference on International Breast Health Care: Guidelines for Countries with Limited Resources. Breast Journal, 2003, 9, S40-S41.	0.4	14
409	Overview of Breast Health Care Guidelines for Countries with Limited Resources. Breast Journal, 2003, 9, S42-S50.	0.4	72
410	FIGO stage IIIC endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival. International Journal of Gynecological Cancer, 2003, 13, 664-672.	1.2	97
411	Thirty years' studies on surgery and related basic research of hepatocellular carcinoma. Annals of the College of Surgeons of Hong Kong, 2003, 7, 11-17.	0.0	0
412	Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. BJU International, 2003, 91, 345-349.	1.3	33
413	Results with radical cystectomy for treating bladder cancer: a â€~reference standard' for high-grade, invasive bladder cancer. BJU International, 2003, 92, 12-17.	1.3	101
414	A qualitative analysis of social concerns of women with ovarian cancer. Psycho-Oncology, 2003, 12, 647-663.	1.0	62
415	ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate, 2003, 54, 34-43.	1.2	134
416	Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms. Prostate, 2003, 54, 194-205.	1.2	86
417	Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate, 2003, 55, 219-237.	1.2	402
418	Familial aggregation of prostate cancer in African-Americans and white Americans. Prostate, 2003, 56, 256-262.	1.2	25
419	Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. Journal of Pathology, 2003, 200, 640-646.	2.1	242
420	Targeted therapy for epithelial ovarian cancer: Current status and future prospects. International Journal of Gynecological Cancer, 2003, 13, 701-734.	1.2	43

#	Article	IF	CITATIONS
421	Racial Differences in the Receipt of Bowel Surveillance Following Potentially Curative Colorectal Cancer Surgery. Health Services Research, 2003, 38, 1885-1904.	1.0	46
422	Lack of effect of human c-Ha-ras proto-oncogene overexpression on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Science, 2003, 94, 1042-1045.	1.7	1
423	Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: Lack of influence of carcinogen or testosterone treatment. Cancer Science, 2003, 94, 153-157.	1.7	24
424	Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Science, 2003, 94, 425-430.	1.7	85
425	Chemotherapy for pancreatic cancer. Alimentary Pharmacology and Therapeutics, 2003, 18, 1049-1069.	1.9	57
426	CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. British Journal of Cancer, 2003, 88, 231-236.	2.9	151
427	A phase II trial of capecitabine (Xeloda $\hat{A}^{@}$) in recurrent ovarian cancer. British Journal of Cancer, 2003, 89, 1843-1848.	2.9	28
428	Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression of three different heat shock proteins. Cancer Gene Therapy, 2003, 10, 411-420.	2.2	45
429	Induction of CD8 T-cell-Ifn- \hat{l}^3 response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Therapy, 2003, 10, 850-858.	2.2	27
430	Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor α2 chain in vivo. Gene Therapy, 2003, 10, 1116-1128.	2.3	21
431	Thalidomide as initial therapy for early-stage myeloma. Leukemia, 2003, 17, 775-779.	3.3	219
432	Expression of VEGF and its receptors by myeloma cells. Leukemia, 2003, 17, 2025-2031.	3.3	140
433	Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene, 2003, 22, 590-601.	2.6	65
434	RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene, 2003, 22, 2135-2142.	2.6	144
435	Inhibition of constitutive NF-l ^o B activity by lloBl±M suppresses tumorigenesis. Oncogene, 2003, 22, 1365-1370.	2.6	143
436	Melanoma etiology: where are we?. Oncogene, 2003, 22, 3042-3052.	2.6	236
437	Apoptosis and melanoma chemoresistance. Oncogene, 2003, 22, 3138-3151.	2.6	757
438	Molecular analysis of transitional cell carcinoma using cDNA microarray. Oncogene, 2003, 22, 7702-7710.	2.6	46

#	Article	IF	Citations
439	Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene, 2003, 22, 8271-8282.	2.6	216
440	Screening for lung cancer: in pursuit of pre-metastatic disease. Nature Reviews Cancer, 2003, 3, 65-73.	12.8	45
441	DNA Methylation, a Biomarker for Colorectal Cancer. Annals of the New York Academy of Sciences, 2003, 983, 251-267.	1.8	30
442	DNA Methylation as a Cancerâ€Specific Biomarker. Annals of the New York Academy of Sciences, 2003, 983, 286-297.	1.8	33
443	Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leukemia Research, 2003, 27, 617-626.	0.4	27
444	Role of IMRT in reducing penile doses in dose escalation for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2003, 55, 970-978.	0.4	46
445	Intraoperative dural irradiation by customized 1921RIDIUM AND 90YTTRIUM brachytherapy plaques. International Journal of Radiation Oncology Biology Physics, 2003, 57, 239-245.	0.4	51
446	Noninvasive Detection of Bladder Cancer in an Orthotopic Murine Model With Green Fluorescence Protein Cytology. Journal of Urology, 2003, 170, 975-978.	0.2	21
447	Immunotherapy of malignant melanoma. Surgical Clinics of North America, 2003, 83, 343-370.	0.5	31
448	MR imaging of the female pelvis. Radiologic Clinics of North America, 2003, 41, 179-192.	0.9	28
449	First-degree relatives of patients with advanced colorectal adenomas have an increased prevalence of colorectal cancer. Clinical Gastroenterology and Hepatology, 2003, 1, 96-102.	2.4	62
450	Well-differentiated carcinoma of the thyroid. Otolaryngologic Clinics of North America, 2003, 36, 73-90.	0.5	18
451	The genetic basis of renal cell carcinoma. Urologic Clinics of North America, 2003, 30, 437-454.	0.8	38
452	Dermatological perspectives of malignant melanoma. Surgical Clinics of North America, 2003, 83, 77-95.	0.5	21
453	Surgical treatment of malignant melanoma. Surgical Clinics of North America, 2003, 83, 109-156.	0.5	95
454	Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery, 2003, 134, 720-727.	1.0	73
455	The role of intraoperative radiotherapy in pancreatic cancer. Surgical Oncology Clinics of North America, 2003, 12, 965-977.	0.6	27
456	Current staging of renal cell carcinoma. Urologic Clinics of North America, 2003, 30, 481-497.	0.8	33

#	Article	IF	CITATIONS
457	Hereditary kidney cancer. Urologic Clinics of North America, 2003, 30, 831-842.	0.8	11
458	Patterns of Care for the Treatment of Bladder Cancer. Journal of Urology, 2003, 169, 1697-1701.	0.2	84
459	Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive Partitioning. Journal of Urology, 2003, 169, 164-169.	0.2	155
460	Is Hispanic Race an Independent Risk Factor for Pathological Stage in Patients Undergoing Radical Prostatectomy?. Journal of Urology, 2003, 170, 2288-2291.	0.2	4
461	Health Related Quality of Life Patterns in Patients Treated With Interstitial Prostate Brachytherapy for Localized Prostate Cancer—Data From CaPSURE. Journal of Urology, 2003, 170, 1822-1827.	0.2	60
462	Oncogenic pathways implicated in ovarian epithelial cancer. Hematology/Oncology Clinics of North America, 2003, 17, 927-943.	0.9	57
463	Po-topic IV-05. Academic Radiology, 2003, 10, 955.	1.3	0
464	Salvage therapy for recurrent epithelial ovarian cancer. Hematology/Oncology Clinics of North America, 2003, 17, 977-988.	0.9	19
465	Malignant melanoma in non-Caucasians: experience from Hawaii. Surgical Clinics of North America, 2003, 83, 275-282.	0.5	31
466	Percutaneous Radiofrequency Ablation of Lung Tumors in a Large Animal Model. Journal of Vascular and Interventional Radiology, 2003, 14, 1037-1043.	0.2	43
467	¿Qué es el sÃndrome doloroso posmastectomÃa?. Nursing (Ed Española), 2003, 21, 50.	0.0	0
468	Reduced 15S-Lipoxygenase-2 Expression in Esophageal Cancer Specimens and Cells and Upregulation In Vitro by the Cyclooxygenase-2 Inhibitor, NS398. Neoplasia, 2003, 5, 121-127.	2.3	34
469	Populations at high risk for prostate cancer. Urologic Clinics of North America, 2003, 30, 669-676.	0.8	25
470	Clinical trials and soft tissue sarcomas. Surgical Oncology Clinics of North America, 2003, 12, 485-497.	0.6	8
471	Incidencia y mortalidad del cÃ;ncer. Historia natural. Gaceta Medica De Bilbao, 2003, 100, 139-143.	0.0	1
472	Does family history still matter in the era of screening colonoscopy?. Clinical Gastroenterology and Hepatology, 2003, 1, 69-70.	2.4	2
473	Non–AIDS-defining cancer in HIV-infected people. Hematology/Oncology Clinics of North America, 2003, 17, 889-899.	0.9	56
474	Management of early lentigo maligna and lentigo maligna melanoma of the head and neck. Facial Plastic Surgery Clinics of North America, 2003, 11, 93-105.	0.9	3

#	Article	IF	CITATIONS
475	Markers and meaning of primary treatment failure. Urologic Clinics of North America, 2003, 30, 377-401.	0.8	72
476	Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 34-39.	1.4	122
477	Pharmacogenetic candidate genes for melanoma. Pharmacogenomics, 2003, 4, 753-765.	0.6	2
478	Multi-scale Nodule Detection in Chest Radiographs. Lecture Notes in Computer Science, 2003, , 602-609.	1.0	19
479	Variation in Continence and Potency by Definition. Journal of Urology, 2003, 170, 1291-1294.	0.2	124
480	Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. New England Journal of Medicine, 2003, 348, 203-213.	13.9	2,930
481	Genetic testing for high-risk colon cancer patients 1 1 Abbreviations used in this paper: FAP, familial adenomatous polyposis; HMPS, hereditary mixed polyposis syndrome; HNPCC, hereditary nonpolyposis colon cancer; JPS, juvenile polyposis; MMR, mutation mismatch repair; MSI, microsatellite instability; PJS, Peutz-Jeghers syndrome; TGF, transforming growth factor Gastroenterology, 2003, 124, 1574-1594.	0.6	194
482	Virtual colonoscopy using oral contrast compared with colonoscopy for the detection of patients with colorectal polyps. Gastroenterology, 2003, 125, 304-310.	0.6	189
483	Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology, 2003, 125, 1203-1218.	0.6	111
484	Design, Synthesis, and Evaluation of Novel Boronic-Chalcone Derivatives as Antitumor Agents. Journal of Medicinal Chemistry, 2003, 46, 2813-2815.	2.9	281
485	Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial. Annals of Surgical Oncology, 2003, 10, 635-44.	0.7	28
486	Can an hour or two of sun protection education keep the sunburn away? Evaluation of the Environmental Protection Agency's Sunwise School Program. Environmental Health, 2003, 2, 13.	1.7	46
487	Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Molecular Cancer, 2003, 2, 12.	7.9	138
488	Genetic alterations in pancreatic carcinoma. Molecular Cancer, 2003, 2, 15.	7.9	102
489	Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Molecular Cancer, 2003, 2, 24.	7.9	197
490	Effects of STI571 (gleevec) on pancreatic cancer cell growth. Molecular Cancer, 2003, 2, 32.	7.9	42
491	Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer. Clinical Breast Cancer, 2003, 4, 318-328.	1,1	101
492	New Agents in the Treatment of Small-Cell Lung Cancer: Focus on Gemcitabine. Clinical Lung Cancer, 2003, 4, S56-S63.	1.1	7

#	Article	IF	CITATIONS
493	Accuracy of esophagoscopy performed by a non-physician endoscopist with a 4-mm diameter battery-powered endoscope. Gastrointestinal Endoscopy, 2003, 57, 305-310.	0.5	24
494	EUS-guided FNA for the diagnosis of gallbladder masses. Gastrointestinal Endoscopy, 2003, 57, 251-254.	0.5	84
495	Diagnosis and Management of Hereditary Non-Polyposis Colon Cancer. Gastrointestinal Endoscopy, 2003, 58, 390-408.	0.5	28
496	A Nomogram For Predicting a Positive Repeat Prostate Biopsy in Patients With a Previous Negative Biopsy Session. Journal of Urology, 2003, 170, 1184-1188.	0.2	88
497	Clinical Features and Treatment Outcome of Hispanic Men With Prostate Cancer Following External Beam Radiotherapy. Journal of Urology, 2003, 170, 1856-1859.	0.2	7
498	Hautmann and Studer Orthotopic Neobladders: A Contemporary Experience. Journal of Urology, 2003, 169, 2188-2191.	0.2	58
499	The challenge of pancreatic cancer. American Journal of Surgery, 2003, 186, 579-582.	0.9	28
500	Racial disparity in incidence patterns and outcome of kidney cancer. Urology, 2003, 62, 1012-1017.	0.5	80
501	Human prostate cancer precursors and pathobiology. Urology, 2003, 62, 55-62.	0.5	229
502	Uveal metastasis from breast cancer in 264 patients. American Journal of Ophthalmology, 2003, 136, 264-271.	1.7	213
503	Classification and Subtype Prediction of Adult Soft Tissue Sarcoma by Functional Genomics. American Journal of Pathology, 2003, 163, 691-700.	1.9	207
504	Krýppel Cripples Prostate Cancer. American Journal of Pathology, 2003, 162, 1047-1052.	1.9	41
505	Amplification and Overexpression of the L-MYC Proto-Oncogene in Ovarian Carcinomas. American Journal of Pathology, 2003, 162, 1603-1610.	1.9	63
506	Is neoadjuvant therapy the answer to adenocarcinoma of the esophagus?. American Journal of Surgery, 2003, 186, 296-300.	0.9	12
507	Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer. Pharmacological Reviews, 2003, 55, 57-103.	7.1	65
508	Hereditary Colorectal Cancer. New England Journal of Medicine, 2003, 348, 919-932.	13.9	1,870
509	The management of cancer in the older adolescent. European Journal of Cancer, 2003, 39, 2584-2599.	1.3	183
510	Diagnostic Potential of Serum Proteomic Patterns in Prostate Cancer. Journal of Urology, 2003, 170, 442-446.	0.2	134

#	ARTICLE	IF	Citations
511	Androgenâ€Induced Prostateâ€Specific Antigen Gene Expression Is Mediated via Dihydrotestosterone in LNCaP Cells. Journal of Andrology, 2003, 24, 681-687.	2.0	46
512	Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. Lung Cancer, 2003, 39, 23-29.	0.9	30
513	Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer, 2003, 39, 197-199.	0.9	100
514	Treatment of relapsed small-cell lung cancer—a focus on the evolving role of topotecan. Lung Cancer, 2003, 40, 229-236.	0.9	24
515	The importance of the eicosanoid pathway in lung cancer. Lung Cancer, 2003, 41, 73-79.	0.9	15
516	Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer, 2003, 41, 163-174.	0.9	13
517	Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer, 2003, 42, 51-57.	0.9	115
518	Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 39-44.	0.8	41
519	Androgen blockade enhances response to melanoma vaccine 1 1This work was supported in part by a Young Investigator Award from the American Society of Clinical Oncology (to Dr. Hsueh). Presented at the annual meeting of the American Society of Clinical Oncology, San Francisco, May 12–15, 2001 Journal of Surgical Research, 2003, 110, 393-398.	0.8	28
520	Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Human Pathology, 2003, 34, 646-653.	1.1	285
521	Informed consent for prostate-specific antigen screening. Urology, 2003, 61, 2-4.	0.5	6
522	Glycoprotein A-80 in the human prostate: immunolocalization in prostatic intraepithelial neoplasia, carcinoma, radiation failure, and after neoadjuvant hormonal therapy. Urology, 2003, 61, 248-252.	0.5	14
523	Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology, 2003, 61, 109-118.	0.5	432
524	Educating African-American men about prostate cancer: impact on awareness and knowledge. Urology, 2003, 61, 308-313.	0.5	69
525	Outcomes after radical retropubic prostatectomy. Urology, 2003, 61, 412-416.	0.5	25
526	Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology, 2003, 61, 314-319.	0.5	122
527	National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology, 2003, 61, 14-24.	0.5	152
528	Randomized prospective trial of a novel local anesthetic technique for extensive prostate biopsy. Urology, 2003, 61, 972-976.	0.5	36

#	Article	IF	CITATIONS
529	Internet use by patients with prostate cancer undergoing radiotherapy. Urology, 2003, 62, 273-277.	0.5	70
530	Continued undertreatment of older men with localized prostate cancer. Urology, 2003, 62, 860-865.	0.5	83
531	Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology, 2003, 62, 1035-1039.	0.5	40
532	Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002. Urology, 2003, 62, 1045-1049.	0.5	10
533	Cervical cancer. Lancet, The, 2003, 361, 2217-2225.	6.3	831
534	Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochemical and Biophysical Research Communications, 2003, 300, 357-363.	1.0	106
535	Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochemical and Biophysical Research Communications, 2003, 305, 598-604.	1.0	63
536	PGE2 is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2003, 306, 887-897.	1.0	112
537	Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointestinal Endoscopy, 2003, 58, 690-695.	0.5	395
538	Diagnosis of ovarian cancer metastatic to the stomach by EUS-guided FNA. Gastrointestinal Endoscopy, 2003, 58, 933-935.	0.5	22
539	The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointestinal Endoscopy, 2003, 57, 817-822.	0.5	58
540	Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Letters, 2003, 190, 183-190.	3.2	159
541	Microvascular flap reconstruction of the mandible: a comparison of bone grafts and bridging plates for restoration of mandibular continuity. Otolaryngology - Head and Neck Surgery, 2003, 129, 48-54.	1.1	65
542	Current strategies in the management of hormone refractory prostate cancer. Cancer Treatment Reviews, 2003, 29, 171-187.	3.4	86
543	Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. Cancer Treatment Reviews, 2003, 29, 21-30.	3.4	69
544	Optimal therapy for oesophageal cancer. Cancer Treatment Reviews, 2003, 29, 275-282.	3.4	23
545	Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treatment Reviews, 2003, 29, 189-198.	3.4	48
546	Hereditary nonpolyposis colorectal cancer: preventive management. Cancer Treatment Reviews, 2003, 29, 461-470.	3.4	53

#	ARTICLE	IF	CITATIONS
547	Early diagnosis and surgical management of prostate cancer. Cancer Treatment Reviews, 2003, 29, 151-160.	3.4	23
548	Prostate Cancer. New England Journal of Medicine, 2003, 349, 366-381.	13.9	970
549	Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer. Seminars in Thoracic and Cardiovascular Surgery, 2003, 15, 438-447.	0.4	3
550	Nonsmall-cell lung cancer: chemoprevention studies. Seminars in Thoracic and Cardiovascular Surgery, 2003, 15, 405-420.	0.4	6
551	Epidemiology of melanoma and nonmelanoma skin cancer. Seminars in Oncology Nursing, 2003, 19, 2-11.	0.7	119
552	Diagnosis and management of stage I/II melanoma. Seminars in Oncology Nursing, 2003, 19, 22-31.	0.7	4
553	Health perceptions and risk behaviors of lung cancer survivors. Heart and Lung: Journal of Acute and Critical Care, 2003, 32, 131-139.	0.8	65
554	The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985-1999. Journal of the American Academy of Dermatology, 2003, 48, 34-41.	0.6	118
555	Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. European Journal of Cancer, 2003, 39, 1242-1250.	1.3	76
556	Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. European Journal of Cancer, 2003, 39, 2403-2410.	1.3	73
557	Multislice helical CT of the pancreas and spleen. European Journal of Radiology, 2003, 45, S59-S72.	1.2	38
558	Diagnosis, treatment, and nursing care of patients with chronic leukemia. Seminars in Oncology Nursing, 2003, 19, 109-117.	0.7	7
559	Relatives of colorectal cancer patients. American Journal of Preventive Medicine, 2003, 25, 187-194.	1.6	88
560	Screening CT colonography. Seminars in Ultrasound, CT and MRI, 2003, 24, 12-22.	0.7	12
561	Melanoma: what the primary care physician needs to know. Primary Care Update for Ob/Gyns, 2003, 10, 51-59.	0.1	0
563	Managing reproductive tract malignancy. Primary Care Update for Ob/Gyns, 2003, 10, 95-104.	0.1	0
564	A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 171-177.	0.8	15
565	Bacillus calmete-guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 354-360.	0.8	68

#	Article	IF	CITATIONS
566	Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 456-462.	0.8	36
567	4-Hydroperoxycyclophosphamide–purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. Biology of Blood and Marrow Transplantation, 2003, 9, 183-188.	2.0	9
568	The role of surgery in the management of oesophageal cancer. Lancet Oncology, The, 2003, 4, 481-488.	5.1	224
569	The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncology, The, 2003, 4, 489-497.	5.1	100
570	Chemoprevention of lung cancer. Lancet Oncology, The, 2003, 4, 659-669.	5.1	52
571	Open Surgical Treatment of Localised Renal Cell Cancer. EAU Update Series, 2003, 1, 220-225.	0.5	10
572	The Allogeneic Effect in Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2003, 44, S91-S97.	0.6	2
573	Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis. Journal of Urology, 2003, 170, 1742-1746.	0.2	163
574	Radical Prostatectomy Nomograms in Black American Men: Accuracy and Applicability. Journal of Urology, 2003, 170, 73-77.	0.2	43
575	Sarcomas of the head and neck. Surgical Oncology Clinics of North America, 2003, 12, 379-417.	0.6	86
576	Colon cancer during pregnancy. Gastroenterology Clinics of North America, 2003, 32, 341-383.	1.0	54
577	Suppression of Ultraviolet B Exposure-Mediated Activation of NF-κB in Normal Human Keratinocytes by Resveratrol. Neoplasia, 2003, 5, 74-82.	2.3	180
578	Evaluation and follow-up strategies for superficial bladder cancer. Urologic Clinics of North America, 2003, 30, 765-776.	0.8	97
579	Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors. Journal of Urology, 2003, 170, 1792-1797.	0.2	331
580	Health Related Quality of Life in Patients Treated With Radical Cystectomy and Urinary Diversion for Urothelial Carcinoma of the Bladder: Development and Validation of a New Disease Specific Questionnaire. Journal of Urology, 2003, 170, 1926-1930.	0.2	111
581	Clinical and Economic Issues in the Treatment of Advanced Breast Cancer with Bisphosphonates. Drugs and Aging, 2003, 20, 631-642.	1.3	6
582	Treatments for Improving Survival of Patients with Prostate Cancer. Drugs and Aging, 2003, 20, 683-699.	1.3	11
583	New approaches for biomarker discovery in lung cancer. Expert Review of Molecular Diagnostics, 2003, 3, 55-67.	1.5	26

#	Article	IF	CITATIONS
584	Concepts and Controversies in Cancer Screening. American Journal of Cancer, 2003, 2, 395-402.	0.4	4
585	Docetaxel Plus Cisplatin. American Journal of Cancer, 2003, 2, 349-356.	0.4	1
586	A Review of Current and Future Treatment Options in Renal Cancer. American Journal of Cancer, 2003, 2, 201-210.	0.4	1
587	Leuprolide Acetate. American Journal of Cancer, 2003, 2, 57-64.	0.4	5
588	Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB or IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2003, 21, 2094-2100.	0.8	60
589	Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease. Expert Opinion on Pharmacotherapy, 2003, 4, 705-716.	0.9	12
590	Adenoma Recurrences After Resection of Colorectal Carcinoma: Results From the Southwest Oncology Group 9041 Calcium Chemoprevention Pilot Study. Annals of Surgical Oncology, 2003, 10, 870-875.	0.7	18
591	Treatment of Locally Advanced Pancreatic Cancer in the Real World: Population-Based Practices and Effectiveness. Journal of Clinical Oncology, 2003, 21, 3409-3414.	0.8	93
592	DNA damage and breast cancer risk. Carcinogenesis, 2003, 24, 883-889.	1.3	129
593	Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study. Journal of Clinical Oncology, 2003, 21, 697-703.	0.8	97
594	Arsenic Trioxide (Trisenox $\hat{A}^{@}$) Therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem Cell Transplantation. Oncologist, 2003, 8, 132-140.	1.9	54
596	Effect of Number of Lymph Nodes Sampled on Outcome in Patients With Stage I Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2003, 21, 1029-1034.	0.8	286
597	Lung cancer * 9: Molecular biology of lung cancer: clinical implications. Thorax, 2003, 58, 892-900.	2.7	110
598	Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist. Journal of Clinical Oncology, 2003, 21, 740-753.	0.8	60
599	Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer. Annals of Pharmacotherapy, 2003, 37, 1644-1653.	0.9	13
600	ESMO takes a stand on supportive and palliative care. Annals of Oncology, 2003, 14, 1335-1337.	0.6	99
601	Effects of dietary folate and aging on gene expression in the colonic mucosa of rats: implications for carcinogenesis. Carcinogenesis, 2003, 25, 69-76.	1.3	50
602	3Â-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4440-4444.	3 . 3	17

#	Article	IF	CITATIONS
603	Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma. Journal of Clinical Oncology, 2003, 21, 3351-3356.	0.8	146
604	Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2003, 95, 341-343.	3.0	99
605	5,10-Methylenetetrahydrofolate Reductase Polymorphisms and Leukemia Risk: A HuGE Minireview. American Journal of Epidemiology, 2003, 157, 571-582.	1.6	249
606	Goals and Objectives in the Management of Metastatic Breast Cancer. Oncologist, 2003, 8, 514-520.	1.9	120
607	Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation. Oncologist, 2003, 8, 474-487.	1.9	81
608	Bringing Threat to the Fore: Participating in Lifelong Surveillance for Genetic Risk of Cancer. Oncology Nursing Forum, 2003, 30, 945-955.	0.5	9
609	Prognosis After Rectal Cancer in Blacks and Whites Participating in Adjuvant Therapy Randomized Trials. Journal of Clinical Oncology, 2003, 21, 413-420.	0.8	47
610	Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial. Journal of Clinical Oncology, 2003, 21, 1313-1319.	0.8	55
611	Interaction of Splenectomy and Perioperative Blood Transfusions on Prognosis of Patients With Proximal Gastric and Gastroesophageal Junction Cancer. Journal of Clinical Oncology, 2003, 21, 4597-4603.	0.8	41
612	Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. European Journal of Haematology, 2003, 70, 268-268.	1.1	12
613	The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. Genes and Development, 2003, 17, 3127-3138.	2.7	104
614	Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5124-5129.	3.3	58
615	Association Between Hemochromatosis (HFE) Gene Mutation Carrier Status and the Risk of Colon Cancer. Journal of the National Cancer Institute, 2003, 95, 154-159.	3.0	119
616	Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer. Journal of Clinical Oncology, 2003, 21, 4277-4284.	0.8	328
617	Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93. Journal of Clinical Oncology, 2003, 21, 2110-2114.	0.8	56
618	Management of Human Melanoma: What Has the Last Decade Wrought?. Oncologist, 2003, 8, 448-450.	1.9	4
619	Many Cases Need to Be Reviewed to Compare Performance in Surgical Pathology?. American Journal of Clinical Pathology, 2003, 119, 388-391.	0.4	25
620	Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis, 2003, 24, 269-274.	1.3	71

#	Article	IF	CITATIONS
621	An Argument Against Routine Prostate Cancer Screening. Archives of Internal Medicine, 2003, 163, 663.	4.3	9
622	A comparison of three scoring systems for predicting complications after major lung resection. European Journal of Cardio-thoracic Surgery, 2003, 23, 35-42.	0.6	90
623	The Transformation Rate of Moles (Melanocytic Nevi) Into Cutaneous Melanoma. Archives of Dermatology, 2003, 139, 282.	1.7	282
624	Legislating Evidenceâ€Based Cancer Care. Oncologist, 2003, 8, 128-131.	1.9	2
625	Gastric cancer: epidemiology, pathology and treatment. Annals of Oncology, 2003, 14, ii31-ii36.	0.6	307
626	Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2003, 21, 999-1006.	0.8	107
627	Alterations of the Birt-Hogg-Dube gene (BHD) in sporadic colorectal tumours. Journal of Medical Genetics, 2003, 40, 511-515.	1.5	31
628	Adjuvant therapy in pancreatic cancer: historical and current perspectives. Annals of Oncology, 2003, 14, 675-692.	0.6	115
629	Non–Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging. Radiology, 2003, 229, 526-533.	3.6	525
630	Evaluation of the SunWise School Program. Journal of School Nursing, 2003, 19, 93-99.	0.9	22
631	The Training of Head and Neck Surgeons: The Care of Head and Neck Patients <subtitle>2002 Presidential Address, American Head and Neck Society</subtitle> . JAMA Otolaryngology, 2003, 129, 9.	1.5	8
632	Lung Cancer Screening at Any Price?. JAMA - Journal of the American Medical Association, 2003, 289, 357.	3.8	10
633	Effects of Dietary Selenium Supplementation on DNA Damage and Apoptosis in Canine Prostate. Journal of the National Cancer Institute, 2003, 95, 237-241.	3.0	98
634	Expression of the Proto-Oncogene Axl in Renal Cell Carcinoma. DNA and Cell Biology, 2003, 22, 533-540.	0.9	65
635	Tomosynthesis-based localization of radioactive seeds in prostate brachytherapy. Medical Physics, 2003, 30, 3135-3142.	1.6	53
636	Phase I Dose Escalation Clinical Trial of Adenovirus Vector Carrying Osteocalcin Promoter-Driven Herpes Simplex Virus Thymidine Kinase in Localized and Metastatic Hormone-Refractory Prostate Cancer. Human Gene Therapy, 2003, 14, 227-241.	1.4	125
637	Massive training artificial neural network (MTANN) for reduction of false positives in computerized detection of lung nodules in low-dose computed tomography. Medical Physics, 2003, 30, 1602-1617.	1.6	226
638	Computerized analysis of shadowing on breast ultrasound for improved lesion detection. Medical Physics, 2003, 30, 1833-1842.	1.6	44

#	ARTICLE	IF	Citations
639	Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2003, 21, 1301-1306.	0.8	164
640	Immune gene therapy for kidney cancer: the search for a magic trigger. Molecular Therapy, 2003, 7, 153-154.	3.7	6
641	Predictors of colorectal cancer screening participation in the United States. American Journal of Gastroenterology, 2003, 98, 2082-2091.	0.2	268
642	Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Molecular Therapy, 2003, 8, 434-440.	3.7	47
643	Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan. Journal of Andrology, 2003, 24, 299-311.	2.0	203
644	Factors Associated with Arm Swelling after Breast Cancer Surgery. Journal of Women's Health, 2003, 12, 921-930.	1.5	68
645	Radiation Improves Intratumoral Gene Therapy for Induction of Cancer Vaccine in Murine Prostate Carcinoma. Human Gene Therapy, 2003, 14, 763-775.	1.4	15
646	Gene therapy for cancer and metastatic disease. Expert Reviews in Molecular Medicine, 2003, 5, 1-18.	1.6	20
647	Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy. Journal of the American Society of Nephrology: JASN, 2003, 14, 2695-2702.	3.0	19
648	Predicting Success in Cancer Prevention Trials. Journal of the National Cancer Institute, 2003, 95, 178-179.	3.0	10
649	Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut, 2003, 52, 1598-1601.	6.1	32
650	Role of Gastrointestinal Hormones in the Proliferation of Normal and Neoplastic Tissues. Endocrine Reviews, 2003, 24, 571-599.	8.9	116
651	Epidermal Growth Factor Receptor in Nonâ€"Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology, 2003, 21, 3798-3807.	0.8	1,333
652	Optimal therapy and management of endometrial cancer. Expert Review of Anticancer Therapy, 2003, 3, 37-47.	1.1	7
653	Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care. Oncologist, 2003, 8, 18-34.	1.9	114
654	Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group Study. Journal of Clinical Oncology, 2003, 21, 2856-2859.	0.8	47
655	Targeting $G\hat{l}^2\hat{l}^3$ Signaling to Inhibit Prostate Tumor Formation and Growth. Journal of Biological Chemistry, 2003, 278, 37569-37573.	1.6	65
656	Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II study. Annals of Oncology, 2003, 14, 580-585.	0.6	65

#	Article	IF	CITATIONS
657	The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. Journal of Molecular Endocrinology, 2003, 31, 169-183.	1.1	61
658	Phase I Trial of Escalating-Dose Irinotecan Given Weekly With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Cancer. Journal of Clinical Oncology, 2003, 21, 2926-2932.	0.8	96
659	Chemoprevention of Melanoma: An Unexplored Strategy. Journal of Clinical Oncology, 2003, 21, 158-165.	0.8	64
660	Prognostic Significance of Visible Lesions on Transrectal Ultrasound in Impalpable Prostate Cancers: Implications for Staging. Journal of Clinical Oncology, 2003, 21, 2860-2868.	0.8	26
661	Radiotherapy Patterns of Care Study in Lung Carcinoma. Journal of Clinical Oncology, 2003, 21, 4553-4559.	0.8	105
662	Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597. Journal of Clinical Oncology, 2003, 21, 1550-1555.	0.8	112
663	Inhibitory effects of soy isoflavones on rat prostate carcinogenesis induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis, 2003, 25, 381-387.	1.3	33
664	Ibritumomab Tiuxetan: The Cancer Smart Bomb. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 437-438.	0.7	0
665	Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel. Oncology, 2003, 64, 399-406.	0.9	16
666	The Outcome of Combined-Modality Therapy for Stage III Non–Small-Cell Lung Cancer in the Elderly. Journal of Clinical Oncology, 2003, 21, 3201-3206.	0.8	223
667	High dose rate 192 Ir afterloading brachytherapy for cancer of the vagina. British Journal of Radiology, 2003, 76, 719-725.	1.0	19
668	Breast cancer in men. BMJ: British Medical Journal, 2003, 327, 239-240.	2.4	25
669	Screening for colorectal cancer. Postgraduate Medicine, 2003, 113, 49-55.	0.9	5
670	A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer. Acta Oncol \tilde{A}^3 gica, 2003, 42, 195-201.	0.8	18
671	Variation of Serum Prostate-Specific Antigen Levels. JAMA - Journal of the American Medical Association, 2003, 289, 2695.	3.8	198
672	High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer., 2003,, CD003139.		17
673	Teaching Patients the ABCs of Preventing Melanoma. Journal of the American Pharmacists Association, 2003, 43, 325-326.	0.6	1
674	System for MR Image–guided Prostate Interventions: Canine Study. Radiology, 2003, 228, 886-894.	3.6	78

#	Article	IF	CITATIONS
675	Efficacy and safety of HLA-B7 \hat{l}^2 -2 microglobulin plasmid DNA/lipid complex (Allovectin-7 $\hat{A}^{\text{@}}$) in patients with metastatic melanoma. Expert Opinion on Biological Therapy, 2003, 3, 377-384.	1.4	14
676	MR Imaging–guided Focused US Ablation of Breast Cancer: Histopathologic Assessment of Effectiveness—Initial Experience. Radiology, 2003, 227, 849-855.	3 . 6	268
677	Endoscopic Ultrasound, Positron Emission Tomography, and Computerized Tomography for Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1293-1297.	2.5	81
678	Androgen Stimulates Matrix Metalloproteinase-2 Expression in Human Prostate Cancer. Endocrinology, 2003, 144, 1656-1663.	1.4	95
679	Cancer Survival in Kentucky and Health Insurance Coverage. Archives of Internal Medicine, 2003, 163, 2135.	4.3	135
680	MR Imaging of the Ipsilateral Breast in Women with Percutaneously Proven Breast Cancer. American Journal of Roentgenology, 2003, 180, 901-910.	1.0	338
681	Insulin-Like Growth Factor I (IGF-I) and IGF Binding Protein-1 Modulate Prostate Cancer Cell Growth and Apoptosis: Possible Mediators for the Effects of Diet and Exercise on Cancer Cell Survival. Endocrinology, 2003, 144, 2319-2324.	1.4	109
682	Physical Activity, Exercise, and Cancer: Prevention to Treatment???Symposium Overview. Medicine and Science in Sports and Exercise, 2003, 35, 1821-1822.	0.2	4
683	Phase II Study of Vinorelbine and Low-Dose Docetaxel in Chemotherapy-Naive Patients with Hormone-Refractory Prostate Cancer. Cancer Journal (Sudbury, Mass), 2003, 9, 286-292.	1.0	18
684	Sarcomas of the head and neck region. Current Opinion in Oncology, 2003, 15, 239-252.	1.1	263
685	CANCER RISKS FROM MEDICAL RADIATION. Health Physics, 2003, 85, 47-59.	0.3	315
686	The Silent Killer. Holistic Nursing Practice, 2003, 17, 300-308.	0.3	36
687	Renal radiofrequency ablation: clinical status 2003. Current Opinion in Urology, 2003, 13, 199-202.	0.9	23
688	Advances in the therapy of chronic lymphocytic leukemia. Current Opinion in Hematology, 2003, 10, 297-305.	1.2	6
689	Renal cell carcinoma. Current Opinion in Oncology, 2003, 15, 213-216.	1.1	24
690	Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer. Nuclear Medicine Communications, 2003, 24, 963-970.	0.5	10
691	Bladder substitution. Current Opinion in Urology, 2003, 13, 477-482.	0.9	24
692	ASC-US and HPV Testing. American Journal of Nursing, 2003, 103, 42-50.	0.2	1

#	Article	IF	Citations
693	Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Current Opinion in Urology, 2003, 13, 117-122.	0.9	17
694	Pulmonary Toxicity During Prostate Cancer Treatment With Docetaxel and Thalidomide. American Journal of Therapeutics, 2003, 10, 228-232.	0.5	23
695	Endoscopic Ultrasound and Upper Gastrointestinal Disorders. Journal of Clinical Gastroenterology, 2003, 36, 103-110.	1.1	20
696	Enteral Nutritional Support of the Patient With Cancer. Journal of Clinical Gastroenterology, 2003, 36, 297-302.	1.1	54
697	Pancreatic neoplasms. Current Opinion in Gastroenterology, 2003, 19, 458-466.	1.0	9
698	Bladder cancer. Current Opinion in Oncology, 2003, 15, 227-233.	1.1	45
699	The rationale for adjuvant chemotherapy for high-risk prostate cancer. Current Opinion in Urology, 2003, 13, 123-131.	0.9	2
700	Expression of Antioxidant Enzymes in Diseases of the Human Pancreas: Another Link Between Chronic Pancreatitis and Pancreatic Cancer. Pancreas, 2003, 26, 23-27.	0.5	106
701	Bladder cancer prevention. Part I: what do I tell my patients about lifestyle changes and dietary supplements?. Current Opinion in Urology, 2003, 13, 363-378.	0.9	13
702	Mechanisms for Radiation-induced Oral Mucositis and the Consequences. Cancer Nursing, 2003, 26, 222-229.	0.7	59
703	Sputum cytology for the detection of early lung cancer. Current Opinion in Pulmonary Medicine, 2003, 9, 309-312.	1.2	18
704	Risk factors and risk reduction of breast and ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2003, 15, 63-68.	0.9	109
705	Diagnostic Dilemmas in Thyroid Pathology: Follicular Variant of Papillary Thyroid Carcinoma and Classic Papillary Thyroid Carcinoma Arising in Lymphocytic Thyroiditis., 2003, 8, 47-56.		11
706	Phase 1 Study of the Intravesical Administration of Recombinant Human Interleukin-12 in Patients With Recurrent Superficial Transitional Cell Carcinoma of the Bladder. Journal of Immunotherapy, 2003, 26, 343-348.	1.2	69
707	Diagnosis, Staging, and Surveillance of Pancreatic Cancer. American Journal of Roentgenology, 2003, 180, 1311-1323.	1.0	100
708	Persistent Knee Pain in a Recreational Runner. Journal of the American Board of Family Medicine, 2003, 16, 435-442.	0.8	1
709	Recent Advances in the Treatment of Stage IIIA Lung Cancer. Clinical Pulmonary Medicine, 2003, 10, 100-110.	0.3	0
710	Physical Activity and Cancer Prevention???Data from Epidemiologic Studies. Medicine and Science in Sports and Exercise, 2003, 35, 1823-1827.	0.2	340

#	Article	IF	CITATIONS
711	Roles of Positron Emission Tomography With Fluorine-18-Deoxyglucose in the Detection of Local Recurrent and Distant Metastatic Sarcoma. Clinical Nuclear Medicine, 2003, 28, 815-820.	0.7	76
712	Prostate Cancer and Bone Metastases: Medical Treatment. Clinical Orthopaedics and Related Research, 2003, 415, S148-S157.	0.7	22
713	Knowledge, Attitudes, and Practices Surrounding Breast Cancer Screening in Educated Appalachian Women. Oncology Nursing Forum, 2003, 30, 659-667.	0.5	33
714	Lung Cancer Guidelines*. Chest, 2003, 123, 1S-2S.	0.4	57
715	Oral Changes Associated with Tobacco Use. American Journal of the Medical Sciences, 2003, 326, 179-182.	0.4	152
716	Sentinel Lymph Node Biopsy in Patients With Thin Melanoma. Archives of Dermatology, 2003, 139, 617.	1.7	59
717	Meaning of Illness and Spirituality in Ovarian Cancer Survivors. Oncology Nursing Forum, 2003, 30, 249-257.	0.5	85
719	Tamoxifen for Prevention of Breast Cancer. Annals of Pharmacotherapy, 2003, 37, 268-273.	0.9	76
720	To Screen or Not To Screen. Chest, 2003, 123, 1788-1792.	0.4	6
721	Cancer from an Unknown Primary Site. American Journal of the Medical Sciences, 2003, 326, 35-46.	0.4	17
722	Gene Expression Profiling of Renal Cell Carcinoma and Its Implications in Diagnosis, Prognosis, and Therapeutics. Advances in Cancer Research, 2003, 89, 157-181.	1.9	31
723	Changes in the General Surgical Workload, 1991-1999. Archives of Surgery, 2003, 138, 417.	2.3	13
724	HNPCC (Lynch Syndrome): Differential Diagnosis, Molecular Genetics and Management - a Review. Hereditary Cancer in Clinical Practice, 2003, 1, 7.	0.6	19
725	Comparative Evaluation of Super High-Resolution CT Scan and Virtual Bronchoscopy for the Detection of Tracheobronchial Malignancies *. Chest, 2003, 124, 1834-1840.	0.4	81
726	KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood, 2003, 101, 4547-4550.	0.6	14
727	Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood, 2003, 101, 4285-4289.	0.6	191
728	Genetically targeted radiotherapy for multiple myeloma. Blood, 2003, 102, 489-496.	0.6	92
729	Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood, 2003, 102, 1075-1077.	0.6	48

#	Article	IF	CITATIONS
730	Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8–mediated apoptosis and down-regulation of c-FLIP protein. Blood, 2003, 102, 652-658.	0.6	163
731	Dual effects of macrophage inflammatory protein-lî± on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 2003, 102, 311-319.	0.6	199
732	Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. Biochemical Journal, 2003, 371, 581-587.	1.7	62
733	Identification and characterization of a prostate-specific androgen-independent protein-binding site in the probasin promoter. Biochemical Journal, 2003, 371, 843-855.	1.7	18
734	Noninvasive Staging of Non-small Cell Lung Cancer*. Chest, 2003, 123, 137S-146S.	0.4	676
735	The Solitary Pulmonary Nodule*. Chest, 2003, 123, 89S-96S.	0.4	300
736	Vitamin C and cancer chemoprevention: reappraisal. American Journal of Clinical Nutrition, 2003, 78, 1074-1078.	2,2	127
737	Pancreatic Carcinoma Surveillance in Patients With Familial Melanoma. Archives of Dermatology, 2003, 139, 1019.	1.7	84
738	Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2003, 21, 2920-2925.	0.8	49
739	Oncodiagnosis Panel: 2002. Radiographics, 2003, 23, 1591-1611.	1.4	9
740	Progress in Lung Cancer Chemoprevention. Cancer Control, 2003, 10, 315-324.	0.7	17
741	Screening for Cancer., 2003,, 375-391.		1
742	Cancer in the Elderly: An Overview. , 2003, , 361-362.		2
743	Provision of Individualized Information to Men and Their Partners to Facilitate Treatment Decision Making in Prostate Cancer. Oncology Nursing Forum, 2003, 30, 107-114.	0.5	125
744	Understanding Non-Hodgkin's Lymphomas. Clinical Journal of Oncology Nursing, 2003, 7, 93-96.	0.3	1
745	Endorectal Ultrasound and the Preoperative Staging of Rectal Cancer. Scandinavian Journal of Surgery, 2003, 92, 25-33.	1.3	14
746	Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer. Journal of Korean Medical Science, 2004, 19, 369.	1.1	15
747	Gender Differences in Hematologic Malignancies. , 2004, , 629-636.		0

#	ARTICLE	IF	CITATIONS
748	Renal Tumours, Epidemiology and Diagnostic Profile. Urologia, 2004, 71, 35-37.	0.3	0
749	The Hereditary Renal Cancer Syndromes. Urologia, 2004, 71, 15-20.	0.3	0
750	Measuring quality of life in prostate cancer: progress and challenges. , 2004, , 126-159.		3
752	STAT Signaling in Cancer: Insights into Pathogenesis and Treatment Strategies. , 2003, 115, 267-291.		41
753	Alcohol, One-Carbon Metabolism, and Colorectal Cancer: Recent Insights from Molecular Studies. Journal of Nutrition, 2004, 134, 2475S-2481S.	1.3	134
754	Oral Cancer Knowledge and Practices of Dentists along the Texas-Mexico Border. Journal of Cancer Education, 2004, 19, 6-11.	0.6	22
755	Induction of experimental mammary carcinogenesis in rats with 7,12-dimethylbenz(a)anthracene. Revista Do Hospital Das Clinicas, 2004, 59, 257-261.	0.5	67
756	Management of Early-Stage Endometrial Cancer. , 2004, , 259-273.		1
757	Nutrition and Cancers of the Breast, Endometrium, and Ovary. , 2004, , 770-782.		0
758	Identification of Clinically Significant Prostate Cancer by Prostate-Specific Antigen Screening. Archives of Internal Medicine, 2004, 164, 1227.	4.3	14
759	Skin Toxicity During Breast Irradiation: Pathophysiology and Management. Southern Medical Journal, 2004, 97, 989-993.	0.3	155
760	Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice—glioma coculture model. Journal of Neurosurgery, 2004, 100, 1049-1059.	0.9	34
761	The importance of an extended lymphadenectomy in the management of high-grade invasive bladder cancer. Expert Review of Anticancer Therapy, 2004, 4, 1007-1016.	1.1	17
762	The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, †Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Annals of Oncology, 2004, 15, 211-217.	0.6	79
763	Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. Journal of Applied Physiology, 2004, 96, 450-454.	1.2	81
764	History of Breast Reconstruction. Seminars in Plastic Surgery, 2004, 18, 65-69.	0.8	69
765	Novel targeted agents in the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2004, 13, 609-629.	1.9	2
766	Proteomic technologies and their application to pancreatic cancer. Expert Review of Proteomics, 2004, 1, 493-501.	1.3	19

#	Article	IF	Citations
767	The Golden S Sign. Radiology, 2004, 233, 790-791.	3.6	23
768	Gemcitabine Combined with Docetaxel for the Treatment of Unresectable Pancreatic Carcinoma. Cancer Investigation, 2004, 22, 505-514.	0.6	26
769	Renal Masses: Quantitative Analysis of Enhancement with Signal Intensity Measurements versus Qualitative Analysis of Enhancement with Image Subtraction for Diagnosing Malignancy at MR Imaging. Radiology, 2004, 232, 373-378.	3.6	148
770	Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma. Journal of Clinical Oncology, 2004, 22, 909-918.	0.8	948
771	Survival data and prognostic factors seen in Pakistani patients with esophageal cancer. Annals of Oncology, 2004, 15, 118-122.	0.6	20
772	Spatial Composition of Prostate Cancer Spheroids in Mixed and Static Cultures. Tissue Engineering, 2004, 10, 1266-1276.	4.9	44
773	Thyroid Disease and Reproductive Health. Thyroid, 2004, 14, 1-3.	2.4	7
774	Hydromorphone Neuroexcitation. Journal of Palliative Medicine, 2004, 7, 545-550.	0.6	52
775	Detection of Breast Cancer in Nipple Aspirate Fluid by CpG Island Hypermethylation. Clinical Cancer Research, 2004, 10, 28-32.	3. 2	160
776	Computer-aided diagnosis of mammographic microcalcification clusters. Medical Physics, 2004, 31, 314-326.	1.6	78
777	Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial. Journal of Clinical Oncology, 2004, 22, 2540-2545.	0.8	79
778	Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing. Cancer Research, 2004, 64, 5982-5987.	0.4	127
779	Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro-Oncology, 2004, 6, 38-43.	0.6	61
781	A Randomized Trial of Direct Mailing of Fecal Occult Blood Tests To Increase Colorectal Cancer Screening. Journal of the National Cancer Institute, 2004, 96, 770-780.	3.0	129
782	A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor \hat{l}_{\pm} Inhibitor in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 6528-6534.	3.2	180
783	Vinorelbine alternating oral and intravenous plus carboplatinin advanced non-small-cell lung cancer: results of a multicentre phase II study. Annals of Oncology, 2004, 15, 921-927.	0.6	17
784	Hath1, Down-Regulated in Colon Adenocarcinomas, Inhibits Proliferation and Tumorigenesis of Colon Cancer Cells. Cancer Research, 2004, 64, 6050-6057.	0.4	117
785	Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group. Journal of Clinical Oncology, 2004, 22, 277-285.	0.8	314

#	ARTICLE	IF	Citations
786	Deregulated Akt3 Activity Promotes Development of Malignant Melanoma. Cancer Research, 2004, 64, 7002-7010.	0.4	526
787	Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2004, 292, 470.	3.8	305
788	The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes. Oncologist, 2004, 9, 9-15.	1.9	57
789	Associations Among Â-TrCP, an E3 Ubiquitin Ligase Receptor, Â-Catenin, and NF-ÂB in Colorectal Cancer. Journal of the National Cancer Institute, 2004, 96, 1161-1170.	3.0	151
790	Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome. Cancer Research, 2004, 64, 8767-8772.	0.4	60
791	Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival. Cancer Research, 2004, 64, 4900-4905.	0.4	108
792	Treatment of Metastatic Head and Neck Cancer: Chemotherapy and Novel Agents., 2003, 114, 295-314.		20
793	"Not Lighting Up": A Case Study of a Woman Who Quit Smoking. Oncology Nursing Forum, 2004, 31, E54-E63.	0.5	0
794	Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy. Journal of Clinical Oncology, 2004, 22, 439-445.	0.8	356
795	FOLFOX-4 in Pre-treated Patients with Advanced Transitional Cell Carcinoma of the Bladder. Japanese Journal of Clinical Oncology, 2004, 34, 747-750.	0.6	27
796	Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2004, 96, 1133-1141.	3.0	367
797	Expression of Complement Factor H by Lung Cancer Cells. Cancer Research, 2004, 64, 6310-6318.	0.4	108
798	Chemopreventive n-3 Polyunsaturated Fatty Acids Reprogram Genetic Signatures during Colon Cancer Initiation and Progression in the Rat. Cancer Research, 2004, 64, 6797-6804.	0.4	136
799	Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells. Cancer Research, 2004, 64, 8057-8061.	0.4	90
800	A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. Clinical Cancer Research, 2004, 10, 2986-2996.	3.2	76
801	Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning. Clinical Cancer Research, 2004, 10, 7799-7811.	3.2	89
802	M34 Actin Regulatory Protein Is a Sensitive Diagnostic Marker for Early- and Late-Stage Mammary Carcinomas. Clinical Cancer Research, 2004, 10, 4437-4443.	3.2	2
803	Androgen Receptor Coregulators in Prostate Cancer. Clinical Cancer Research, 2004, 10, 2208-2219.	3.2	98

#	Article	IF	CITATIONS
804	Overcoming Obstacles to Skin Cancer Examinations and Prevention Counseling for High-Risk Patients: Results of a National Survey of Primary Care Physicians. Journal of the American Board of Family Medicine, 2004, 17, 416-423.	0.8	85
805	RUNX3 expression in primary and metastatic pancreatic cancer. Journal of Clinical Pathology, 2004, 57, 294-299.	1.0	47
806	Histopathological patterns of melanoma metastases in sentinel lymph nodes. Journal of Clinical Pathology, 2004, 57, 64-67.	1.0	35
807	Weekly Irinotecan in Patients with Metastatic Gastric Cancer Failing Cisplatin-based Chemotherapy. Japanese Journal of Clinical Oncology, 2004, 34, 8-13.	0.6	68
808	Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 1110-1117.	0.8	171
809	Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology, 2004, 22, 537-556.	0.8	189
810	The Effect of Breast Cancer Screening Messages on Knowledge, Attitudes, Perceived Risk, and Mammography Screening of African American Women in the Rural South. Oncology Nursing Forum, 2004, 31, 801-808.	0.5	39
811	Expression of Hepatoma-Derived Growth Factor Is a Strong Prognostic Predictor for Patients With Early-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 3230-3237.	0.8	109
812	Treatment of Carcinogenesis., 2004,, 607-673.		1
813	HOXA10 Expression in Endometrial Adenocarcinoma. Tumor Biology, 2004, 25, 264-269.	0.8	18
814	Small-Area Incidence Trends in Breast Cancer. Epidemiology, 2004, 15, 300-307.	1.2	11
815	Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2004, 10, 5327-5334.	3.2	221
816	Innovations and Challenges in Renal Cancer. Clinical Cancer Research, 2004, 10, 6277S-6281S.	3.2	38
817	Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 6371S-6376S.	3.2	24
818	Chemopreventive drug treatment in subjects with genetic predisposition to cancer: prescriber liability and healthcare disparities. Pharmacogenomics, 2004, 5, 319-329.	0.6	4
819	Novel Therapeutic Strategies in Prostate Cancer. Cancer Biology and Therapy, 2004, 3, 371-376.	1.5	10
820	Molecular Targets for Cancer Therapy and Prevention. Chest, 2004, 125, 97S-101S.	0.4	11
821	Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2004, 10, 5930-5939.	3.2	131

#	Article	IF	CITATIONS
822	Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group. Journal of Clinical Oncology, 2004, 22, 446-453.	0.8	366
823	Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 4193-4201.	0.8	67
824	Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 255-259.	1.1	39
825	Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Research, 2004, 64, 5882-5890.	0.4	884
826	Of What Value Genomics in Colorectal Cancer? Opportunities and Challenges. Journal of Clinical Oncology, 2004, 22, 1538-1539.	0.8	3
827	Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2004, 22, 120-126.	0.8	17
828	Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer. Clinical Cancer Research, 2004, 10, 2832-2845.	3.2	179
829	A Breast Cancer Fear Scale: Psychometric Development. Journal of Health Psychology, 2004, 9, 753-762.	1.3	150
830	Down Regulation of High in Normal-1 (HIN-1) is a Frequent Event in Stage I Non-Small Cell Lung Cancer and Correlates with Poor Clinical Outcome. Clinical Cancer Research, 2004, 10, 1338-1343.	3.2	27
831	XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy. Journal of Clinical Oncology, 2004, 22, 2594-2601.	0.8	289
832	Resveratrol-induced Autophagocytosis in Ovarian Cancer Cells. Cancer Research, 2004, 64, 696-703.	0.4	359
833	Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. British Journal of Cancer, 2004, 90, 93-99.	2.9	159
834	Predictors of Proximal Neoplasia in Patients Without Distal Adenomatous Pathology. American Journal of Gastroenterology, 2004, 99, 472-477.	0.2	49
835	Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. British Journal of Cancer, 2004, 90, 245-252.	2.9	44
836	Assessment of Health State Utilities and Quality of Life in Patients With Malignant Esophageal Dysphagia. American Journal of Gastroenterology, 2004, 99, 1044-1049.	0.2	34
837	Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. Molecular Therapy, 2004, 10, 1059-1070.	3.7	25
838	Novel Agents in Epithelial Ovarian Cancer. Cancer Investigation, 2004, 22, 29-44.	0.6	16
839	Targeting Prostate Cancer with Conditionally Replicative Adenovirus Using PSMA Enhancer. Molecular Therapy, 2004, 10, 1051-1058.	3.7	18

#	Article	IF	CITATIONS
840	Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci. British Journal of Cancer, 2004, 90, 510-514.	2.9	32
841	Reduced Apaf-1 expression in human cutaneous melanomas. British Journal of Cancer, 2004, 91, 1089-1095.	2.9	55
842	Oncolysis of Multifocal Hepatocellular Carcinoma in the Rat Liver by Hepatic Artery Infusion of Vesicular Stomatitis Virus. Molecular Therapy, 2004, 9, 368-376.	3.7	79
843	99mTc-Depreotide Scintigraphy in the Evaluation of Indeterminate Pulmonary Lesions: Clinical Experience. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 253-259.	0.7	13
844	Parametric Shape Modeling Using Deformable Superellipses for Prostate Segmentation. IEEE Transactions on Medical Imaging, 2004, 23, 340-349.	5.4	129
845	Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Annals of Oncology, 2004, 15, 28-32.	0.6	239
846	Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 4837-4845.	0.8	350
847	Detection of Invasive Colon Cancer Using a Novel, Targeted, Library-Derived Fluorescent Peptide. Cancer Research, 2004, 64, 6247-6251.	0.4	134
848	Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145. Carcinogenesis, 2004, 25, 1359-1370.	1.3	82
849	A phase II study of carboplatin and paclitaxel in esophageal cancer. Annals of Oncology, 2004, 15, 960-965.	0.6	46
850	Management of muscle-invasive bladder cancer in the elderly. Expert Review of Anticancer Therapy, 2004, 4, 1017-1035.	1.1	8
851	Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2004, 22, 2610-2616.	0.8	466
852	Merging Claims Databases with a Tumor Registry to Evaluate Variations in Cancer Mortality: Results from a Pilot Study of 698 Colorectal Cancer Patients Treated at One Hospital in the 1990s. Cancer Investigation, 2004, 22, 225-233.	0.6	4
853	Optimal Use of a Panel of Methylation Markers with GSTP1 Hypermethylation in the Diagnosis of Prostate Adenocarcinoma. Clinical Cancer Research, 2004, 10, 5518-5522.	3.2	82
854	Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu. Cancer Investigation, 2004, 22, 706-712.	0.6	176
855	An analysis of risk factors for biochemical progression in patients with seminal vesicle invasion: validation of Kattan's nomogram in a pathological subgroup. BJU International, 2004, 93, 961-964.	1.3	25
856	State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU International, 2004, 94, 268-271.	1.3	33
857	Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Ecological Management and Restoration, 2004, 17, 38-43.	0.2	50

#	Article	IF	CITATIONS
858	Modern management of pancreatic carcinoma. Internal Medicine Journal, 2004, 34, 475-481.	0.5	38
859	Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer Science, 2004, 95, 588-591.	1.7	53
860	Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. Cancer Science, 2004, 95, 481-486.	1.7	247
861	Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. British Journal of Haematology, 2004, 125, 156-161.	1.2	94
862	Primary clinical analysis of medical disorders in Chinese women with endometrial carcinoma. International Journal of Gynecological Cancer, 2004, 14, 502-507.	1.2	4
863	Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival. International Journal of Gynecological Cancer, 2004, 14, 133-137.	1.2	29
864	Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma*. International Journal of Gynecological Cancer, 2004, 14, 540-542.	1.2	2
865	Photodynamic therapy in cholangiocarcinomas. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 147-154.	1.0	25
866	The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nature Reviews Cancer, 2004, 4, 519-527.	12.8	290
867	Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer, 2004, 4, 707-717.	12.8	489
868	Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplantation, 2004, 33, 955-962.	1.3	67
869	Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Therapy, 2004, 11, 477-486.	2.2	63
870	Identification of genes whose expression patterns differ in benign lymphoid tissue and follicular, mantle cell, and small lymphocytic lymphoma. Leukemia, 2004, 18, 841-855.	3.3	17
871	The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia, 2004, 18, 1207-1214.	3.3	125
872	Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene, 2004, 23, 71-81.	2.6	68
873	IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene, 2004, 23, 1125-1135.	2.6	93
874	Identification of Kr $\tilde{A}^{1}/_{4}$ ppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene, 2004, 23, 395-402.	2.6	282
875	Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas. Oncogene, 2004, 23, 1166-1176.	2.6	90

#	Article	IF	CITATIONS
876	Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene, 2004, 23, 2367-2378.	2.6	133
877	A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene, 2004, 23, 4780-4788.	2.6	65
878	Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. British Journal of Cancer, 2004, 90, 535-541.	2.9	131
879	Alterations of DNA mismatch repair proteins and microsatellite instability levels in gastric cancer cell lines. Laboratory Investigation, 2004, 84, 915-922.	1.7	25
880	Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2004, 7, 343-349.	2.0	5
881	Cancer in the elderly: pancreatic cancer. Surgical Oncology, 2004, 13, 201-210.	0.8	41
882	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion markers in CD-1 mouse skin by oleandrin. Toxicology and Applied Pharmacology, 2004, 195, 361-369.	1.3	50
883	Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 1366-1372.	0.4	46
884	Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 1579-1586.	0.4	41
885	Imaging, diagnosis, and staging of bone tumors: A primer. Seminars in Roentgenology, 2004, 39, 361-372.	0.2	19
886	Numerical aberrations of chromosomes 8, 9, 11, and 17 in squamous cell carcinoma of the pharynx and larynx: a fluorescence in situ hybridization and DNA flow cytometric analysis of 50 cases. Oral Oncology, 2004, 40, 409-417.	0.8	15
887	Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell, 2004, 5, 489-500.	7.7	589
888	Evaluation of breast abnormalities (Guidelines). Apollo Medicine, 2004, 1, 171-178.	0.0	0
889	Molecular classification and molecular genetics of human lung cancers. Seminars in Oncology, 2004, 31, 4-19.	0.8	56
890	Surgery in older patients. Seminars in Oncology, 2004, 31, 175-184.	0.8	31
891	The impact on nodal staging of lymphatic mapping in carcinoma of the colon and rectum. Seminars in Oncology, 2004, 31, 403-408.	0.8	5
892	Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: Preliminary results from a phase II trial. Seminars in Oncology, 2004, 31, 20-24.	0.8	13
893	Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Seminars in Oncology, 2004, 31, 24-29.	0.8	29

#	Article	IF	CITATIONS
894	Molecular biology of upper gastrointestinal malignancies. Seminars in Oncology, 2004, 31, 476-486.	0.8	61
895	Epidemiology of upper gastrointestinal malignancies. Seminars in Oncology, 2004, 31, 450-464.	0.8	296
896	Current management of glioblastoma multiforme. Seminars in Oncology, 2004, 31, 635-644.	0.8	206
897	Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. Oral Oncology, 2004, 40, 28-35.	0.8	28
898	Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen- \hat{l} ±, estrogen- \hat{l} 2 and progesterone; a case controlled study. Gynecologic Oncology, 2004, 92, 553-558.	0.6	33
899	Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecologic Oncology, 2004, 92, 596-602.	0.6	25
900	Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. Gynecologic Oncology, 2004, 92, 789-793.	0.6	121
901	Ovarian cancer surgery in Maryland: volume-based access to care. Gynecologic Oncology, 2004, 93, 353-360.	0.6	37
902	Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecologic Oncology, 2004, 94, 98-106.	0.6	15
903	The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecologic Oncology, 2004, 94, 67-73.	0.6	43
904	Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecologic Oncology, 2004, 94, 495-501.	0.6	60
905	Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecologic Oncology, 2004, 94, 502-508.	0.6	31
906	An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecologic Oncology, 2004, 94, 368-374.	0.6	45
907	A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecologic Oncology, 2004, 94, 442-448.	0.6	66
908	Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer. Gynecologic Oncology, 2004, 94, 705-712.	0.6	16
909	Adherence to an Annual PSA Screening Program over 3 Years for Brothers and Sons of Men with Prostate Cancer. European Urology, 2004, 45, 280-286.	0.9	24
910	Cell cycle arrest and autoschizis in a human bladder carcinoma cell line following Vitamin C and Vitamin K3 treatment. Biochemical Pharmacology, 2004, 67, 337-351.	2.0	42
911	Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genetics and Cytogenetics, 2004, 154, 63-66.	1.0	53

#	Article	IF	Citations
912	Focus on endometrial and cervical cancer. Cancer Cell, 2004, 5, 533-538.	7.7	99
913	Radiofrequency ablation of renal tumors. European Radiology, 2004, 14, 1449-55.	2.3	57
914	Completion hysterectomy after radiation therapy for bulky cervical cancer stages IB, IIA, and IIB: Complications and survival rates. American Journal of Obstetrics and Gynecology, 2004, 191, 654-658.	0.7	13
915	Rationale and design of the National Program of Cancer Registries' breast, colon, and prostate cancer patterns of care study. Cancer Causes and Control, 2004, 15, 1057-1066.	0.8	18
916	Epigenetic changes in colorectal cancer. Cancer and Metastasis Reviews, 2004, 23, 29-39.	2.7	276
917	Current and future trends in colorectal cancer screening. Cancer and Metastasis Reviews, 2004, 23, 137-144.	2.7	20
918	Synergistic Anti-Cancer Effects of Grape Seed Extract and Conventional Cytotoxic Agent Doxorubicin Against Human Breast Carcinoma Cells. Breast Cancer Research and Treatment, 2004, 85, 1-12.	1.1	123
919	The Full Potential of Breast Cancer Screening Use to Reduce Mortality has not yet been Realized in the United States. Breast Cancer Research and Treatment, 2004, 85, 219-222.	1.1	42
920	High-Fat Corn Oil Diet Promotes the Development of High Histologic Grade Rat DMBA-Induced Mammary Adenocarcinomas, While High Olive Oil Diet Does Not. Breast Cancer Research and Treatment, 2004, 86, 225-235.	1.1	40
921	Colonoscopy effects on serum prostate specific antigen levels. International Urology and Nephrology, 2004, 36, 203-206.	0.6	5
922	Phase II Clinical Trial of 5-Fluorouracil, Trimetrexate, and Leucovorin (NFL) in Patients With Advanced Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2004, 34, 079-086.	0.4	6
923	Is Reporting of Recurrence Data Important in Pancreatic Cancer?. Annals of Surgical Oncology, 2004, 11, 304-309.	0.7	22
924	Sentinel Lymph Node Mapping of the Colon and Stomach Using Lymphoseek in a Pig Model. Annals of Surgical Oncology, 2004, 11, 674-681.	0.7	26
925	Laparoscopic Biliary Bypass and Current Management Algorithms for the Palliation of Malignant Obstructive Jaundice. Annals of Surgical Oncology, 2004, 11, 815-817.	0.7	5
926	Nonmenstrual bleeding in women under 40 years of age. The Obstetrician and Gynaecologist, 2004, 6, 153-158.	0.2	8
927	An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. Clinical and Experimental Metastasis, 2004, 21, 7-12.	1.7	45
928	Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clinical and Experimental Metastasis, 2004, 21, 285-292.	1.7	80
929	Gail Model Risk Assessment and Risk Perceptions. Journal of Behavioral Medicine, 2004, 27, 205-214.	1.1	25

#	ARTICLE	IF	CITATIONS
930	Examination of the Short-Term Efficacy of a Parent-Based Intervention to Prevent Skin Cancer. Journal of Behavioral Medicine, 2004, 27, 393-412.	1.1	27
931	Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 509-17.	1.4	66
932	Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 518-26.	1.4	43
933	Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. Journal of Cancer Research and Clinical Oncology, 2004, 130, 52-56.	1.2	80
934	A decade?s studies on metastasis of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2004, 130, 187-196.	1.2	406
935	Enhancing Skin Self-Examination with Imaging: Evaluation of a Mole-Mapping Program. Journal of Cutaneous Medicine and Surgery, 2004, 8, 1-5.	0.6	15
936	Does Positron Emission Tomography Change Management in Primary Rectal Cancer? A Prospective Assessment. Diseases of the Colon and Rectum, 2004, 47, 451-458.	0.7	107
937	Endorectal Ultrasound in the Follow-Up of Rectal Cancer Patients Treated by Local Excision or Radical Surgery. Diseases of the Colon and Rectum, 2004, 47, 818-824.	0.7	50
938	Practice Parameters for the Surveillance and Follow-Up of Patients With Colon and Rectal Cancer. Diseases of the Colon and Rectum, 2004, 47, 807-817.	0.7	115
939	Oncologic Outcomes of Salvage Surgery for Epidermoid Carcinoma of the Anus Initially Managed With Combined Modality Therapy. Diseases of the Colon and Rectum, 2004, 47, 1136-1144.	0.7	107
940	Continuous care in the cancer patient: palliative care in the 21st century. Clinical and Translational Oncology, 2004, 6, 448-457.	1.2	2
942	Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1048-1055.	0.4	205
943	Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. International Journal of Radiation Oncology Biology Physics, 2004, 58, 972-975.	0.4	104
944	Targeted therapies for non–small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. International Journal of Radiation Oncology Biology Physics, 2004, 59, S27-S38.	0.4	52
945	The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 6107-6111.	1.0	33
946	Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clinical Biochemistry, 2004, 37, 823-829.	0.8	47
947	Cancer in Jews: introduction and overview. Familial Cancer, 2004, 3, 177-192.	0.9	24
948	Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Research and Treatment, 2004, 88, 161-176.	1.1	58

#	Article	IF	CITATIONS
949	Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Research and Treatment, 2004, 88, 109-116.	1.1	91
950	3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer. Strahlentherapie Und Onkologie, 2004, 180, 225-232.	1.0	106
952	99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1399-404.	3.3	8
953	Badania nad skutecznoÅsciÄ radiochemioterapii chorych na zaawansowanego raka szyjki macicy. Reports of Practical Oncology and Radiotherapy, 2004, 9, S131-S199.	0.3	1
954	Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non–small-cell lung cancer: a meta-analysis. International Journal of Radiation Oncology Biology Physics, 2004, 58, 196-203.	0.4	29
955	A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. International Journal of Radiation Oncology Biology Physics, 2004, 58, 779-785.	0.4	6
956	Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. Journal of Pathology, 2004, 204, 65-74.	2.1	86
957	CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate, 2004, 58, 183-192.	1.2	122
958	Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER® microspheres) and radiation. Prostate, 2004, 58, 291-298.	1.2	27
959	Therapeutic potential of curcumin in prostate cancer?IV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate, 2004, 60, 1-17.	1.2	54
960	Immunotherapy (APC8015, Provenge $\hat{A}^{@}$) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate, 2004, 60, 197-204.	1.2	176
961	A comprehensive characterization of the peptide and protein constituents of human seminal fluid. Prostate, 2004, 61, 171-181.	1.2	128
962	Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics, 2004, 4, 3394-3400.	1.3	66
963	Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. British Journal of Surgery, 2004, 91, 1592-1599.	0.1	59
964	Cancer mortality and incidence among a cohort of benzidine and dichlorobenzidine dye manufacturing workers. American Journal of Industrial Medicine, 2004, 46, 505-512.	1.0	26
965	Simple and complex genetics of colorectal cancer susceptibility. American Journal of Medical Genetics Part A, 2004, 129C, 35-43.	2.4	25
966	A clinically comprehensive ethical framework for offering and recommending cancer treatment before and during pregnancy. Cancer, 2004, 100, 215-222.	2.0	33
967	Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer, 2004, 100, 28-35.	2.0	88

#	Article	IF	Citations
968	Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer, 2004, 100, 300-307.	2.0	21
969	Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer, 2004, 100, 465-469.	2.0	174
970	Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma. Cancer, 2004, 100, 590-597.	2.0	45
971	Primary care provider perceptions of barriers to and facilitators of colorectal cancer screening in a managed care setting. Cancer, 2004, 100, 1843-1852.	2.0	68
972	DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens. Cancer, 2004, 102, 259-268.	2.0	59
973	Leukemia incidence following primary breast carcinoma treatment. Cancer, 2004, 101, 1529-1536.	2.0	29
974	Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer, 2004, 101, 2170-2176.	2.0	66
975	Nuclear factor-?B and I?B kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer, 2004, 101, 2351-2362.	2.0	284
976	Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer, 2004, 101, 2034-2041.	2.0	6
977	Flow cytometric enrichment for respiratory epithelial cells in sputum. Cytometry, 2004, 60A, 1-7.	1.8	10
978	Stromal cell-derived factor-1?-induced cell proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma. International Journal of Cancer, 2004, 110, 652-659.	2.3	49
979	Indian hedgehog signaling pathway: Expression and regulation in pancreatic cancer. International Journal of Cancer, 2004, 110, 668-676.	2.3	91
980	Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. International Journal of Cancer, 2004, 112, 286-294.	2.3	89
981	Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. International Journal of Cancer, 2004, 112, 570-576.	2.3	28
982	Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. Journal of Cellular Biochemistry, 2004, 91, 483-190.	1.2	354
983	Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. Journal of Cellular Biochemistry, 2004, 91, 459-477.	1.2	164
984	Abnormal cell cycle regulation in primary human uveal melanoma cultures. Journal of Cellular Biochemistry, 2004, 93, 708-720.	1.2	22
985	Improving the physical status and quality of life of women treated for breast cancer: A pilot study of a structured exercise intervention. Journal of Surgical Oncology, 2004, 86, 141-146.	0.8	86

#	Article	IF	CITATIONS
986	Identification of novel differentially expressed genes by the effect of a high-fat n-6 diet in experimental breast cancer. Molecular Carcinogenesis, 2004, 40, 73-78.	1.3	42
987	Phase II enzyme inducer, sulforaphane, inhibits UVB-induced AP-1 activation in human keratinocytes by a novel mechanism. Molecular Carcinogenesis, 2004, 41, 179-186.	1.3	48
988	5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. Journal of Gene Medicine, 2004, 6, 514-525.	1.4	34
989	Erectile dysfunction and radiation dose to penile base structures: a lack of correlation. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1039-1046.	0.4	65
990	[11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorganic and Medicinal Chemistry, 2004, 12, 2887-2893.	1.4	67
991	Overview: epidemiology, indications, goals, extent, and nature of work-up. Journal of Gastrointestinal Surgery, 2004, 8, 259-261.	0.9	6
992	Current management of gastric cancer. Journal of Gastrointestinal Surgery, 2004, 8, 905-912.	0.9	7
993	Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). Medical Dosimetry, 2004, 29, 196-203.	0.4	5
994	Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clinical Biochemistry, 2004, 37, 772-779.	0.8	78
995	The role of targeted therapy in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2004, 51, 29-44.	2.0	21
996	Detection of pigment network in dermatoscopy images using texture analysis. Computerized Medical Imaging and Graphics, 2004, 28, 225-234.	3.5	61
997	Inhibition of Cell Growth by Overexpression of Manganese Superoxide Dismutase (MnSOD) in Human Pancreatic Carcinoma. Free Radical Research, 2004, 38, 1223-1233.	1.5	67
998	Hereditary Non-Polyposis Colorectal Cancer Risk Assessment Based on Al Analysis of Pedigree Data. , 2004, 2004, 3229-32.		0
999	A cost–benefit analysis of chemotherapy for gastric cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 2109-2114.	0.9	2
1000	Induction of Quinone Reductase as a Primary Screen for Natural Product Anticarcinogens. Methods in Enzymology, 2004, 382, 380-414.	0.4	83
1002	Ovarian Cancer: Review of the National Institute for Clinical Excellence (NICE) Guidance Recommendations. Cancer Investigation, 2004, 22, 730-742.	0.6	24
1003	A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 23-30.	0.8	2,112
1004	Treatment of Pancreatic Cancer Cells with Dicumarol Induces Cytotoxicity and Oxidative Stress. Clinical Cancer Research, 2004, 10, 4550-4558.	3.2	63

#	ARTICLE	IF	CITATIONS
1005	The Expanding Role of Systemic Therapy in Head and Neck Cancer. Journal of Clinical Oncology, 2004, 22, 1743-1752.	0.8	199
1006	Use of Bipolar Energy for Transurethral Resection of Bladder Tumors: Pathologic Considerations. Journal of Endourology, 2004, 18, 578-582.	1.1	62
1007	Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Annals of Oncology, 2004, 15, 1535-1542.	0.6	58
1008	Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology, 2004, 4, 454-460.	0.5	71
1009	PROGNOSIS OF SEMINAL VESICLE INVOLVEMENT BY TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal of Urology, 2004, 172, 81-84.	0.2	25
1010	Current state of imaging for lung cancer staging. Thoracic Surgery Clinics, 2004, 14, 1-13.	0.4	15
1011	The Virginia Mason approach to localized pancreatic cancer. Surgical Oncology Clinics of North America, 2004, 13, 663-674.	0.6	24
1012	Chemotherapy and radiation of anal canal cancer: the first approach. Surgical Oncology Clinics of North America, 2004, 13, 309-320.	0.6	17
1013	Molecular diagnosis of solid and cystic lesions of the pancreas. Gastroenterology Clinics of North America, 2004, 33, 891-906.	1.0	16
1014	Inhibition of Nicotine-Induced Toxicity by Curcumin and Curcumin Analog: A Comparative Study. Journal of Medicinal Food, 2004, 7, 467-471.	0.8	18
1015	lodine 131 (131I) as adjuvant therapy of differentiated thyroid cancer. Surgical Oncology Clinics of North America, 2004, 13, 129-149.	0.6	3
1016	Screening CT colonography. Radiologic Clinics of North America, 2004, 42, 757-766.	0.9	1
1017	SPERMATIC CORD ANESTHESIA BLOCK FOR SCROTAL PROCEDURES IN OUTPATIENT CLINIC SETTING. Journal of Urology, 2004, 172, 2358-2361.	0.2	27
1018	LONG-TERM SURVIVAL PROBABILITY IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER: A CASE-CONTROL, PROPENSITY MODELING STUDY STRATIFIED BY RACE, AGE, TREATMENT AND COMORBIDITIES. Journal of Urology, 2004, 171, 1513-1519.	0.2	160
1020	Clinical evaluation of a new digitizing device for improved film mammography1. Academic Radiology, 2004, 11, 1242-1250.	1.3	1
1021	Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Hematology/Oncology Clinics of North America, 2004, 18, 895-913.	0.9	12
1022	Use of sugars in cryopreserving human oocytes. Reproductive BioMedicine Online, 2004, 9, 179-186.	1.1	51
1023	Photodynamic therapy in cholangiocarcinoma: an overview. Photodiagnosis and Photodynamic Therapy, 2004, 1, 85-92.	1.3	7

#	Article	IF	Citations
1024	Photodynamic therapy for pancreatic carcinoma: experimental and clinical studies. Photodiagnosis and Photodynamic Therapy, 2004, 1, 145-155.	1.3	10
1025	Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Gastroenterology, 2004, 127, 1391-1400.	0.6	30
1026	SIGNALING PATHWAYS IN INTESTINAL DEVELOPMENT AND CANCER. Annual Review of Cell and Developmental Biology, 2004, 20, 695-723.	4.0	453
1027	The Diminishing Role of Surgery in the Treatment of Gastric Lymphoma. Annals of Surgery, 2004, 240, 28-37.	2.1	98
1028	Clinical course of lung cancer in patients with chronic kidney disease. Lung Cancer, 2004, 43, 297-300.	0.9	20
1029	Small cell lung cancer: state of the art and future perspectives. Lung Cancer, 2004, 45, 105-117.	0.9	150
1030	Skin reactivity to histamine and expression of histamine receptors mRNA in lymphocytes of healthy subjects and non-small-cell lung cancer patients before and after surgery. Lung Cancer, 2004, 45, 31-38.	0.9	1
1031	First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer. Drugs, 2004, 64, 27-44.	4.9	21
1032	Prospective Randomized Phase III Trial of Etoposide/Cisplatin Versus High-Dose Epirubicin/Cisplatin in Small-Cell Lung Cancer. Clinical Lung Cancer, 2004, 6, 175-183.	1.1	31
1033	Association of Splenectomy With Postoperative Complications in Patients With Proximal Gastric and Gastroesophageal Junction Cancer. Annals of Surgical Oncology, 2004, 11, 682-689.	0.7	34
1034	Quality of life of 5-10 year breast cancer survivors diagnosed between age 40 and 49. Health and Quality of Life Outcomes, 2004, 2, 25.	1.0	116
1035	Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets. Cancer Research, 2004, 64, 2424-2433.	0.4	130
1036	Palliative Endovascular Interventions. Journal of Vascular and Interventional Radiology, 2004, 15, P149-P152.	0.2	0
1037	Melanoma of the head and neck: current concepts in staging, diagnosis, and management. Surgical Oncology Clinics of North America, 2004, 13, 201-229.	0.6	30
1038	Robust Classification of Renal Cell Carcinoma Based on Gene Expression Data and Predicted Cytogenetic Profiles. Cancer Research, 2004, 64, 4117-4121.	0.4	99
1039	Chromosomal Alterations during Lymphatic and Liver Metastasis Formation of Colorectal Cancer. Neoplasia, 2004, 6, 23-28.	2.3	72
1040	Resection of superior sulcus tumors (posterior approach). Thoracic Surgery Clinics, 2004, 14, 217-228.	0.4	21
1041	Transcriptional Repression of Catalase in Mouse Skin Tumor Progression. Neoplasia, 2004, 6, 440-448.	2.3	60

#	Article	IF	CITATIONS
1042	DC therapy for prostate cancer. Cytotherapy, 2004, 6, 164-171.	0.3	6
1043	Primary care update on kidney and bladder cancer. Medical Clinics of North America, 2004, 88, 309-328.	1.1	1
1044	Image-guided ablation of renal cell carcinoma. Magnetic Resonance Imaging Clinics of North America, 2004, 12, 429-447.	0.6	33
1045	A Diagnostic Test for Prostate Cancer From Gene Expression Profiling Data. Journal of Urology, 2004, 171, 903-906.	0.2	35
1046	Improving health care for adult survivors of childhood cancer: recommendations from a delphi panel of health policy experts. Health Policy, 2004, 69, 169-178.	1.4	97
1047	Novel molecular aspects of prostate carcinogenesis. Biomedicine and Pharmacotherapy, 2004, 58, 10-16.	2.5	6
1048	Analysis of potential prognostic factors in 111 patients with ovarian cancer. Cancer Letters, 2004, 206, 97-106.	3.2	26
1049	Pro-oxidant environment of the colon compared to the small intestine may contribute to greater cancer susceptibility. Cancer Letters, 2004, 208, 155-161.	3.2	61
1050	CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Letters, 2004, 214, 231-241.	3.2	89
1051	Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung. European Journal of Cancer, 2004, 40, 1082-1094.	1.3	68
1052	Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. European Journal of Cancer, 2004, 40, 1825-1836.	1.3	313
1053	Does fluid hysteroscopy increase the stage or worsen the prognosis in patients with endometrial cancer?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 115, 211-215.	0.5	41
1054	Associations between breast cancer risk factors and religious practices in Utah. Preventive Medicine, 2004, 38, 28-38.	1.6	21
1055	A pragmatic and successful approach to treating nonsmall-cell lung carcinoma. AORN Journal, 2004, 80, 839-857.	0.2	5
1056	The androgen receptor: a potential target for therapy of prostate cancer. Steroids, 2004, 69, 79-85.	0.8	65
1057	A New Assay to Screen for Head and Neck Squamous cell Carcinoma Using the Tumor Marker Metallopanstimulin. Otolaryngology - Head and Neck Surgery, 2004, 131, 466-471.	1.1	12
1058	Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer. Urology, 2004, 63, 492-498.	0.5	10
1059	Impact of surgical volume on mortality and length of stay after nephrectomy. Urology, 2004, 63, 862-867.	0.5	68

#	ARTICLE	IF	CITATIONS
1060	Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology, 2004, 64, 157-161.	0.5	21
1061	General versus spinal anesthesia in patients undergoing radical retropubic prostatectomy: results of a prospective, randomized study. Urology, 2004, 64, 95-100.	0.5	52
1062	Second neoplasms in survivors of childhood and adolescent cancer are often treatable. Journal of Adolescent Health, 2004, 34, 324-329.	1.2	6
1063	Effects of 3H-1,2-dithiole-3-thione, 1,4-phenylenebis(methylene)selenocyanate, and selenium-enriched yeast individually and in combination on benzo[a]pyrene-induced mutagenesis in oral tissue and esophagus in lacZ mice. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2004, 559. 199-210.	0.9	12
1064	Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models*1. Human Pathology, 2004, 35, 798-807.	1.1	13
1065	Effect of Onosma echioides on DMBA/croton oil mediated carcinogenic response, hyperproliferation and oxidative damage in murine skin. Life Sciences, 2004, 75, 2391-2410.	2.0	27
1066	Gadd $45\hat{l}^3$ is androgen-responsive and growth-inhibitory in prostate cancer cells. Molecular and Cellular Endocrinology, 2004, 213, 121-129.	1.6	14
1067	BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide. Journal of Clinical Neuroscience, 2004, 11, 374-375.	0.8	11
1068	Survival after resection for lung cancer is the outcome that matters. American Journal of Surgery, 2004, 188, 598-602.	0.9	27
1069	Stratégies thérapeutiques actuelles du cancer de la prostate hormonorésistant. Annales D'Urologie, 2004, 38, 85-102.	0.1	0
1071	Surgical resection of lung metastases from epithelial tumors. Annals of Thoracic Surgery, 2004, 77, 431-437.	0.7	43
1072	Percutaneous venovenous Perfusion-Induced systemic hyperthermia for lung cancer: a phase I safety study. Annals of Thoracic Surgery, 2004, 77, 1916-1925.	0.7	26
1073	Do fluorescence decays remitted from tissues accurately reflect intrinsic fluorophore lifetimes?. Optics Letters, 2004, 29, 1512.	1.7	36
1074	Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 20-24.	0.8	26
1075	Gender, racial and age differences in bladder cancer incidence and mortality. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 86-92.	0.8	147
1076	Molecular therapy in pancreatic adenocarcinoma. Lancet Oncology, The, 2004, 5, 541-549.	5.1	69
1077	Increased expression of NF-κB subunits in human pancreatic cancer cells1,2. Journal of Surgical Research, 2004, 118, 9-14.	0.8	77
1078	Metachronous and Synchronous Lung Tumors: Five Malignant Lung Pathologies in 1 Patient During 7 Years. Annals of Thoracic Surgery, 2004, 78, 2154-2155.	0.7	9

#	Article	IF	CITATIONS
1079	A robotic system for transrectal needle insertion into the prostate with integrated ultrasound. , 2004, , .		30
1080	Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer and Metastasis Reviews, 2004, 23, 101-117.	2.7	429
1081	Changes in Psychological Distress of Women With Breast Cancer in Long-Term Remission and Their Husbands. Psychosomatics, 2004, 45, 58-68.	2.5	33
1082	Is there an association between multiple myeloma and prostate cancer?. Medical Hypotheses, 2004, 63, 226-231.	0.8	13
1083	Nursing roles in cancer prevention position statements. Seminars in Oncology Nursing, 2004, 20, 111-120.	0.7	7
1084	Accuracy of EUS in staging of T4 lung cancer. Gastrointestinal Endoscopy, 2004, 59, 345-348.	0.5	82
1085	Chemotherapy in Locally Advanced and Metastatic Bladder Cancer. European Urology Supplements, 2004, 3, 79-88.	0.1	0
1086	Consumption of dairy products and the risk of breast cancer: a review of the literature. American Journal of Clinical Nutrition, 2004, 80, 5-14.	2.2	129
1087	Long-Chain (n-3) Fatty Acid Intake and Risk of Cancers of the Breast and the Prostate: Recent Epidemiological Studies, Biological Mechanisms, and Directions for Future Research. Journal of Nutrition, 2004, 134, 3412S-342OS.	1.3	77
1088	Laparoscopic versus Open Nephrectomy for Renal Cell Carcinoma?. Scandinavian Journal of Surgery, 2004, 93, 132-136.	1.3	9
1089	Diagnosis, Clinical Staging, and Treatment of Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 185-190.	0.6	6
1090	Use of intensive care at the end of life in the United States: An epidemiologic study*. Critical Care Medicine, 2004, 32, 638-643.	0.4	1,732
1091	Prostatitis as a Risk Factor for Prostate Cancer. Epidemiology, 2004, 15, 93-99.	1.2	115
1092	Loss of β-Catenin Is Associated With Poor Survival in Ovarian Carcinomas. International Journal of Gynecological Pathology, 2004, 23, 337-346.	0.9	22
1093	Hepatic Artery Infusion Chemotherapy for Metastatic Colorectal Cancer to the Liver at the Lahey Clinic. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 376-383.	0.6	14
1094	DNA repair pathways in drug resistance in melanoma. Anti-Cancer Drugs, 2004, 15, 421-426.	0.7	48
1095	Acute and Chronic Results of Adjuvant Radiotherapy After Mastectomy and Transverse Rectus Abdominis Myocutaneous (TRAM) Flap Reconstruction for Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 389-394.	0.6	33
1096	Oral Cancer Information in Health Education Textbooks. Journal of Cancer Education, 2004, 19, 12-16.	0.6	10

#	Article	IF	CITATIONS
1097	A new partial volume segmentation approach to extract bladder wall for computer-aided detection in virtual cystoscopy. , 2004 , , .		16
1098	Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells. Anti-Cancer Drugs, 2004, 15, 559-568.	0.7	16
1099	Colorectal Cancer Knowledge, Perceptions, and Behaviors in African Americans. Cancer Nursing, 2004, 27, 206-215.	0.7	133
1100	Human Leukocyte Antigens as Genetic Markers in Greek Patients With Sporadic Pancreatic Cancer. Pancreas, 2004, 29, 41-44.	0.5	4
1101	Progression of Malignancy in Clear Cell Renal Cell Carcinomas. Scandinavian Journal of Surgery, 2004, 93, 112-117.	1.3	8
1102	Role of vitamins in the risk, prevention, and treatment of breast cancer. Current Opinion in Obstetrics and Gynecology, 2004, 16, 19-25.	0.9	38
1103	Pancreatic Enzyme Extract Improves Survival in Murine Pancreatic Cancer. Pancreas, 2004, 28, 401-412.	0.5	12
1104	Editorial Overview: Reduced-intensity allogeneic hematopoietic cell transplantation: shifting paradigms, new definitions, new challenges. Current Opinion in Organ Transplantation, 2004, 9, 36-38.	0.8	0
1105	Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Current Opinion in Urology, 2004, 14, 295-300.	0.9	16
1106	Management of brain metastases in patients with melanoma. Current Opinion in Oncology, 2004, 16, 161-166.	1.1	54
1107	Accuracy of Breath-Hold Magnetic Resonance Imaging in Preoperative Staging of Organ-Confined Renal Cell Carcinoma. Journal of Computer Assisted Tomography, 2004, 28, 327-332.	0.5	20
1109	Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood, 2004, 103, 3516-3520.	0.6	33
1110	A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 2004, 105, 959-967.	0.6	371
1111	Population screening for lung cancer. British Journal of Hospital Medicine, 2004, 65, 404-411.	0.3	2
1112	Emerging drugs in pancreatic cancer. Expert Opinion on Emerging Drugs, 2004, 9, 73-89.	1.0	2
1113	Actual and Predicted Postoperative Changes in Lung Function After Pneumonectomy. Chest, 2004, 125, 1735-1741.	0.4	30
1114	A Novel Natural Inhibitor of Extracellular Signal-Regulated Kinases and Human Breast Cancer Cell Growth. Experimental Biology and Medicine, 2004, 229, 163-169.	1.1	72
1116	Sentinel Node Biopsy for High-Risk Nonmelanoma Cutaneous Malignancy. Archives of Dermatology, 2004, 140, 75-9.	1.7	107

#	Article	IF	CITATIONS
1118	The Collaborative Ocular Melanoma Study: An Overview. Cancer Control, 2004, 11, 304-309.	0.7	114
1119	Enhancing Skin Self-Examination with Imaging: Evaluation of a Mole-Mapping Program. Journal of Cutaneous Medicine and Surgery, 2004, 8, 1-5.	0.6	21
1120	Prostate Cancer Incidence and Mortality Rates and Trends in the United States and Canada. Public Health Reports, 2004, 119, 174-186.	1.3	112
1121	The Impact of C-kit and Ki-67 Expression on Patients Prognosis in Advanced Ovarian Serous Carcinoma. International Journal of Gynecological Pathology, 2005, 24, 228-234.	0.9	20
1122	Analytical Validation and Interobserver Reproducibility of EnzMet GenePro. American Journal of Surgical Pathology, 2005, 29, 1505-1511.	2.1	46
1123	High-performance broad-band spectroscopy for breast cancer risk assessment., 2005,,.		1
1124	Radiofrequency Ablation of Primary Lung Cancer. Chest, 2005, 128, 3507-3511.	0.4	82
1125	Contemporary Issues in Staging of Lung Cancer. , 2005, , 31-44.		0
1126	The Molecular Pathogenesis of Human Prostate Cancer., 2005,, 34-44.		2
1127	The Notch Signaling Pathway Is Related to Neurovascular Progression of Pancreatic Cancer. Annals of Surgery, 2005, 242, 791-801.	2.1	89
1128	Neighborhood Racial Composition, Neighborhood Poverty, and the Spatial Accessibility of Supermarkets in Metropolitan Detroit. American Journal of Public Health, 2005, 95, 660-667.	1.5	725
1129	Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anti-Cancer Drugs, 2005, 16, 1017-1021.	0.7	22
1130	A Phase II Study of Alternating Cycles of Split Course Radiation Therapy and Gemcitabine Chemotherapy for Inoperable Pancreatic or Biliary Tract Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 234-241.	0.6	24
1131	The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast. American Journal of Surgical Pathology, 2005, 29, 1221-1227.	2.1	119
1133	Automatic Segmentation of Pancreatic Tumors in Computed Tomography., 2005,, 183-228.		2
1134	Ultrasonography Using Simple Diagnostic Criteria vs Palpation for the Detection of Regional Lymph Node Metastases of Melanoma. Archives of Dermatology, 2005, 141, 183-9.	1.7	47
1135	Hyperbaric oxygenation for tumour sensitisation to radiotherapy., 2005,, CD005007.		22
1136	Acute promyelocytic leukemia: A model of molecular target based therapy. Hematology, 2005, 10, 270-280.	0.7	19

#	Article	IF	CITATIONS
1137	Similar Long-term Survival of Elderly Patients With Non-small Cell Lung Cancer Treated With Lobectomy or Wedge Resection Within the Surveillance, Epidemiology, and End Results Database. Chest, 2005, 128, 237-245.	0.4	312
1139	Cancro do pulmão – O que mudou em duas décadas. Revista Portuguesa De Pneumologia, 2005, 11, 135-154.	0.7	4
1140	A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2–independent mechanism. Blood, 2005, 105, 2504-2509.	0.6	67
1141	Smoking and Timing of Cessation. Chest, 2005, 127, 1977-1983.	0.4	250
1142	A predictive mathematical model in the recurrence of bladder cancer. Mathematical and Computer Modelling, 2005, 42, 621-634.	2.0	6
1143	Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1444-1450.	0.4	68
1144	Identification of peptides that bind to irradiated pancreatic tumor cells. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1497-1503.	0.4	10
1145	Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 389-393.	1.0	47
1146	Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 271-276.	1.0	57
1147	Gleason Scoring Varies Among Pathologists and this Affects Clinical Risk in Patients with Prostate Cancer. Clinical Oncology, 2005, 17, 655-658.	0.6	29
1148	A Role for Hath1, a bHLH Transcription Factor, in Colon Adenocarcinoma. Annals of the New York Academy of Sciences, 2005, 1059, 174-183.	1.8	25
1149	Photodynamic Therapy for Pancreatic and Biliary Tract Carcinoma. International Journal of Gastrointestinal Cancer, 2005, 35, 001-014.	0.4	29
1150	Liver Resection after Irinotecan, 5-Fluorouracil, and Folinic Acid for Patients with Unresectable Colorectal Liver Metastases: A Multicenter Phase II Study by the Cancer Therapeutic Research Group. Medical Oncology, 2005, 22, 303-312.	1.2	53
1151	Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma. International Journal of Gynecological Cancer, 2005, 15, 1073-1080.	1.2	16
1152	Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer. International Journal of Gynecological Cancer, 2005, 15, 319-324.	1.2	135
1153	Management of advanced renal cancer. Kidney International, 2005, 67, 2069-2082.	2.6	14
1154	Factors contributing to the racial differences in prostate cancer mortality. BJU International, 2005, 96, 1247-1252.	1.3	60
1155	Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1913-1919.	1.4	69

#	Article	IF	CITATIONS
1156	Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology, 2005, 47, 141-146.	1.6	540
1157	Electrogene transfer of an Epstein-Barr virus-based plasmid replicon vector containing the diphtheria toxin A gene suppresses mammary carcinoma growth in SCID mice. Cancer Science, 2005, 96, 434-440.	1.7	8
1158	Hypermethylation of the $5\hat{a} \in ^2$ CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. British Journal of Cancer, 2005, 92, 760-769.	2.9	43
1159	Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. British Journal of Cancer, 2005, 92, 1051-1054.	2.9	15
1160	NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nature Reviews Drug Discovery, 2005, 4, 1015-1026.	21.5	207
1161	Internet websites selling herbal treatments for erectile dysfunction. International Journal of Impotence Research, 2005, 17, 196-200.	1.0	10
1162	VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-κB-dependent mechanism. Oncogene, 2005, 24, 1563-1570.	2.6	55
1163	PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene, 2005, 24, 1111-1116.	2.6	82
1164	Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene, 2005, 24, 4442-4449.	2.6	157
1165	The role of TGF- \hat{l}^2 and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene, 2005, 24, 5775-5789.	2.6	153
1166	Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology. Journal of Oral Pathology and Medicine, 2005, 34, 77-86.	1.4	30
1167	Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses. Cancer Genetics and Cytogenetics, 2005, 161, 140-145.	1.0	10
1168	Benzene and the hemopoietic stem cell. Chemico-Biological Interactions, 2005, 153-154, 217-222.	1.7	26
1169	Pfannenstiel versus Vertical Laparotomy in Patients Undergoing Radical Retropubic Prostatectomy with Spinal Anesthesia: Results of a Prospective, Randomized Trial. European Urology, 2005, 47, 202-208.	0.9	15
1170	Using Tree Analysis Pattern and SELDI-TOF-MS to Discriminate Transitional Cell Carcinoma of the Bladder Cancer from Noncancer Patients. European Urology, 2005, 47, 456-462.	0.9	63
1171	Transient Receptor Potential Vanilloid Type 1 (TRPV1) Expression Changes from Normal Urothelium to Transitional Cell Carcinoma of Human Bladder. European Urology, 2005, 48, 691-698.	0.9	97
1172	The imaging manifestations of lung cancer. Seminars in Roentgenology, 2005, 40, 98-108.	0.2	7
1173	Early Diagnosis of Prostate Cancer: Why and How?. Apollo Medicine, 2005, 2, 201-204.	0.0	0

#	Article	IF	Citations
1174	Understanding breast cancer risk - where do we stand in 2005?. Journal of Cellular and Molecular Medicine, 2005, 9, 208-221.	1.6	369
1175	Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib. Journal of Controlled Release, 2005, 104, 167-179.	4.8	16
1176	Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. Surgery, 2005, 138, 422-430.	1.0	23
1177	The ABC's of Complex Maxillofacial Reconstruction. Journal of Oral and Maxillofacial Surgery, 2005, 63, 138.	0.5	0
1178	First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study. BMC Cancer, 2005, 5, 151.	1.1	22
1179	Clonal selection of adenocarcinoma of the lung as determined by loss of heterozygosity. Experimental and Molecular Pathology, 2005, 78, 135-139.	0.9	11
1180	Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecologic Oncology, 2005, 96, 227-231.	0.6	50
1181	Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecologic Oncology, 2005, 96, 287-295.	0.6	154
1182	Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecologic Oncology, 2005, 97, 924-927.	0.6	98
1183	Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Gynecologic Oncology, 2005, 97, 365-373.	0.6	36
1184	Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecologic Oncology, 2005, 99, 26-35.	0.6	87
1185	Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin–paclitaxel chemotherapy. Gynecologic Oncology, 2005, 99, 343-347.	0.6	20
1186	Erythropoeitin receptor function and expression in epithelial ovarian carcinoma. Gynecologic Oncology, 2005, 99, 571-577.	0.6	36
1187	Who should operate on patients with ovarian cancer? An evidence-based review. Gynecologic Oncology, 2005, 99, 447-461.	0.6	168
1188	Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. Journal of Cellular Physiology, 2005, 202, 880-890.	2.0	54
1189	The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice. Genes Chromosomes and Cancer, 2005, 44, 365-372.	1.5	40
1190	Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology, 2005, 41, 196-203.	3.6	55
1191	Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. International Journal of Cancer, 2005, 114, 806-816.	2.3	701

#	Article	IF	CITATIONS
1192	Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. International Journal of Cancer, 2005, 116, 914-919.	2.3	71
1193	Radical cystectomy in the elderly. Cancer, 2005, 103, 546-552.	2.0	61
1194	Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer, 2005, 103, 1165-1171.	2.0	120
1195	A novel automated screening and interpretation process for cervical cytology using the internet transmission of low-resolution images. Cancer, 2005, 105, 199-206.	2.0	25
1196	Closing the divide: Diverse populations and cancer survivorship. Cancer, 2005, 104, 2577-2583.	2.0	43
1197	Liposome-encapsulated curcumin. Cancer, 2005, 104, 1322-1331.	2.0	589
1198	Background features of endometrial carcinoma on ThinPrep® cytology. Diagnostic Cytopathology, 2005, 33, 162-165.	0.5	9
1199	Breast cancer in women with HIV/AIDS: Report of five cases with a review of the literature. Journal of Surgical Oncology, 2005, 89, 23-27.	0.8	40
1200	SAGE profiling of UV-induced mouse skin squamous cell carcinomas, comparison with acute UV irradiation effects. Molecular Carcinogenesis, 2005, 42, 40-52.	1.3	40
1201	In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 668-673.	3.3	107
1202	In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1296-1304.	3.3	23
1203	Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunology, Immunotherapy, 2005, 54, 254-264.	2.0	186
1204	Tissue MicroArray Analyses of Pancreatic Duodenal Homeobox-1 in Human Cancers. World Journal of Surgery, 2005, 29, 334-338.	0.8	43
1205	Access to Care and Satisfaction in Colorectal Cancer Patients. World Journal of Surgery, 2005, 29, 1444-1451.	0.8	30
1206	Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemotherapy and Pharmacology, 2005, 55, 189-196.	1.1	25
1208	Assessing task ?burden? of daily activities requiring upper body function among women following breast cancer treatment. Supportive Care in Cancer, 2005, 13, 255-265.	1.0	20
1209	Diabetes mellitus: a risk factor for pancreatic cancer?. Langenbeck's Archives of Surgery, 2005, 390, 66-72.	0.8	23
1210	Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. International Journal of Clinical Oncology, 2005, 10, 405-410.	1.0	65

#	Article	IF	Citations
1211	Interpretation of Magnetic Resonance Imaging for Locally Advanced Rectal Carcinoma After Preoperative Chemoradiation Therapy. Diseases of the Colon and Rectum, 2005, 48, 23-28.	0.7	157
1212	The treatment of malignant gliomas. Current Treatment Options in Neurology, 2005, 7, 293-303.	0.7	15
1213	Imatinib mesylate and its potential implications for gynecologic cancers. Current Treatment Options in Oncology, 2005, 6, 115-120.	1.3	10
1214	Adjuvant chemotherapy for transitional cell carcinoma of the bladder: Paradigms for the design of clinical trials. Current Oncology Reports, 2005, 7, 207-214.	1.8	2
1215	Prostate Cancer in the Elderly. International Urology and Nephrology, 2005, 37, 797-806.	0.6	7
1216	Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. Investigational New Drugs, 2005, 23, 563-567.	1.2	9
1217	A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study. Investigational New Drugs, 2005, 23, 485-487.	1.2	132
1218	Up-regulation of neuropoiesis generating glial progenitors that infiltrate ratintracranial glioma. Journal of Neuro-Oncology, 2005, 71, 245-255.	1.4	19
1219	The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study. Breast Cancer Research and Treatment, 2005, 93, 61-66.	1.1	63
1220	Interaction Between Estrogen Receptor Alpha, Ionizing Radiation and (anti-) Estrogens in Breast Cancer Cells. Breast Cancer Research and Treatment, 2005, 93, 207-215.	1.1	21
1221	Colorectal cancer screening in average risk individuals. Cancer Causes and Control, 2005, 16, 171-188.	0.8	39
1222	Are risk factors for breast cancer associated with follow-up procedures in diverse women with abnormal mammography?. Cancer Causes and Control, 2005, 16, 245-253.	0.8	8
1223	Carcinoembryonic antigen promotes tumor cell survival in liver through an IL-10-dependent pathway. Clinical and Experimental Metastasis, 2005, 21, 709-717.	1.7	37
1224	An Orthotopic Model of Lung Cancer to Analyze Primary and Metastatic NSCLC Growth in Integrin $\hat{l}\pm 1$ -Null Mice. Clinical and Experimental Metastasis, 2005, 22, 185-193.	1.7	24
1225	C/EBP? is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate, 2005, 63, 143-154.	1.2	45
1226	Ethnic and racial differences in prostate stromal estrogen receptor α. Prostate, 2005, 65, 101-109.	1.2	23
1227	Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry. Proteomics, 2005, 5, 2680-2688.	1.3	43
1228	Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS. Proteomics, 2005, 5, 4980-4993.	1.3	37

#	Article	IF	CITATIONS
1229	Estimating the growth rates of primary lung tumours from samples with missing measurements. Statistics in Medicine, 2005, 24, 1117-1134.	0.8	7
1231	Selective Sentinel Lymphadenectomy for Gynecologic Cancer. Cancer Treatment and Research, 2005, 127, 167-185.	0.2	0
1232	Pap Smear Rates among Haitian Immigrant Women in Eastern Massachusetts. Public Health Reports, 2005, 120, 133-139.	1.3	29
1233	Cardiovascular Effects of Cancer Therapy. , 2005, , 133-159.		4
1234	Chemoprevention of Colorectal Cancer: Ready for Routine Use?., 2005, 166, 213-230.		27
1235	Dietary Carbohydrate Intake Is Not Associated with the Breast Cancer Incidence Rate Ratio in Postmenopausal Danish Women. Journal of Nutrition, 2005, 135, 124-128.	1.3	60
1236	Prostate Cancer and the Gay Male. Journal of Gay and Lesbian Psychotherapy, 2005, 9, 9-27.	0.4	17
1237	The Spectrum of Pediatric Tumors in Infancy, Childhood, and Adolescence: A Comprehensive Review with Emphasis on Special Techniques in Diagnosis. Ultrastructural Pathology, 2005, 29, 175-202.	0.4	20
1238	Toluidine Blue Staining Identifies High-Risk Primary Oral Premalignant Lesions with Poor Outcome. Cancer Research, 2005, 65, 8017-8021.	0.4	143
1239	VSGP/F-Spondin: A New Ovarian Cancer Marker. Tumor Biology, 2005, 26, 245-257.	0.8	24
1240	Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model. Carcinogenesis, 2005, 26, 1256-1262.	1,3	96
1241	Computer-Aided Diagnosis of Mammographic Calcification Clusters: Impact of Segmentation. , 2005, , 707-751.		1
1242	Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen Has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia. Journal of Clinical Oncology, 2005, 23, 9387-9393.	0.8	223
1243	Surveillance Patterns and Polyp Recurrence following Diagnosis and Excision of Colorectal Polyps in a Medicare Population. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 417-421.	1.1	20
1244	Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases. Journal of Clinical Oncology, 2005, 23, 1473-1482.	0.8	274
1245	Protein Expression and Prognostic Value of Genes in the erb-b Signaling Pathway in Advanced Ovarian Carcinomas. American Journal of Clinical Pathology, 2005, 124, 392-401.	0.4	46
1246	X-Linked Inhibitor of Apoptosis Protein Expression Level in Colorectal Cancer Is Regulated by Hepatocyte Growth Factor/C-Met Pathway via Akt Signaling. Clinical Cancer Research, 2005, 11, 7621-7628.	3.2	47
1247	Preclinical Evaluation of Gemcitabine Combination Regimens for Application in Acute Myeloid Leukemia. Clinical Cancer Research, 2005, 11, 4225-4233.	3.2	24

#	Article	IF	CITATIONS
1248	Self-Renewal and Cancer of the Gut: Two Sides of a Coin. Science, 2005, 307, 1904-1909.	6.0	642
1249	S100P Promotes Pancreatic Cancer Growth, Survival, and Invasion. Clinical Cancer Research, 2005, 11, 5356-5364.	3.2	212
1250	Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy. Clinical Cancer Research, 2005, 11 , 5300-5309.	3.2	92
1251	Overexpression of Platelet-Derived Growth Factor Receptor \hat{l}_{\pm} in Endothelial Cells of Hepatocellular Carcinoma Associated with High Metastatic Potential. Clinical Cancer Research, 2005, 11, 8557-8563.	3.2	90
1252	Feasibility of US-guided High-Intensity Focused Ultrasound Treatment in Patients with Advanced Pancreatic Cancer: Initial Experience. Radiology, 2005, 236, 1034-1040.	3.6	252
1253	Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients. Clinical Cancer Research, 2005, 11, 7470-7479.	3.2	53
1254	AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice. Clinical Cancer Research, 2005, 11, 1963-1973.	3.2	53
1255	Proteomic Profiling of Pancreatic Cancer for Biomarker Discovery. Molecular and Cellular Proteomics, 2005, 4, 523-533.	2.5	128
1256	Binding of Activated α2-Macroglobulin to Its Cell Surface Receptor GRP78 in 1-LN Prostate Cancer Cells Regulates PAK-2-dependent Activation of LIMK. Journal of Biological Chemistry, 2005, 280, 26278-26286.	1.6	158
1257	Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis, 2005, 27, 23-31.	1.3	189
1258	How will lung cancer be treated in the future?. Future Oncology, 2005, 1, 551-559.	1.1	1
1259	Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets. Expert Review of Anticancer Therapy, 2005, 5, 1011-1022.	1.1	3
1260	Efficacy of beta-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1. Cancer Biology and Therapy, 2005, 4, 102-109.	1.5	153
1261	Management of Hepatic Metastases from Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2005, 18, 215-223.	0.5	74
1262	Laparoscopic Splenectomy for Metastatic Squamous Cell Cancer of the Neck. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2005, 15, 383-386.	0.5	8
1263	Establishing a Murine Pancreatic Cancer CaSm Model: Up-regulation of CaSm Is Required for the Transformed Phenotype of Murine Pancreatic Adenocarcinoma. Molecular Therapy, 2005, 11, 363-372.	3.7	9
1264	Characterization of the Bystander Effect of Somatostatin Receptor sst2 After In Vivo Gene Transfer into Human Pancreatic Cancer Cells. Human Gene Therapy, 2005, 16, 1175-1193.	1.4	34
1265	CYP3A43 Pro340Ala Polymorphism and Prostate Cancer Risk in African Americans and Caucasians. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1257-1261.	1.1	36

#	Article	IF	CITATIONS
1266	Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer. Journal of Clinical Oncology, 2005, 23, 1736-1750.	0.8	79
1267	Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk. Clinical Cancer Research, 2005, 11, 6505-6511.	3.2	212
1268	Phase III Study of Matrix Metalloproteinase Inhibitor Prinomastat in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 842-849.	0.8	190
1269	Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. Gut, 2005, 54, 807-813.	6.1	51
1270	Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Annals of Oncology, 2005, 16, 81-89.	0.6	36
1271	Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 5918-5928.	0.8	30
1272	Impact of Hysterectomy on Endometrial Carcinoma Rates in the United States. Journal of the National Cancer Institute, 2005, 97, 1700-1702.	3.0	50
1273	Genistein Inhibits Insulin-Like Growth Factor-I Receptor Signaling in HT-29 Human Colon Cancer Cells: A Possible Mechanism of the Growth Inhibitory Effect of Genistein. Journal of Medicinal Food, 2005, 8, 431-438.	0.8	63
1274	Preventing and detecting oral cancer. Journal of the American Dental Association, 2005, 136, 594-601.	0.7	62
1275	Environmental influences in cancer aetiology. Journal of Nutritional and Environmental Medicine, 2005, 15, 56-114.	0.1	16
1276	Improving Palliative Care For Patients In The Intensive Care Unit. Journal of Palliative Medicine, 2005, 8, 840-854.	0.6	49
1277	A Comparison of Multi-Layer Neural Network and Logistic Regression in Hereditary Non-Polyposis Colorectal Cancer Risk Assessment. , 2005, 2005, 2417-20.		1
1278	Prognostic Factors in a Recent Series of Patients Treated with Radical Cystectomy for Bladder Cancer. Urologia Internationalis, 2005, 75, 10-16.	0.6	7
1279	TWIST2 Demonstrates Differential Methylation in Immunoglobulin Variable Heavy Chain Mutated and Unmutated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 3877-3885.	0.8	92
1280	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. Cancer Research, 2005, 65, 1213-1222.	0.4	202
1281	Clinical Recognition of Actinic Keratoses in a High-Risk Population. Archives of Dermatology, 2005, 141, 507-9.	1.7	58
1282	Ultrasound guided cytological aspiration of supraclavicular lymph nodes in patients with suspected lung cancer. Thorax, 2005, 60, 229-233.	2.7	54
1283	Treatment Effects in Pediatric Soft Tissue and Bone Tumors. American Journal of Clinical Pathology, 2005, 123, 75-90.	0.4	60

#	Article	IF	CITATIONS
1284	Checkpoint Kinase 1 Regulates Diallyl Trisulfide-induced Mitotic Arrest in Human Prostate Cancer Cells. Journal of Biological Chemistry, 2005, 280, 28519-28528.	1.6	91
1285	Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Annals of Oncology, 2005, 16, 425-429.	0.6	145
1286	An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9901-9906.	3.3	102
1287	Cystic Renal Neoplasia Following Conditional Inactivation of Apc in Mouse Renal Tubular Epithelium. Journal of Biological Chemistry, 2005, 280, 3938-3945.	1.6	124
1288	An Investigation of the Effects of Late-Onset Dietary Restriction on Prostate Cancer Development in the TRAMP Mouse. Toxicologic Pathology, 2005, 33, 386-397.	0.9	41
1289	Characterization of Chemical Constituents in Scutellaria baicalensis with Antiandrogenic and Growth-Inhibitory Activities toward Prostate Carcinoma. Clinical Cancer Research, 2005, 11, 3905-3914.	3.2	126
1290	Dietary Supplementation with Silymarin Inhibits 3,2'-Dimethyl-4-Aminobiphenyl-Induced Prostate Carcinogenesis in Male F344 Rats. Clinical Cancer Research, 2005, 11, 4962-4967.	3.2	31
1291	Cancer Gene Therapy. Technology in Cancer Research and Treatment, 2005, 4, 315-330.	0.8	32
1292	Soft-Tissue Sarcomas of the Chest Wall. Chest, 2005, 127, 902-908.	0.4	71
1293	Plasma Gelatinase Activity Does Not Reflect Disease Activity after Operation for Colorectal Cancer. Oncology, 2005, 68, 256-262.	0.9	6
1294	Alterations of Rb Pathway Components Are Frequent Events in Patients with Oral Epithelial Dysplasia and Predict Clinical Outcome in Patients with Squamous Cell Carcinoma. Oncology, 2005, 68, 314-325.	0.9	82
1295	Prostate Cancer Relapse after Therapy with Curative Intention: A Diagnostic and Therapeutic Dilemma. Oncology Research and Treatment, 2005, 28, 361-366.	0.8	15
1296	Microarray Analysis of Ovarian Cancer. , 0, , .		7
1298	Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomedicine and Pharmacotherapy, 2005, 59, S276-S280.	2.5	68
1299	CD24 and human carcinoma: tumor biological aspects. Biomedicine and Pharmacotherapy, 2005, 59, S351-S354.	2.5	97
1300	Decitabine in Chronic Leukemias. Seminars in Hematology, 2005, 42, S43-S49.	1.8	17
1301	Combined-Modality Therapy With Gemcitabine and Radiotherapy as a Bladder Preservation Strategy: Results of a Phase I Trial. Journal of Urology, 2005, 173, 1535-1535.	0.2	0
1303	Endoscopic ultrasound and staging of non–small cell lung cancer. Gastrointestinal Endoscopy Clinics of North America, 2005, 15, 157-167.	0.6	10

#	Article	IF	CITATIONS
1304	Molecular Diagnosis of Solid and Cystic Lesions of the Pancreas. Clinics in Laboratory Medicine, 2005, 25, 101-116.	0.7	16
1305	Analysis of promoter methylation in stool: A novel method for the detection of colorectal cancer. Clinical Gastroenterology and Hepatology, 2005, 3, 142-149.	2.4	113
1306	Gastrointestinal, Pancreatic, and Hepatic Cancer During Pregnancy. Obstetrics and Gynecology Clinics of North America, 2005, 32, 641-660.	0.7	15
1307	Alcohol in Hepatocellular Cancer. Clinics in Liver Disease, 2005, 9, 151-169.	1.0	67
1308	Immunoprofiles of 11 Biomarkers Using Tissue Microarrays Identify Prognostic Subgroups in Colorectal Cancer. Neoplasia, 2005, 7, 741-747.	2.3	72
1309	Adeno-Associated Virus 2-Mediated Intratumoral Prostate Cancer Gene Therapy: Long-Term Maspin Expression Efficiently Suppresses Tumor Growth. Human Gene Therapy, 2005, 16, 699-710.	1.4	48
1310	Immunotherapy for gynaecological malignancies. Expert Opinion on Biological Therapy, 2005, 5, 1193-1210.	1.4	31
1311	A Review of Evidence-Based Treatment of Stage IIB to Stage IV Melanoma. Cancer Investigation, 2005, 23, 323-337.	0.6	5
1312	The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opinion on Therapeutic Targets, 2005, 9, 769-790.	1.5	27
1313	Tumor Motion Control in the Treatment of Non Small Cell Lung Cancer. Cancer Investigation, 2005, 23, 129-133.	0.6	12
1314	The Safety and Accuracy of Sentinel-Node Biopsy in Early-Stage Invasive Breast Cancerâ€"Turkish Experience. Journal of Investigative Surgery, 2005, 18, 129-134.	0.6	3
1315	Treatment options in the management of ovarian cancer. Expert Opinion on Pharmacotherapy, 2005, 6, 743-754.	0.9	19
1316	Epidermal Growth Factor Receptor–Related Protein Inhibits Cell Growth and Induces Apoptosis of BxPC3 Pancreatic Cancer Cells. Cancer Research, 2005, 65, 3877-3882.	0.4	28
1317	The NF-κB/ÎκB signaling system: A molecular target in breast cancer therapy. Journal of Surgical Research, 2005, 123, 158-169.	0.8	189
1318	No apparent association between genetic polymorphisms (â^'102 C>T) and (â^'9 T>C) in the human manganese superoxide dismutase gene and gastric cancer1. Journal of Surgical Research, 2005, 124, 92-97.	0.8	27
1319	Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Human Pathology, 2005, 36, 562-570.	1.1	55
1320	Different effect of beta-carotene on proliferation of prostate cancer cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1740, 189-201.	1.8	29
1321	Differential control of growth, cell cycle progression, and expression of NF-κB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochemical and Biophysical Research Communications, 2005, 337, 224-231.	1.0	135

#	Article	IF	CITATIONS
1322	The role of carbonic anhydrase IX overexpression in kidney cancer. European Journal of Cancer, 2005, 41, 2935-2947.	1.3	145
1323	A comparison of two invasive techniques in the management of intractable pain due to inoperable pancreatic cancer: neurolytic celiac plexus block and videothoracoscopic splanchnicectomy. European Journal of Surgical Oncology, 2005, 31, 768-773.	0.5	58
1324	Pain predicts non-adherence to pap smear screening among middle-aged African American women. Preventive Medicine, 2005, 41, 439-445.	1.6	86
1325	Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends in Endocrinology and Metabolism, 2005, 16, 273-279.	3.1	88
1326	Gene expression profiling of renal cell carcinoma and clinical implications. Urology, 2005, 65, 231-237.	0.5	5
1327	Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 16-21.	0.8	23
1328	Predictors of prostate cancer screening among health fair participants. Public Health, 2005, 119, 686-693.	1.4	30
1329	Bilateral oophorectomy and premature menopause. American Journal of Medicine, 2005, 118, 131-135.	0.6	59
1330	Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Molecular Cancer, 2005, 4, 2.	7.9	51
1331	Synthesis and Identification of Small Molecules that Potently Induce Apoptosis in Melanoma Cells through G1 Cell Cycle Arrest. Journal of the American Chemical Society, 2005, 127, 8686-8696.	6.6	96
1333	Herpes Simplex Virus Amplicon Delivery of a Hypoxia-Inducible Soluble Vascular Endothelial Growth Factor Receptor (sFlk-1) Inhibits Angiogenesis and Tumor Growth in Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2005, 12, 1025-1036.	0.7	20
1334	Interventions to Improve Care during Withdrawal of Life-Sustaining Treatments. Journal of Palliative Medicine, 2005, 8, s-116-s-131.	0.6	24
1335	Progressive elimination of microinjected trehalose during mouse embryonic development. Reproductive BioMedicine Online, 2005, 10, 503-510.	1.1	27
1336	Stool screening for colorectal cancer: Molecular approaches. Gastroenterology, 2005, 128, 192-206.	0.6	221
1337	The adolescent and young adult gap in cancer care and outcome. Current Problems in Pediatric and Adolescent Health Care, 2005, 35, 182-217.	0.8	139
1338	Genetically engineered mouse models for lung cancer. Drug Discovery Today: Disease Models, 2005, 2, 35-40.	1.2	1
1339	Surgical mediastinal staging in daily practice. Lung Cancer, 2005, 47, 243-251.	0.9	39
1340	Hyperbaric oxygen therapy for late radiation tissue injury. , 2005, , CD005005.		68

#	Article	IF	CITATIONS
1341	Tumores óseos metastáticos. Revista Española De CirugÃa Ortopédica Y TraumatologÃa, 2005, 49, 326-333	.0.1	0
1342	VARDENAFIL IMPROVED PATIENT SATISFACTION WITH ERECTILE HARDNESS, ORGASMIC FUNCTION AND SEXUAL EXPERIENCE IN MEN WITH ERECTILE DYSFUNCTION FOLLOWING NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 2067-2071.	0.2	82
1343	Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic Cancer. Cancer Research, 2005, 65, 9064-9072.	0.4	224
1344	Clinical trials: The sensitizing side of Onyx-015. Gene Therapy, 2005, 12, 386-387.	2.3	6
1345	Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Research, 2005, 7, R862-70.	2.2	67
1346	Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Research, 2006, 8, R36.	2.2	30
1347	Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer. American Journal of Cancer, 2006, 5, 223-244.	0.4	2
1349	Current Treatment Strategies for Pancreatic Cancer in the Elderly. Drugs and Aging, 2006, 23, 403-410.	1.3	11
1350	A Serum Proteomic Pattern for the Detection of Colorectal Adenocarcinoma Using Surface Enhanced Laser Desorption and Ionization Mass Spectrometry. Cancer Investigation, 2006, 24, 747-753.	0.6	55
1351	Hsp90 Inhibitors in the Clinic., 2006, , 331-358.		88
1352	Gene Extraction and Identification Tumor/Cancer for Microarray Data of Ovarian Cancer., 2006, , .		3
1353	Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial. Journal of Clinical Oncology, 2006, 24, 3347-3353.	0.8	205
1355	Approach to the Complications of Treatment for Acute Leukemia in the Elderly. Seminars in Hematology, 2006, 43, 134-143.	1.8	6
1356	Connective tissue growth factor–specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Molecular Cancer Therapeutics, 2006, 5, 1108-1116.	1.9	144
1358	Incidencia y mortalidad del cáncer epitelial de ovario en el Ãrea Sanitaria de León. Progresos En Obstetricia Y Ginecologia, 2006, 49, 415-423.	0.0	1
1359	Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress. Molecular Cancer Research, 2006, 4, 575-589.	1.5	37
1361	Epidemiology of Adenocarcinoma of the Esophagogastric Junction. Surgical Oncology Clinics of North America, 2006, 15, 687-696.	0.6	45
1362	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. PET Clinics, 2006, 1, 347-352.	1.5	1

#	Article	IF	CITATIONS
1363	Primary care physician attitudes toward endoscopic screening for GERD symptoms and unsedated esophagoscopy. Gastrointestinal Endoscopy, 2006, 63, 228-233.	0.5	18
1364	4 Gy single fraction palliative radiotherapy for the treatment of painful recurrent soft plate carcinoma by high-dose-rate mold brachytherapy: A case report. Oral Oncology, 2006, 42, 305-307.	0.7	0
1365	The role of Rac1 in maintaining malignant phenotype of mouse skin tumor cells. Cancer Letters, 2006, 231, 326-338.	3.2	21
1366	Diorganotin(IV) and triorganotin(IV) complexes of meso-tetra(4-sulfonatophenyl)porphine induce apoptosis in A375 human melanoma cells. Cancer Letters, 2006, 238, 284-294.	3.2	12
1367	Postablative Reconstruction Techniques for Oral Cancer. Oral and Maxillofacial Surgery Clinics of North America, 2006, 18, 573-604.	0.4	0
1368	Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients. Cancer Treatment Reviews, 2006, 32, 325-332.	3.4	17
1369	Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?. Drug Resistance Updates, 2006, 9, 1-18.	6.5	46
1370	Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers. European Journal of Cancer, 2006, 42, 650-655.	1.3	11
1371	Male breast cancer: incompatible and incomparable. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2006, 3, 160-165.	0.3	15
1372	Differential Gene Expression in Patients Genetically Predisposed to Pancreatic Cancer. Journal of Surgical Research, 2006, 135, 317-322.	0.8	10
1373	Genitourinary malignancies. Update on Cancer Therapeutics, 2006, 1, 443-466.	0.9	1
1374	Epidemiology of gastric cancer. World Journal of Gastroenterology, 2006, 12, 354.	1.4	1,584
1375	Cytokeratin Profiles Identify Diagnostic Signatures in Colorectal Cancer Using Multiplex Analysis of Tissue Microarrays. Analytical Cellular Pathology, 2006, 28, 167-175.	0.7	42
1376	Tumor Infiltrating Lymphocytes in Uveal Melanoma: A Link with Clinical Behavior?. International Journal of Immunopathology and Pharmacology, 2006, 19, 205873920601900.	1.0	32
1378	 Effects of gamma-radiation on cell growth, cycle arrest, death, and superoxide dismutase expression by DU 145 human prostate cancer cells. Brazilian Journal of Medical and Biological Research, 2006, 39, 227-236.	0.7	27
1379	Aqueous Vernomia amygdalina Extracts Alter MCF-7 Cell Membrane Permeability and Efflux. International Journal of Environmental Research and Public Health, 2006, 3, 174-179.	1.2	21
1381	Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. Journal of Medical Investigation, 2006, 53, 9-19.	0.2	21
1382	The Role of Prevalence in the Diagnosis of Prostate Cancer. Cancer Control, 2006, 13, 158-168.	0.7	73

#	ARTICLE	IF	CITATIONS
1384	Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer?. Journal of Thoracic Oncology, 2006, 1, 564-570.	0.5	2
1385	Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study. Anti-Cancer Drugs, 2006, 17, 345-351.	0.7	4
1386	Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. Anti-Cancer Drugs, 2006, 17, 1193-1200.	0.7	6
1387	Maspin Expression Is Characteristic for Cisplatin-Sensitive Ovarian Cancer Cells and for Ovarian Cancer Cases of Longer Survival Rates. International Journal of Gynecological Pathology, 2006, 25, 131-139.	0.9	18
1388	Ethanol and the Tobacco-specific Carcinogen, NNK, Contribute to Signaling in Immortalized Human Pancreatic Duct Epithelial Cells. Pancreas, 2006, 33, 53-62.	0.5	31
1389	POPs in breast milk: women's breast cancer risk. Nutrition and Food Science, 2009, 39, 360-369.	0.4	1
1390	Phase II Study of Carboplatin Combined with Biweekly Docetaxel for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1 , 979-983.	0.5	1
1391	Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin. Anti-Cancer Drugs, 2006, 17, 1031-1039.	0.7	6
1392	A Phase I Dose Finding Study of Cisplatin, Gemcitabine, and Weekly Docetaxel for Patients With Advanced Transitional Cell Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 3-7.	0.6	1
1393	Pathologic Findings of Lung Tumors Diagnosed on Baseline CT Screening. American Journal of Surgical Pathology, 2006, 30, 606-613.	2.1	65
1394	A Phase II Study of Docetaxel, Doxorubicin, and Infusional 5-Fluorouracil in the Treatment of Patients With Locally Advanced Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 484-489.	0.6	3
1395	Aberrant Expression of PTCH (Patched Gene) and Smo (Smoothened Gene) in Human Pancreatic Cancerous Tissues and Its Association With Hyperglycemia. Pancreas, 2006, 33, 38-44.	0.5	19
1396	Update on epidemiology classification, and management of thyroid cancer. Libyan Journal of Medicine, 2006, 1, 83-95.	0.8	4
1397	Autoschizis of human ovarian carcinoma cells: Scanning electron and light microscopy of a new cell death induced by sodium ascorbate: Menadione treatment. Scanning, 2003, 25, 137-149.	0.7	16
1398	Differential expression and pathological significance of autocrine motility factor/glucose-6-phosphate isomerase expression in human lung carcinomas. Journal of Pathology, 2006, 210, 431-440.	2.1	15
1399	Gene therapy for prostate cancer: Current strategies and new cell-based approaches. Prostate, 2006, 66, 470-494.	1.2	26
1400	Quantitative proteomic profiling of pancreatic cancer juice. Proteomics, 2006, 6, 3871-3879.	1.3	118
1401	Identification and analysis of altered $\hat{l}\pm 1,6$ -fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics, 2006, 6, 5857-5867.	1.3	50

#	Article	IF	CITATIONS
1402	Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1596-1603.	1.4	45
1403	Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. International Journal of Gynecological Cancer, 2006, 16, 183-189.	1.2	91
1404	Rare case of stage IA epithelial ovarian cancer with bone as the first site of recurrent metastasis. International Journal of Gynecological Cancer, 2006, 16, 322-326.	1.2	8
1405	Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Science, 2006, 97, 938-944.	1.7	26
1406	Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. British Journal of Cancer, 2006, 95, 339-346.	2.9	47
1407	Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. British Journal of Cancer, 2006, 95, 705-709.	2.9	46
1408	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Modern Pathology, 2006, 19, 986-998.	2.9	17
1409	Suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cells. Cancer Gene Therapy, 2006, 13, 194-202.	2.2	12
1410	Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Therapy, 2006, 13, 1534-1544.	2.3	42
1411	High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer. Brachytherapy, 2006, 5, 1-4.	0.2	3
1412	The chromogranin-A (CgA) in prostate cancer. Archives of Gerontology and Geriatrics, 2006, 43, 117-126.	1.4	29
1413	Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 670-677.	0.4	36
1414	Genistein modulates prostate epithelial cell proliferation via estrogen- and extracellular signal-regulated kinase-dependent pathways. Journal of Nutritional Biochemistry, 2006, 17, 204-210.	1.9	42
1415	Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas. Hpb, 2006, 8, 451-457.	0.1	12
1416	Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma. Investigational New Drugs, 2006, 24, 255-260.	1.2	10
1417	Racial Differences in Clinical Progression Among Medicare Recipients After Treatment for Localized Prostate Cancer (United States). Cancer Causes and Control, 2006, 17, 803-811.	0.8	53
1418	Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas. Cell Biology and Toxicology, 2006, 22, 73-80.	2.4	42
1419	The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clinical and Experimental Metastasis, 2006, 23, 19-31.	1.7	40

#	Article	IF	CITATIONS
1420	Garlic Compound, Diallyl Disulfide Induces Cell Cycle Arrest in Prostate Cancer Cell Line PC-3. Molecular and Cellular Biochemistry, 2006, 288, 107-113.	1.4	61
1421	Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. Journal of Neuro-Oncology, 2006, 77, 143-152.	1.4	28
1422	Symptom evaluation in palliative medicine: patient report vs systematic assessment. Supportive Care in Cancer, 2006, 14, 444-453.	1.0	212
1423	Effective Screening for Bowel Cancer: A United Kingdom Perspective. Diseases of the Colon and Rectum, 2006, 49, 895-908.	0.7	8
1424	Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?. Clinical Rheumatology, 2006, 25, 175-182.	1.0	3
1425	Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin. Journal of Cancer Research and Clinical Oncology, 2006, 132, 257-264.	1.2	21
1426	Rapid diagnosis and follow up of bladder cancer patients using urinary high molecular weight cytokeratins. World Journal of Urology, 2006, 24, 345-352.	1.2	6
1427	Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 525-531.	3.3	135
1428	Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 140-147.	3.3	61
1429	Lung squamous cell carcinoma and adenocarcinoma cell lines use different mediators to induce comparable phenotypic and functional changes in human monocyte-derived dendritic cells. Cancer Immunology, Immunotherapy, 2006, 55, 598-611.	2.0	21
1430	Antimetastatic effect of a lipophilic ascorbic acid derivative with antioxidation through inhibition of tumor invasion. Cancer Chemotherapy and Pharmacology, 2006, 57, 584-590.	1.1	17
1433	Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecologic Oncology, 2006, 100, 116-127.	0.6	53
1434	Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecologic Oncology, 2006, 100, 152-159.	0.6	61
1435	Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study. Gynecologic Oncology, 2006, 100, 324-329.	0.6	10
1436	Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecologic Oncology, 2006, 102, 61-66.	0.6	71
1437	ISSM SYMPOSIUM: Do Patients and Partners Really Want to Have a Sex Life After Prostate Cancer? Psychological Impact of Diagnosis and Treatment. Journal of Sexual Medicine, 2006, 3, 83-84.	0.3	0
1438	Magnetic Resonance–Guided Focused Ultrasound Surgery of Breast Cancer: Reliability and Effectiveness. Journal of the American College of Surgeons, 2006, 203, 54-63.	0.2	258
1439	Health maintenance and screening in breast cancer survivors in the United States. Cancer Detection and Prevention, 2006, 30, 52-57.	2.1	42

#	Article	IF	CITATIONS
1440	In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells. Biochemical Pharmacology, 2006, 72, 308-319.	2.0	78
1441	Breast conservation without mammography? Oncology practice in the real world of limited resource countries. Breast, 2006, 15, 575-579.	0.9	4
1442	Radiologic Diagnosis and Staging of Renal and Bladder Cancer. Seminars in Roentgenology, 2006, 41, 121-138.	0.2	36
1443	Cancer Risk Analysis in Families With Hereditary Nonpolyposis Colorectal Cancer. IEEE Transactions on Information Technology in Biomedicine, 2006, 10, 581-587.	3.6	4
1444	Minimally invasive sentinel lymph node mapping of the pig colon with Lymphoseek. Surgery, 2006, 139, 217-223.	1.0	16
1445	Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery, 2006, 139, 347-356.	1.0	129
1446	Tumours of familial origin in the head and neck. Oral Oncology, 2006, 42, 965-978.	0.8	44
1447	CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. , 2006, 111, 27-52.		83
1448	Efficacy of conventional and implant-supported mandibular resection prostheses: Study overview and treatment outcomes. Journal of Prosthetic Dentistry, 2006, 96, 13-24.	1.1	123
1449	Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer, 2006, 6, 153.	1.1	41
1450	Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics, 2006, 7, 202.	1.2	91
1451	Systematic review of outcome of synchronous portal–superior mesenteric vein resection during pancreatectomy for cancer. British Journal of Surgery, 2006, 93, 662-673.	0.1	235
1452	Chemopreventive activity of selenocysteine prodrugs against tobacco-derived nitrosamine (NNK) induced lung tumors in the A/J mouse. Journal of Biochemical and Molecular Toxicology, 2006, 19, 396-405.	1.4	43
1453	Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. Journal of Cellular Biochemistry, 2006, 98, 1163-1184.	1.2	43
1454	Androgen inducibility of Fgf8 in Shionogi carcinoma 115 cells correlates with an adjacent t(5;19) translocation. Genes Chromosomes and Cancer, 2006, 45, 169-181.	1.5	5
1455	Design and Synthesis of a PSMA Inhibitor–Doxorubicin Conjugate for Targeted Prostate Cancer Therapy. ChemMedChem, 2006, 1, 299-302.	1.6	35
1456	Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer, 2006, 106, 106-111.	2.0	39
1457	Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer, 2006, 106, 2337-2344.	2.0	131

#	ARTICLE	IF	CITATIONS
1458	Quality of life in long-term survivors of bladder cancer. Cancer, 2006, 106, 2355-2362.	2.0	115
1459	Adolescents and young adults with cancer. Cancer, 2006, 107, 1645-1655.	2.0	299
1460	Acute myeloid leukemia: Epidemiology and etiology. Cancer, 2006, 107, 2099-2107.	2.0	500
1461	Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors. Cancer, 2006, 107, 2873-2880.	2.0	139
1462	Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head and Neck, 2006, 28, 614-619.	0.9	48
1463	MF tricyclic and sulindac retard tumor formation in an animal model. International Journal of Cancer, 2006, 118, 11-16.	2.3	6
1464	Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. International Journal of Cancer, 2006, 118, 1420-1425.	2.3	33
1465	Selenium binding protein 1 in ovarian cancer. International Journal of Cancer, 2006, 118, 2433-2440.	2.3	90
1466	Optical diagnosis of cervical cancer by fluorescence spectroscopy technique. International Journal of Cancer, 2006, 119, 139-145.	2.3	49
1467	The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. International Journal of Cancer, 2006, 119, 1014-1022.	2.3	100
1468	Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. International Journal of Cancer, 2006, 119, 2651-2656.	2.3	46
1469	In vivo electrogene transfer ofinterleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas. Journal of Gene Medicine, 2006, 8, 335-352.	1.4	30
1470	Oral Cancer Prevention and Early Detection: Knowledge, Practices, and Opinions of Oral Health Care Providers in New York State. Journal of Cancer Education, 2006, 21, 157-162.	0.6	57
1471	Direct, Androgen Receptor-Mediated Regulation of the FKBP5 Gene via a Distal Enhancer Element. Endocrinology, 2006, 147, 590-598.	1.4	151
1472	Recurrent Renal Cell Carcinoma Postnephrectomy With Intracardiac Extensions. Journal of Diagnostic Medical Sonography, 2006, 22, 127-130.	0.1	0
1473	A Phase I Study of Eniluracil/5-FU in Combination with Radiation Therapy for Potentially Resectable and/or Unresectable Cancer of the Pancreas and Distal Biliary Tract. Cancer Investigation, 2006, 24, 9-17.	0.6	9
1474	Ketoconazole as a Secondary Hormonal Intervention in Advanced Prostate Cancer. Clinical Journal of Oncology Nursing, 2006, 10, 361-366.	0.3	7
1475	Role of Carbonic Anhydrases in the Progression of Renal Cell Carcinoma Subtypes: Proposal of a Unified Hypothesis. Cancer Investigation, 2006, 24, 754-779.	0.6	31

#	Article	IF	CITATIONS
1476	Promoter Hypermethylation of Multiple Genes in Sputum Precedes Lung Cancer Incidence in a High-Risk Cohort. Cancer Research, 2006, 66, 3338-3344.	0.4	363
1477	Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells. Molecular Cancer Therapeutics, 2006, 5, 2251-2260.	1.9	135
1478	Prognostic Significance of Nuclear Factor- \hat{l}° B p105/p50 in Human Melanoma and Its Role in Cell Migration. Cancer Research, 2006, 66, 8382-8388.	0.4	38
1479	Decreased Mitochondrial DNA Content in Posttreatment Salivary Rinses from Head and Neck Cancer Patients. Clinical Cancer Research, 2006, 12, 1564-1569.	3.2	51
1480	Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer. Oncology, 2006, 71, 320-326.	0.9	30
1481	Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut, 2006, 55, 68-73.	6.1	62
1482	Gene Promoter Hypermethylation in Mouse Lung Tumors. Molecular Cancer Research, 2006, 4, 267-273.	1.5	38
1483	Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma. Clinical Cancer Research, 2006, 12, 718-725.	3.2	135
1484	Survivin and Granzyme B–induced apoptosis, a novel anticancer therapy. Molecular Cancer Therapeutics, 2006, 5, 693-703.	1.9	28
1485	Pulmonary metastases from epithelial tumours: late results of surgical treatmentâ [†] . European Journal of Cardio-thoracic Surgery, 2006, 30, 217-222.	0.6	28
1486	Serum Amino-Terminal Propeptide of Type 1 Procollagen (P1NP) in Prostate Cancer: A Potential Predictor of Bone Metastases and Prognosticator for Disease Progression and Survival. Urologia Internationalis, 2006, 76, 67-71.	0.6	24
1487	Carcinoembryonic Antigen–Targeted Selective Gene Therapy for Gastric Cancer through FZ33 Fiber-Modified Adenovirus Vectors. Clinical Cancer Research, 2006, 12, 3803-3813.	3.2	44
1488	Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Annals of Oncology, 2006, 17, vii97-vii102.	0.6	133
1489	Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1041-1046.	3.3	140
1490	Activation and Cross-talk between Akt, NF-κB, and Unfolded Protein Response Signaling in 1-LN Prostate Cancer Cells Consequent to Ligation of Cell Surface-associated GRP78. Journal of Biological Chemistry, 2006, 281, 13694-13707.	1.6	236
1491	Angiotensin II Type 1 Receptor Antagonist Candesartan as an Angiogenic Inhibitor in a Xenograft Model of Bladder Cancer. Clinical Cancer Research, 2006, 12, 2888-2893.	3.2	90
1492	Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells Clinical Cancer Research, 2006, 12, 1144-1151.	3.2	564
1493	Characterization of Biochemical Recurrence after Radical Prostatectomy. Urologia Internationalis, 2006, 77, 130-134.	0.6	39

#	Article	IF	CITATIONS
1494	Alpha-tocopheryl succinate, in contrast to alpha-tocopherol and alpha-tocopheryl acetate, inhibits prostaglandin E2 production in human lung epithelial cells. Carcinogenesis, 2006, 27, 2308-2315.	1.3	30
1495	In vitro and In vivo Evidence of Metallopanstimulin-1 in Gastric Cancer Progression and Tumorigenicity. Clinical Cancer Research, 2006, 12, 4965-4973.	3.2	38
1496	OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancerâ€"A GERCOR Study. Journal of Clinical Oncology, 2006, 24, 394-400.	0.8	750
1497	Metastatic tumors in the jaws. Journal of the American Dental Association, 2006, 137, 1667-1672.	0.7	147
1498	Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXA. Cancer Research, 2006, 66, 9636-9645.	0.4	88
1499	A New Tumor Suppressor DnaJ-like Heat Shock Protein, HLJ1, and Survival of Patients With Non–Small-Cell Lung Carcinoma. Journal of the National Cancer Institute, 2006, 98, 825-838.	3.0	108
1500	A KNOWLEDGE-BASED LUNG NODULE DETECTION SYSTEM FOR HELICAL CT IMAGES. International Journal of Computational Intelligence and Applications, 2006, 06, 371-387.	0.6	2
1501	Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Molecular Cancer Therapeutics, 2007, 6, 1357-1367.	1.9	207
1502	A Transition State Analogue of 5′-Methylthioadenosine Phosphorylase Induces Apoptosis in Head and Neck Cancers. Journal of Biological Chemistry, 2007, 282, 21477-21486.	1.6	67
1503	MSH2 â~118T>C and MSH6 â~159C>T promoter polymorphisms and the risk of colorectal cancer. Carcinogenesis, 2007, 28, 2575-2580.	1.3	22
1504	Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. British Journal of Cancer, 2007, 96, 1278-1283.	2.9	99
1505	Evaluation of Twenty Human Adenoviral Types and One Infectivity-Enhanced Adenovirus for the Therapy of Soft Tissue Sarcoma. Human Gene Therapy, 2007, 18, 51-62.	1.4	23
1506	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. Expert Review of Dermatology, 2007, 2, 179-190.	0.3	0
1507	Decoy Receptor-2 Small Interfering RNA (siRNA) Strategy Employing Three Different siRNA Constructs in Combination Defeats Adenovirus-Transferred Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Lung Cancer Cells. Human Gene Therapy, 2007, 18, 39-50.	1.4	33
1508	Enjoy the Silence: The Story of let-7 MicroRNA and Cancer. Current Genomics, 2007, 8, 229-233.	0.7	78
1509	Role of 99mTc-Octreotide Acetate Scintigraphy in Suspected Lung Cancer Compared with 18F-FDG Dual-Head Coincidence Imaging. Journal of Nuclear Medicine, 2007, 48, 1442-1448.	2.8	15
1510	Crossing over: transforming palliative care nursing services. International Journal of Palliative Nursing, 2007, 13, 366-376.	0.2	7
1511	Overexpression of PTEN Suppresses Growth and Induces Apoptosis by Inhibiting the Expression of Survivin in Bladder Cancer Cells. Tumor Biology, 2007, 28, 9-15.	0.8	15

#	Article	IF	CITATIONS
1512	Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer. Oncology, 2007, 73, 2-8.	0.9	6
1513	Prognostic Factors and Prognostic Index for Chemona \tilde{A}^- ve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer. Oncology, 2007, 73, 41-51.	0.9	58
1514	Endovascular Therapy for Palliative Care of Cancer Patients. Seminars in Interventional Radiology, 2007, 24, 382-390.	0.3	8
1515	Colonic Adenocarcinomas: Near-Infrared Microcatheter Imaging of Smart Probes for Early Detection—Study in Mice. Radiology, 2007, 244, 232-238.	3.6	100
1516	Ghrelin and Prostate Cancer. Vitamins and Hormones, 2007, 77, 301-324.	0.7	24
1517	Clinicopathologic Correlation of Cutaneous Metastases. Archives of Dermatology, 2007, 143, 613-20.	1.7	161
1518	Targeting Neuropilin 1 as an Antitumor Strategy in Lung Cancer. Clinical Cancer Research, 2007, 13, 4759-4768.	3.2	172
1519	Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Human Molecular Genetics, 2007, 16, 2333-2340.	1.4	68
1520	Sanguinarine-Dependent Induction of Apoptosis in Primary Effusion Lymphoma Cells. Cancer Research, 2007, 67, 3888-3897.	0.4	122
1521	Retinoblastoma Deficiency Increases Chemosensitivity in Lung Cancer. Cancer Research, 2007, 67, 8264-8273.	0.4	38
1522	Clinical Significance of p53 Gene Mutation in T1-2N0 Non-Small Cell Lung Cancer. Asian Cardiovascular and Thoracic Annals, 2007, 15, 35-38.	0.2	6
1523	Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Annals of Oncology, 2007, 18, 77-81.	0.6	46
1524	Endocrine signaling in ovarian surface epithelium and cancer. Human Reproduction Update, 2007, 13, 143-162.	5.2	72
1525	Primary Prevention of Breast Cancer by Hormone-Induced Differentiation., 2007, 174, 111-130.		39
1526	CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions. Carcinogenesis, 2007, 28, 2552-2559.	1.3	39
1527	Environmental influences on the high mortality from colorectal cancer in African Americans. Postgraduate Medical Journal, 2007, 83, 583-589.	0.9	33
1528	In vivo Effects of Vaccination with Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer. Cancer Research, 2007, 67, 1344-1351.	0.4	97
1529	Vascular Endothelial Growth Factors C and D Represent Novel Prognostic Markers in Colorectal Carcinoma Using Quantitative Image Analysis. European Surgical Research, 2007, 39, 229-238.	0.6	27

#	Article	IF	CITATIONS
1530	Comparative Proteomics Analysis of Barrett Metaplasia and Esophageal Adenocarcinoma Using Two-dimensional Liquid Mass Mapping. Molecular and Cellular Proteomics, 2007, 6, 987-999.	2.5	33
1531	Colon Cancer Screening in Women. Women's Health, 2007, 3, 163-172.	0.7	5
1533	Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease., 2007,, CD004569.		26
1534	Development of a murine model for blastoid variant mantle-cell lymphoma. Blood, 2007, 109, 4899-4906.	0.6	38
1535	Metastatic Angiosarcoma of the Scalp Causing Kasabach-Merritt Syndrome. American Journal of the Medical Sciences, 2007, 333, 293-295.	0.4	15
1536	Comparison of Pancreas Juice Proteins from Cancer Versus Pancreatitis Using Quantitative Proteomic Analysis. Pancreas, 2007, 34, 70-79.	0.5	93
1537	Preoperative Hepatic and Regional Arterial Chemotherapy in the Prevention of Liver Metastasis After Colorectal Cancer Surgery. Annals of Surgery, 2007, 245, 583-590.	2.1	43
1538	The contribution of high-resolution ultrasonography in preoperatively detecting sentinel-node metastases in melanoma patients. Melanoma Research, 2007, 17, 233-237.	0.6	33
1539	The role of FDG PET in the management of lymphoma: what is the evidence base?. Nuclear Medicine Communications, 2007, 28, 335-354.	0.5	43
1541	The Aryl Propionic Acid R-Flurbiprofen Selectively Induces p75NTR-Dependent Decreased Survival of Prostate Tumor Cells. Cancer Research, 2007, 67, 3254-3262.	0.4	51
1542	Impact of PET/CT in Comparison With Same Day Contrast Enhanced CT in Breast Cancer Management. Clinical Nuclear Medicine, 2007, 32, 429-434.	0.7	41
1544	Use of Spinal Anesthesia Does Not Reduce Intraoperative Blood Loss. Urology, 2007, 70, 523-526.	0.5	8
1545	Uveal Melanoma in Saudi Arabia. Ophthalmology, 2007, 114, 194.e1-194.e2.	2.5	0
1546	High intensity focused ultrasound in the treatment of abdominal and gynaecological diseases. International Journal of Hyperthermia, 2007, 23, 173-182.	1.1	69
1547	Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening. Annals of Thoracic Surgery, 2007, 84, 959-966.	0.7	72
1548	Development of time-resolved immunofluorometric assays for CA 72-4 and application in sera of patients with gastric tumors. Clinica Chimica Acta, 2007, 380, 106-111.	0.5	18
1549	Survival from adolescent cancer. Cancer Treatment Reviews, 2007, 33, 609-615.	3.4	54
1550	The cancer incidence temporality index: An index to show temporal changes in the age of onset of overall and specific cancer (England and Wales, 1971–1999). Biomedicine and Pharmacotherapy, 2007, 61, 623-630.	2.5	6

#	Article	IF	CITATIONS
1551	Lifestyle-related factors and environmental agents causing cancer: An overview. Biomedicine and Pharmacotherapy, 2007, 61, 640-658.	2.5	251
1552	Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Letters, 2007, 245, 121-126.	3.2	26
1553	Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Letters, 2007, 247, 48-55.	3.2	60
1554	A novel peptide that selectively binds highly metastatic hepatocellular carcinoma cell surface is related to invasion and metastasis. Cancer Letters, 2007, 247, 234-242.	3.2	23
1555	RB Activity Alters Checkpoint Response and Chemosensitivity in Lung Cancer Lines. Journal of Surgical Research, 2007, 142, 364-372.	0.8	9
1556	Prognostic value of humbug gene overexpression in stage II colon cancer. Human Pathology, 2007, 38, 17-25.	1.1	27
1557	Lack of Noggin Expression by Cancer Cells Is a Determinant of the Osteoblast Response in Bone Metastases. American Journal of Pathology, 2007, 170, 160-175.	1.9	93
1558	Pulmão e gravidez. Revista Portuguesa De Pneumologia, 2007, 13, 213-237.	0.7	1
1559	The Breast Health Global Initiative: A Framework for Improving Breast Health Care in Limited-Resource Countries. Breast Diseases, 2007, 17, 314-317.	0.0	0
1560	Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF- \hat{l}_{\pm} mice. Breast Cancer Research, 2007, 9, R91.	2.2	80
1561	Leukemias., 2007,, 1-3.		0
1562	Metastasis of Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2007, , .	0.1	4
1563	Lung Cancer and Lung Stem Cells. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 547-553.	2.5	165
1564	Investigational agents against platinum-resistant ovarian cancer. Expert Opinion on Investigational Drugs, 2007, 16, 325-336.	1.9	4
1565	A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo. Neoplasia, 2007, 9, 625-633.	2.3	19
1566	Photodynamic Therapy Using Verteporfin Photosensitization in the Pancreas and Surrounding Tissues in the Syrian Golden Hamster. Pancreatology, 2007, 7, 20-27.	0.5	43
1567	MLH1 -93G>A Promoter Polymorphism and the Risk of Microsatellite-Unstable Colorectal Cancer. Journal of the National Cancer Institute, 2007, 99, 463-474.	3.0	116
1568	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. Radiologic Clinics of North America, 2007, 45, 639-644.	0.9	26

#	Article	IF	CITATIONS
1569	Detecting extrathoracic metastases in patients with non-small cell lung cancer: Is routine scanning necessary?. Lung Cancer, 2007, 58, 59-67.	0.9	6
1571	Ovarian Cancer Activity of Cyclic Amine and Thiaether Metal Complexes. Journal of Medicinal Chemistry, 2007, 50, 1703-1706.	2.9	25
1572	Synthesis of Poly[APMA]-DOTA- ⁶⁴ Cu Conjugates for Interventional Radionuclide Therapy of Prostate Cancer: Assessment of Intratumoral Retention by Micro–Positron Emission Tomography. Molecular Imaging, 2007, 6, 7290.2006.00030.	0.7	12
1573	Towards Automatic Risk Analysis for Hereditary Non-Polyposis Colorectal Cancer Based on Pedigree Data., 2007,, 319-337.		3
1574	Oral Cancer Screening in a High-Risk Underserved Community: Vancouver Downtown Eastside. Journal of Health Care for the Poor and Underserved, 2007, 18, 767-778.	0.4	25
1575	Noninvasive quantitative assessment of oral tongue cancer by intraoral ultrasonography. Head and Neck, 2007, 29, 307-314.	0.9	40
1576	Mutant p53 proteins: Between loss and gain of function. Head and Neck, 2007, 29, 488-496.	0.9	45
1577	Routine endometrial sampling of asymptomatic premenopausal women shedding normal endometrial cells in papanicolaou tests is not cost effective. Cancer, 2007, 111, 26-33.	2.0	26
1578	Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer, 2007, 109, 1439-1445.	2.0	126
1579	Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: An international collaborative study. Cancer, 2007, 110, 1033-1041.	2.0	90
1580	Molecular profiling and risk stratification of adenocarcinoma of the colon. Journal of Surgical Oncology, 2007, 96, 693-703.	0.8	48
1581	Pancreatic cancer: From pathogenesis to cure. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 997-1014.	1.0	11
1582	Chemotherapy in Small Bowel Adenocarcinoma: 10-year Experience of the British Columbia Cancer Agency. Clinical Oncology, 2007, 19, 143-149.	0.6	79
1583	Squamous Cell Carcinoma Antigen in Follow-Up of Cervical Cancer Treated With Radiotherapy: Evaluation of Cost-Effectiveness. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1145-1149.	0.4	41
1584	Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate, 2007, 67, 924-932.	1.2	40
1585	Exploration of target molecules for prostate cancer gene therapy. Prostate, 2007, 67, 1163-1173.	1.2	24
1586	Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells. Oncogene, 2007, 26, 1533-1545.	2.6	27
1587	Cigarette smoke induces demethylation of prometastatic oncogene synuclein-γ in lung cancer cells by downregulation of DNMT3B. Oncogene, 2007, 26, 5900-5910.	2.6	95

#	Article	IF	CITATIONS
1588	Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. Cancer Gene Therapy, 2007, 14, 19-29.	2.2	18
1589	Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis. Cancer Gene Therapy, 2007, 14, 268-278.	2.2	10
1590	Prognostic significance of folate metabolism polymorphisms for lung cancer. British Journal of Cancer, 2007, 97, 247-252.	2.9	31
1591	PGC- \hat{l} ± induces apoptosis in human epithelial ovarian cancer cells through a PPAR \hat{l} 3-dependent pathway. Cell Research, 2007, 17, 363-373.	5.7	92
1592	Screening colonoscopy in asymptomatic average-risk Koreans: Analysis in relation to age and sex. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1003-1008.	1.4	64
1593	Markers of prostate region-specific epithelial identity define anatomical locations in the mouse prostate that are molecularly similar to human prostate cancers. Differentiation, 2007, 75, 49-61.	1.0	23
1594	Adjuvant treatment in the management of testis-confined germ cell tumours after orchidectomy. BJU International, 2007, 101, 070723101711007-???.	1.3	0
1595	Genetics of melanoma tumorigenesis. British Journal of Dermatology, 2008, 158, 15-21.	1.4	46
1596	Translational Mini-Review Series on Vaccines: Dendritic cell-based vaccines in renal cancer. Clinical and Experimental Immunology, 2007, 147, 395-400.	1.1	16
1597	Ovarian cancer incidence and survival in Korea: 1993-2002. International Journal of Gynecological Cancer, 2007, 17, 595-600.	1.2	34
1598	Sentinel lymph node in endometrial cancer. International Journal of Gynecological Cancer, 2007, 17, 1113-1117.	1.2	62
1599	Photoprotective effects of green tea polyphenols. Photodermatology Photoimmunology and Photomedicine, 2007, 23, 48-56.	0.7	119
1600	Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. Journal of Pineal Research, 2007, 42, 191-202.	3.4	68
1601	Improving Survival for Patients with Breast Cancer Compared with Intramural and Extramural Benchmarks. Clinical Breast Cancer, 2007, 7, 480-485.	1.1	3
1602	Expression and genomic profiling of colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1775, 103-137.	3.3	77
1603	Diagnosis of abnormal uterine bleeding. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2007, 21, 891-903.	1.4	14
1604	"Learning to live with it― Coping with the transition to cancer survivorship in older adults. Journal of Aging Studies, 2007, 21, 93-106.	0.7	36
1605	Irradiation-induced epithelial–mesenchymal transition (EMT) related to invasive potential in endometrial carcinoma cells. Gynecologic Oncology, 2007, 107, 500-504.	0.6	66

#	Article	IF	CITATIONS
1607	Prediction of prostate cancer using hair trace element concentration and support vector machine method. Biological Trace Element Research, 2007, 116, 257-271.	1.9	27
1608	Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemotherapy and Pharmacology, 2007, 60, 681-691.	1.1	37
1609	Folate Status and Risk of Colorectal Polyps in African Americans. Digestive Diseases and Sciences, 2007, 52, 1462-1470.	1.1	27
1610	Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapy. Breast Cancer Research and Treatment, 2007, 101, 207-214.	1.1	39
1611	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative―breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment, 2007, 105, 319-326.	1.1	369
1612	The black:white disparity in breast cancer mortality: the example of Chicago. Cancer Causes and Control, 2007, 18, 323-333.	0.8	82
1613	Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor–stromal interaction. Clinical and Experimental Metastasis, 2007, 24, 423-429.	1.7	21
1614	Synthesis of 5α-androstan-3β,17β-diol from tigogenin. Chemistry of Natural Compounds, 2007, 43, 97-99.	0.2	7
1615	Adjuvant Immunochemotherapy with Protein-Bound Polysaccharide K for Colon Cancer in Relation to Oncogenic \hat{l}^2 -Catenin Activation. Diseases of the Colon and Rectum, 2007, 50, 1169-1181.	0.7	13
1616	From the genome to the proteome—biomarkers in colorectal cancer. Langenbeck's Archives of Surgery, 2007, 393, 93-104.	0.8	24
1617	Colorectal cancer in HIV-infected patients: a case control study. International Journal of Colorectal Disease, 2007, 22, 1217-1221.	1.0	39
1618	Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. Endocrine, 2007, 31, 311-320.	2.2	20
1619	High dose rate brachytherapy (HDR-BT) in locally advanced oesophageal cancer. Clinic response and survival related to biological equivalent dose (BED). Clinical and Translational Oncology, 2007, 9, 385-391.	1.2	7
1620	Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer. Oncology Reviews, 2007, 1, 3-13.	0.8	1
1621	Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: An observational study. Critical Reviews in Oncology/Hematology, 2008, 68, 178-182.	2.0	26
1622	Sporadic Colon Cancer: Mismatch Repair Immunohistochemistry and Microsatellite Instability in Omani Subjects. Digestive Diseases and Sciences, 2008, 53, 2723-2731.	1.1	25
1623	Proteome Analysis of Human Pancreatic Ductal Adenocarcinoma Tissue Using Two-Dimensional Gel Electrophoresis and Tandem Mass Spectrometry for Identification of Disease-Related Proteins. Digestive Diseases and Sciences, 2008, 53, 65-72.	1.1	17
1624	How Adequate is Digital Rectal Exam for Prostate Cancer Screening at Colonoscopy? Can Adequacy be Improved?. Digestive Diseases and Sciences, 2008, 53, 719-722.	1.1	30

#	Article	IF	Citations
1625	Diffusion-weighted single-shot echo planar MR imaging of normal human prostate using different b values. Journal of Huazhong University of Science and Technology [Medical Sciences], 2008, 28, 737-740.	1.0	2
1626	E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway. Medical Oncology, 2008, 25, 222-228.	1.2	6
1627	Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis. Journal of Human Genetics, 2008, 53, 340-348.	1.1	36
1628	Experimental and Systems Biology Studies of the Molecular Basis for the Radioresistance of Prostate Carcinoma Cells. Annals of Biomedical Engineering, 2008, 36, 831-838.	1.3	7
1629	Clinical assessment, gross examination, frozen section of ovarian masses: do patients benefit?. Archives of Gynecology and Obstetrics, 2008, 278, 209-213.	0.8	9
1630	Effect of race on vincristineâ€associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatric Blood and Cancer, 2008, 50, 769-771.	0.8	113
1631	Regional differences in colorectal cancer incidence, stage, and subsite among American Indians and Alaska Natives, 1999-2004. Cancer, 2008, 113, 1179-1190.	2.0	51
1632	Downâ€regulation of Baxâ€interacting factorâ€1 in colorectal adenocarcinoma. Cancer, 2008, 113, 2665-2670.	2.0	80
1633	MicroRNA alterations in head and neck squamous cell carcinoma. International Journal of Cancer, 2008, 123, 2791-2797.	2.3	239
1634	PKD, PKD2, and p38 MAPK mediate Hsp27 serine-82 phosphorylation induced by neurotensin in pancreatic cancer PANC-1 cells. Journal of Cellular Biochemistry, 2008, 103, 648-662.	1.2	68
1635	Regulation of apoptosis by modified naringenin derivatives in human colorectal carcinoma RKO cells. Journal of Cellular Biochemistry, 2008, 104, 259-273.	1.2	34
1636	Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology, 2008, 47, 1964-1973.	3.6	163
1637	Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells. Journal of Proteomics, 2008, 71, 561-571.	1.2	15
1638	Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1910-1915.	1.0	29
1639	Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2008, 15, 3521-3531.	0.7	43
1640	Prognostic factors for recurrence and survival in primary vulvar squamous cell cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 1143-1149.	1.3	8
1641	Neurotransmission and cancer: implications for prevention and therapy. Anti-Cancer Drugs, 2008, 19, 655-671.	0.7	78
1642	LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells. Acta Pharmacologica Sinica, 2008, 29, 489-498.	2.8	23

#	Article	IF	CITATIONS
1643	Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. Modern Pathology, 2008, 21, 950-960.	2.9	47
1644	cGMPâ€independent antiâ€tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines. British Journal of Pharmacology, 2008, 155, 804-813.	2.7	16
1645	Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Therapy, 2008, 15, 526-534.	2.2	21
1646	A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. British Journal of Cancer, 2008, 98, 316-322.	2.9	34
1647	Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase $1/2$. British Journal of Cancer, 2008, 99, 283-293.	2.9	33
1648	The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. British Journal of Cancer, 2008, 99, 1476-1483.	2.9	119
1649	Methodological Considerations in Cost of Prostate Cancer Studies: A Systematic Review. Value in Health, 2008, 11, 878-885.	0.1	60
1650	Gail Model Risk Factors: Impact of Adding an Extended Family History for Breast Cancer. Breast Journal, 2008, 14, 221-227.	0.4	11
1651	Breast Cancer Burden in Maiduguri, North Eastern Nigeria. Breast Journal, 2008, 14, 284-286.	0.4	22
1652	Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1852-1859.	1.4	59
1653	Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. International Journal of Urology, 2008, 15, 19-26.	0.5	29
1654	Endoscopic ultrasoundâ€guided fineâ€needle aspiration when combined with positron emission tomography improves specificity and overall diagnostic accuracy in unexplained mediastinal lymphadenopathy and staging of nonâ€smallâ€cell lung cancer. Internal Medicine Journal, 2008, 38, 837-844	0.5	22
1655	Aberrant expression and demethylation of γâ€synuclein in colorectal cancer, correlated with progression of the disease. Cancer Science, 2008, 99, 1924-1932.	1.7	9
1656	Genetics of melanoma predisposition. British Journal of Dermatology, 2008, 159, 286-291.	1.4	36
1657	Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecologic Oncology, 2008, 111, 111-119.	0.6	47
1658	Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma. BMC Cancer, 2008, 8, 109.	1.1	46
1659	An integrated algorithm for gene selection and classification applied to microarray data of ovarian cancer. Artificial Intelligence in Medicine, 2008, 42, 81-93.	3.8	57
1660	Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 611-617.	0.4	47

#	Article	IF	CITATIONS
1661	Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer, 2008, 61, 340-349.	0.9	166
1662	Segmentation of multispectral bladder MR images with inhomogeneity correction for virtual cystoscopy. Proceedings of SPIE, 2008, , .	0.8	7
1664	Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Molecular Immunology, 2008, 45, 169-179.	1.0	67
1665	Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nuclear Medicine and Biology, 2008, 35, 623-634.	0.3	53
1666	Decreased Bladder Cancer Growth in Parous Mice. Urology, 2008, 72, 470-473.	0.5	26
1667	Angiotensin II Induces Oxidative Stress in Prostate Cancer. Molecular Cancer Research, 2008, 6, 250-258.	1.5	38
1668	The release of fibroblast growth factor-1 from melanoma cells requires copper ions and is mediated by phosphatidylinositol 3-kinase/Akt intracellular signaling pathway. Cancer Letters, 2008, 267, 67-74.	3.2	22
1669	Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation. Cancer Letters, 2008, 270, 132-143.	3.2	28
1670	Gastrointestinal, Urologic and Lung Malignancies During Pregnancy., 2008, 178, 137-164.		14
1671	Expression and Clinical Significance of CacyBP/SIP in Pancreatic Cancer. Pancreatology, 2008, 8, 470-477.	0.5	21
1672	Multidisciplinary Management of Metastatic Sarcoma. Surgical Clinics of North America, 2008, 88, 661-672.	0.5	17
1673	Screening and early diagnosis in lung cancer. Expert Review of Anticancer Therapy, 2008, 8, 1529-1531.	1.1	4
1674	Data-driven Networking Reveals 5-Genes Signature for Early Detection of Lung Cancer., 2008,,.		1
1675	Screening for lung cancer, an ongoing debate. Annals of Oncology, 2008, 19, vii25-vii27.	0.6	5
1676	Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity. Cancer Research, 2008, 68, 861-869.	0.4	157
1677	Multiple Diagnostic X-rays for Spine Deformities and Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 605-613.	1.1	133
1678	A retrospective study of treatment and outcome in 39 cases of male breast cancer. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 98-105.	0.6	2
1679	Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine. Clinical Cancer Research, 2008, 14, 5426-5436.	3.2	12

#	Article	IF	CITATIONS
1680	A Combination of Serum Tumor Markers Identifies High-Risk Patients with Early-Stage Squamous Cervical Cancer. Tumor Biology, 2008, 29, 9-17.	0.8	20
1681	Combined Effects of p53 Gene Therapy and Leptomycin B in Human Esophageal Squamous Cell Carcinoma. Oncology, 2008, 75, 113-119.	0.9	5
1682	Effect of aberrant promoter methylation of <i>FHIT </i> and <i> RASSF1A </i> genes on susceptibility to cervical cancer in a North Indian population. Biomarkers, 2008, 13, 597-606.	0.9	32
1683	Lymphedema After Breast Cancer: Incidence, Risk Factors, and Effect on Upper Body Function. Journal of Clinical Oncology, 2008, 26, 3536-3542.	0.8	353
1684	Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Review of Molecular Diagnostics, 2008, 8, 277-288.	1.5	58
1685	Using SELDIâ€TOF MS to identify serum biomarkers of rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2008, 37, 94-102.	0.6	14
1686	Diffusion Magnetic Resonance Imaging in Brain Tumors. , 2008, , 215-238.		1
1687	Antidepressants and risk of prostate cancer: a nested case – control study. Prostate Cancer and Prostatic Diseases, 2008, 11, 53-60.	2.0	20
1688	PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Molecular Cancer Therapeutics, 2008, 7, 1297-1308.	1.9	73
1689	Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program. Clinical Cancer Research, 2008, 14, 1913-1919.	3.2	52
1690	Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult. Cmaj, 2008, 179, 338-340.	0.9	37
1691	High-Intensity Focused Ultrasound: Current Potential and Oncologic Applications. American Journal of Roentgenology, 2008, 190, 191-199.	1.0	317
1692	The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. Yearbook of Medicine, 2008, 2008, 466-467.	0.1	0
1693	Association Between Colorectal Cancer and Urologic Cancers. Archives of Internal Medicine, 2008, 168, 1003.	4.3	21
1695	Mammograms in Cosmetic Breast Surgery. The American Journal of Cosmetic Surgery, 2008, 25, 105-109.	0.1	1
1696	Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Research, 2008, 18, 346-352.	0.6	58
1697	A Phase II Trial of Paclitaxel and Cisplatin in Patients With Advanced Squamous-Cell Carcinoma of the Esophagus. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 29-33.	0.6	49
1698	Tolerance and Efficacy of Gemcitabine and Gemcitabine-Based Regimens in Elderly Patients With Advanced Pancreatic Cancer. Pancreas, 2008, 36, e16-e21.	0.5	58

#	Article	IF	Citations
1699	The Expression of Heat Shock Protein 60 kDa in Tissues and Cell Lines of Breast Cancer. Journal of Breast Cancer, 2008, 11, 161.	0.8	1
1700	Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma. Yonsei Medical Journal, 2008, 49, 620.	0.9	13
1701	Protein Alterations in Infiltrating Ductal Carcinomas of the Breast as Detected by Nonequilibrium pH Gradient Electrophoresis and Mass Spectrometry. Journal of Biomedicine and Biotechnology, 2008, 2008, 1-10.	3.0	22
1702	Medical Radiation-Induced Cancer. , 2008, , 261-265.		O
1703	Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Medicine Circulatory, Respiratory and Pulmonary Medicine, 2008, 2, CCRPM.S578.	0.4	1
1704	Spectrum of complaints presented at a specialist breast Clinic In Kumasi, Ghana. Ghana Medical Journal, 2009, 42, 110-3.	0.2	13
1705	Diagnostic Efficacy of PET/CT Plus Brain MR Imaging for Detection of Extrathoracic Metastases in Patients with Lung Adenocarcinoma. Journal of Korean Medical Science, 2009, 24, 1132.	1.1	45
1706	Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clinical Medicine Therapeutics, 2009, 1, CMT.S9.	0.1	27
1707	Suppression of Akt1 expression by small interference RNA inhibits SGC7901 cell growth in vitro and in vivo. Oncology Reports, 2009, 22, 1305-13.	1.2	1
1708	Cisplatin and Vinorelbine Chemotherapy in Recurrent Vulvar Carcinoma. Oncology, 2009, 77, 281-284.	0.9	38
1709	An improving gene selection for microarray data. , 2009, , .		0
1710	Diagnosis and management of thyroid carcinoma: a focus on serum thyroglobulin. Expert Review of Endocrinology and Metabolism, 2009, 4, 25-43.	1.2	44
1711	Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening. Prostate Cancer and Prostatic Diseases, 2009, 12, 52-56.	2.0	22
1712	Evaluation Model for Breast Cancer Susceptibly Gene and its Implementation Using Cytoscape. , 2009, , .		2
1713	Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Annals of Oncology, 2009, 20, 1042-1047.	0.6	37
1714	Oxaliplatin Combined with Continuous Infusion of 5-Fluorouracil as First-Line Chemotherapy in Patients with Metastatic or Recurrent Gastric Adenocarcinoma. Chemotherapy, 2009, 55, 200-206.	0.8	6
1715	Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. Molecular Cancer Therapeutics, 2009, 8, 1350-1362.	1.9	91
1716	Radiation-Stimulated Epigenetic Reprogramming of Adaptive-Response Genes in the Lung: An Evolutionary Gift for Mounting Adaptive Protection against Lung Cancer. Dose-Response, 2009, 7, dose-response.0.	0.7	43

#	Article	IF	CITATIONS
1717	Alteration in TWIST Expression: Possible Role in Paclitaxel-induced Apoptosis in Human Laryngeal Carcinoma Hep-2 Cell Line. Croatian Medical Journal, 2009, 50, 536-542.	0.2	19
1718	Efficient confocal microscopy with a dual-wedge scanner. , 2009, , .		13
1719	Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma. Acta Oncol \tilde{A}^3 gica, 2009, 48, 154-156.	0.8	2
1720	Association of <i>XPD</i> Polymorphisms with Severe Toxicity in Non–Small Cell Lung Cancer Patients in a Chinese Population. Clinical Cancer Research, 2009, 15, 3889-3895.	3.2	43
1721	Preoperative Assessment of Cutaneous Melanoma Thickness Using 10-MHz Sonography. American Journal of Roentgenology, 2009, 193, 639-643.	1.0	44
1722	Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer — A phase II study. Gynecologic Oncology, 2009, 112, 384-388.	0.6	21
1723	Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecologic Oncology, 2009, 112, 475-480.	0.6	32
1724	Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecologic Oncology, 2009, 114, 121-127.	0.6	301
1725	Side population of a murine mantle cell lymphoma model contains tumourâ€initiating cells responsible for lymphoma maintenance and dissemination. Journal of Cellular and Molecular Medicine, 2010, 14, 1532-1545.	1.6	19
1726	Pregnancy after breast cancer: The importance of active counselling and planning. Breast, 2009, 18, 345-350.	0.9	39
1727	Patient outcomes in the acute recovery phase following robotic-assisted prostate surgery: A prospective study. International Journal of Nursing Studies, 2009, 46, 442-449.	2.5	5
1728	Growth inhibition of head and neck carcinomas by <scp>D</scp> â€allose. Head and Neck, 2009, 31, 1049-1055.	0.9	42
1729	Microtubuleâ€damaging agents enhance RASSF1Aâ€induced cell death in lung cancer cell lines. Cancer, 2009, 115, 1253-1266.	2.0	10
1730	Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis, 2009, 30, 1132-1144.	1.3	53
1731	Fluorescence detection and diagnosis of nonâ€melanoma skin cancer at an early stage. Lasers in Surgery and Medicine, 2009, 41, 96-103.	1.1	59
1732	Ultrastructural changes of platelet aggregates and fibrin networks in a patient with renal clear cell adenocarcinoma: A scanning electron microscopy study. Microscopy Research and Technique, 2009, 72, 679-683.	1.2	4
1733	Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2009, 14, 43-47.	1.0	7
1734	The detection and treatment of cancer-related functional problems in an outpatient setting. Supportive Care in Cancer, 2009, 17, 61-67.	1.0	150

#	Article	IF	CITATIONS
1735	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study. Critical Reviews in Oncology/Hematology, 2009, 71, 233-241.	2.0	32
1736	Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model. Clinical and Experimental Metastasis, 2009, 26, 981-992.	1.7	28
1737	Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma. Pituitary, 2009, 12, 280-283.	1.6	21
1738	Insulin: a novel agent in the pathogenesis of prostate cancer. International Urology and Nephrology, 2009, 41, 267-272.	0.6	43
1739	Evaluation of Oxidative Stress, Antioxidant Status and Serum Vitamin C Levels in Cancer Patients. Biological Trace Element Research, 2009, 130, 1-6.	1.9	50
1740	Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed. Clinical and Translational Oncology, 2009, 11 , $28-34$.	1.2	24
1741	Assessment of colorectal cancer knowledge and patient attitudes towards screening: is Ireland ready to embrace colon cancer screening?. Irish Journal of Medical Science, 2009, 178, 7-12.	0.8	14
1742	Microsatellite instability in the evaluation of hereditary nonpolyposis colorectal cancer. Current Colorectal Cancer Reports, 2009, 5, 40-47.	1.0	0
1743	Endotherapy for Barrett's Esophagus with High-Grade Dysplasia and Intramucosal Carcinoma. Journal of Gastrointestinal Surgery, 2009, 13, 1172-1178.	0.9	6
1744	Concurrent hyperfractionated radiotherapy and chemotherapy for patients with limited small-cell lung cancer. Results from a single institution. Reports of Practical Oncology and Radiotherapy, 2009, 14, 46-52.	0.3	2
1745	Spatio-temporal cluster analysis of county-based human West Nile virus incidence in the continental United States. International Journal of Health Geographics, 2009, 8, 43.	1.2	74
1746	Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Science, 2009, 100, 1510-1519.	1.7	46
1747	Expression of Ret finger protein correlates with outcomes in endometrial cancer. Cancer Science, 2009, 100, 1895-1901.	1.7	29
1748	Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Modern Pathology, 2009, 22, 128-133.	2.9	61
1749	Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. Oncogene, 2009, 28, 4095-4104.	2.6	54
1750	Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. Journal of Oral Pathology and Medicine, 2010, 39, 299-305.	1.4	195
1751	Trends of oral and pharyngeal cancer in Israel, by gender, age, ethnic group, and country of origin: 1970–2006. Community Dentistry and Oral Epidemiology, 2009, 37, 547-554.	0.9	12
1752	Phase II study of Sâ€1 and irinotecan combination chemotherapy as a firstâ€ine therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05â€02. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 46-54.	0.7	3

#	Article	IF	CITATIONS
1753	Ectopic expression of guanylyl cyclase C in gastric cancer as a potential biomarker and therapeutic target. Journal of Digestive Diseases, 2009, 10, 272-285.	0.7	7
1754	The Use of High-Resolution Ultrasonography for Preoperative Detection of Metastases in Sentinel Lymph Nodes of Patients with Cutaneous Melanoma. Dermatologic Surgery, 2009, 35, 1757-1765.	0.4	30
1755	Radiotherapy in Larynx Squamous Cell Carcinoma is not Associated with an Increased Diagnosis of Second Primary Tumours. Clinical Oncology, 2009, 21, 315-319.	0.6	16
1756	Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations. Comptes Rendus Chimie, 2009, 12, 1110-1116.	0.2	10
1757	Gastric cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 127-164.	2.0	347
1758	Acidic heterocycles as novel hydrophilic pharmacophore of androgen receptor ligands with a carborane core structure. Bioorganic and Medicinal Chemistry, 2009, 17, 344-350.	1.4	34
1759	Intravenous contrast ultrasound examination using contrastâ€tuned imaging (CnTlâ"¢) and the contrast medium SonoVue® for discrimination between benign and malignant adnexal masses with solid components. Ultrasound in Obstetrics and Gynecology, 2009, 34, 699-710.	0.9	50
1760	Uncovering Growth-Suppressive MicroRNAs in Lung Cancer. Clinical Cancer Research, 2009, 15, 1177-1183.	3.2	167
1761	Diagnostic accuracy and tolerability of contrast enhanced CT colonoscopy in symptomatic patients with increased risk for colorectal cancer. European Journal of Radiology, 2009, 71, 513-518.	1.2	11
1762	Multicolor fluorescence in situ hybridization and comparative genomic hybridization reveal molecular events in lung adenocarcinomas and squamous cell lung carcinomas. Biomedicine and Pharmacotherapy, 2009, 63, 396-403.	2.5	17
1763	Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Letters, 2009, 273, 257-265.	3.2	39
1764	Male breast cancer: A retrospective analysis. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2009, 13, 103-107.	0.6	38
1765	Proteomics-based identification of $\hat{l}\pm 1$ -antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clinica Chimica Acta, 2009, 404, 111-118.	0.5	56
1766	Impact of Declining Fertility Rates in Canada on Donor Options in Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 1634-1637.	2.0	27
1767	Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine, 2009, 27, G52-G59.	1.7	33
1768	Apoptosis-Inducing Factor and Colon Cancer. Journal of Surgical Research, 2009, 151, 163-170.	0.8	62
1769	The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence―with meta-analysis. Human Pathology, 2009, 40, 356-365.	1.1	42
1770	Aplicación de un panel de metilación para el diagnóstico de cáncer de pulmón en broncoaspirados. Resultados preliminares. Revista Del Laboratorio ClÃnico, 2009, 2, 107-114.	0.1	0

#	Article	IF	CITATIONS
1771	TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer, 2009, 63, 98-105.	0.9	19
1772	An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients. Lung Cancer, 2009, 63, 259-263.	0.9	5
1773	The clinical impact of integrated FDG PET–CT on management decisions in patients with lung cancer. Lung Cancer, 2009, 64, 301-307.	0.9	61
1774	Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. Lung Cancer, 2009, 65, 237-241.	0.9	14
1775	Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer, 2009, 65, 230-236.	0.9	85
1776	Clinical Genomics Identifies the Expression of Human Ovarian Carcinoma. International Journal of Gerontology, 2009, 3, 163-169.	0.7	0
1777	Synthesis of 7-chloroquinolinyl-4 Scientia Pharmaceutica, 2009, 77, .	0.7	37
1778	Sphingosine Kinase 1 Is Associated with Gastric Cancer Progression and Poor Survival of Patients. Clinical Cancer Research, 2009, 15, 1393-1399.	3.2	163
1779	Cancer, Chemistry, and the Cell: Molecules that Interact with the Neurotensin Receptors. ACS Chemical Biology, 2009, 4, 503-525.	1.6	69
1780	Induction of Cell Death by Ternary Copper(II) Complexes of <scp>l</scp> -Tyrosine and Diimines: Role of Coligands on DNA Binding and Cleavage and Anticancer Activity. Inorganic Chemistry, 2009, 48, 1309-1322.	1.9	239
1781	Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. Journal of Experimental and Clinical Cancer Research, 2009, 28, 126.	3.5	21
1782	Prognostic value of metastin expression in human pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2009, 28, 9.	3.5	42
1783	Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics, 2009, 10, 1839-1851.	0.6	17
1784	Successful Cryopreservation of Mouse Oocytes by Using Low Concentrations of Trehalose and Dimethylsulfoxide1. Biology of Reproduction, 2009, 80, 70-78.	1.2	66
1785	Expression of DBC1 and SIRT1 Is Associated with Poor Prognosis of Gastric Carcinoma. Clinical Cancer Research, 2009, 15, 4453-4459.	3.2	192
1786	p53 Mutations in Carcinoma of the Esophagus and Gastroesophageal Junction. Cancer Investigation, 2009, 27, 96-104.	0.6	9
1787	Multi-criteria evaluation model reveals SMC4L1 gene maybe a breast cancer susceptibility gene. , 2009, , .		1
1788	Patterns of care and outcome in elderly cervical cancer patients: A special focus on brachytherapy. Radiotherapy and Oncology, 2009, 91, 197-201.	0.3	36

#	Article	IF	CITATIONS
1789	Prognostic significance of several histological features in intermediate and highâ€risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 107-113.	0.9	8
1790	Place du cetuximab dans le traitement des stades III non chirurgicaux : des résultats encourageants des essais de phase II avec la radiothérapie. Revue De Pneumologie Clinique, 2009, 65, H2-H5.	0.0	О
1791	Total Cystectomy Versus Bladder Preservation Therapy for Locally Invasive Bladder Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 592-606.	0.6	18
1792	CORNEOSCLERAL NECROSIS AFTER EPISCLERAL AU-198 BRACHYTHERAPY OF UVEAL MELANOMA. Retina, 2009, 29, 73-79.	1.0	20
1793	Photodynamic therapy for pancreatic and biliary tract carcinoma. , 2009, , .		0
1794	Selective internal radiation therapy for liver metastases from colorectal cancer. The Cochrane Library, 2009, , CD007045.	1.5	19
1795	Epidemiological, Clinical, Molecular Features and Early Detection Strategy of Most Frequent Hereditary Cancers in Latvia. Proceedings of the Latvian Academy of Sciences, 2009, 63, 131-140.	0.0	0
1796	Potent Bactericidal Constituents from Mallotus philippinensis against Clarithromycin and Metronidazole Resistant Strains of Japanese and Pakistani Helicobacter pylori. Biological and Pharmaceutical Bulletin, 2009, 32, 631-636.	0.6	34
1797	A Retrospective Study of Patients With Locally Advanced Cancer of the Cervix Treated With Neoadjuvant Chemotherapy Followed by Radical Surgery. International Journal of Gynecological Cancer, 2009, 19, 417-422.	1.2	15
1800	EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?. Current Drug Targets, 2010, 11, 682-698.	1.0	12
1801	PKC Delta (PKCÎ) Promotes Tumoral Progression of Human Ductal Pancreatic Cancer. Pancreas, 2010, 39, e31-e41.	0.5	56
1802	Cancers of the breast, uterus, ovary and cervix among Alaska Native women, 1974–2003. International Journal of Circumpolar Health, 2010, 69, 72-86.	0.5	16
1803	Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives. Frontiers of Medicine in China, 2010, 4, 356-362.	0.1	6
1804	Nerve Growth Factorâ€Î² Expression Is Associated with Lymph Node Metastasis and Nerve Infiltration in Human Hilar Cholangiocarcinoma. World Journal of Surgery, 2010, 34, 1039-1045.	0.8	27
1805	Vascular Reconstruction During Pancreatoduodenectomy for Ductal Adenocarcinoma of the Pancreas Improves Resectability but does not Achieve Cure. World Journal of Surgery, 2010, 34, 2648-2661.	0.8	63
1807	Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. Journal of Gastroenterology, 2010, 45, 1146-1154.	2.3	33
1808	Expression of estrogen alpha and beta receptors in prostate cancer and hyperplasia: Immunohistochemical analysis. African Journal of Urology, 2010, 16, 79-87.	0.1	5
1809	Advances in esophageal stenting: the evolution of fully covered stents for malignant and benign disease. Advances in Therapy, 2010, 27, 413-425.	1.3	23

#	Article	IF	CITATIONS
1810	Effect of spindle checkpoint on Akt2-mediated paclitaxel-resistance in A2780 ovarian cancer cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2010, 30, 206-211.	1.0	4
1811	Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer. Medical Oncology, 2010, 27, 1303-1308.	1.2	39
1812	E-cadherin mediates the aggregation of breast cancer cells induced by tamoxifen and epidermal growth factor. Breast Cancer Research and Treatment, 2010, 121, 79-89.	1.1	9
1813	17Î ² -Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells. Molecular and Cellular Biochemistry, 2010, 342, 63-70.	1.4	24
1814	In Vitro and In Vivo Anticancer Activity of a Novel Nano-sized Formulation Based on Self-assembling Polymers Against Pancreatic Cancer. Pharmaceutical Research, 2010, 27, 2694-2703.	1.7	30
1815	A Coupled Level Set Framework for Bladder Wall Segmentation With Application to MR Cystography. IEEE Transactions on Medical Imaging, 2010, 29, 903-915.	5.4	68
1816	Ultrasonography for Intraoperative Determination of Tumor Thickness and Resection Margin in Tongue Carcinomas. Journal of Oral and Maxillofacial Surgery, 2010, 68, 1746-1752.	0.5	59
1817	STAMP alters the growth of transformed and ovarian cancer cells. BMC Cancer, 2010, 10, 128.	1.1	6
1818	Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-κB. European Journal of Pharmacology, 2010, 631, 1-9.	1.7	125
1819	Development of a multiplex MethyLight assay for the detection ofÂmultigene methylation in human colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 202, 1-10.	1.0	94
1820	The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radical Biology and Medicine, 2010, 48, 1601-1609.	1.3	46
1821	The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor. Gynecologic Oncology, 2010, 117, 32-36.	0.6	23
1822	Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer, 2010, 116, 3025-3033.	2.0	34
1823	The effect of GHRH antagonists on human glioblastomas and their mechanism of action. International Journal of Cancer, 2010, 127, 2313-2322.	2.3	14
1824	The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. Journal of Surgical Oncology, 2010, 102, 539-542.	0.8	7
1825	Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.02,6]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4491-4495.	1.0	11
1826	Forecasting age-related changes in breast cancer mortality among white and black US women: A functional data approach. Cancer Epidemiology, 2010, 34, 542-549.	0.8	14
1827	Increased expression of cysteine cathepsins in ovarian tissue from chickens with ovarian cancer. Reproductive Biology and Endocrinology, 2010, 8, 100.	1.4	20

#	Article	IF	CITATIONS
1828	Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): A tissue microarray study (TMA). Prostate, 2010, 70, 1429-1436.	1.2	16
1829	Establishment of a primary human sarcoma model in athymic nude mice. Human Cell, 2010, 23, 50-57.	1.2	10
1830	Apoptin Enhances Radiationâ€Induced Cell Death in Poorly Responding Head and Neck Squamous Cell Carcinoma Cells. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 130-134.	1.2	7
1831	Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene, 2010, 29, 3758-3769.	2.6	42
1832	Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope, 2010, 113, 1687-1702.	1.1	48
1833	Lung cancer: Progress in diagnosis, staging and therapy. Respirology, 2010, 15, 44-50.	1.3	80
1834	Optimal management of sarcopenia. Clinical Interventions in Aging, 2010, 5, 217.	1.3	193
1835	Local Ablative Techniques in the Treatment of Locally Advanced Pancreatic Cancer. Medical Radiology, 2010, , 167-173.	0.0	0
1836	Another anticancer elemanolide from <i>Vernonia amygdalina</i> Del. International Journal of Biological and Chemical Sciences, 2010, 4, .	0.1	11
1837	Transplante de células-tronco hematopoéticas e leucemia mieloide aguda: diretrizes brasileiras. Revista Brasileira De Hematologia E Hemoterapia, 0, 32, 61-65.	0.7	4
1838	Treatment and Outcomes of Melanoma in Acral Location in Korean Patients. Yonsei Medical Journal, 2010, 51, 562.	0.9	56
1839	Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway. Annals of Oncology, 2010, 21, 263-268.	0.6	160
1840	Fluorescent Taxoid Probes for Microtubule Research. Methods in Cell Biology, 2010, 95, 353-372.	0.5	17
1841	In vitro and in vivo Effects of D-Allose: Up-Regulation of Thioredoxin-Interacting Protein in Head and Neck Cancer Cells. Annals of Otology, Rhinology and Laryngology, 2010, 119, 567-571.	0.6	18
1842	Analysis of NSAID-Activated Gene 1 Expression in Prostate Cancer. Urologia Internationalis, 2010, 84, 198-202.	0.6	17
1843	EIF2C Is Overexpressed and Amplified in Head and Neck Squamous Cell Carcinoma. Orl, 2010, 72, 337-343.	0.6	22
1844	The Superparamagnetic Nanoparticles Carrying the <i>E1A</i> Gene Enhance the Radiosensitivity of Human Cervical Carcinoma in Nude Mice. Molecular Cancer Therapeutics, 2010, 9, 2123-2130.	1.9	23
1845	Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opinion on Medical Diagnostics, 2010, 4, 53-65.	1.6	59

#	Article	IF	CITATIONS
1846	Rectal cancer: Pattern and outcome of management in University of Ilorin teaching hospital, Ilorin, Nigeria. Annals of African Medicine, 2010, 9, 164.	0.2	5
1847	DNA Vaccination: Using the Patient's Immune System to Overcome Cancer. Clinical and Developmental Immunology, 2010, 2010, 1-14.	3.3	11
1848	Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. Cancer Biology and Therapy, 2010, 9, 142-152.	1.5	75
1849	Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer and Prostatic Diseases, 2010, 13, 65-70.	2.0	61
1850	Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. Oncology, 2010, 79, 78-84.	0.9	14
1851	Bladder wall flattening with conformal mapping for MR cystography. , 2010, , .		2
1852	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. Thoracic Surgery Clinics, 2010, 20, 25-30.	0.4	15
1853	Radiofrequency Ablation of Lung Tumors. Clinics in Chest Medicine, 2010, 31, 151-163.	0.8	26
1854	Recent Advances in the Use of Stents for Esophageal Disease. Gastrointestinal Endoscopy Clinics of North America, 2010, 20, 103-121.	0.6	25
1855	Location-related differences in sporadic microsatellite unstable colorectal cancer. Digestive and Liver Disease, 2010, 42, 611-615.	0.4	10
1856	Clozapine treatment associated with increased risk of acute myeloid leukemia (AML). Schizophrenia Research, 2010, 123, 270-272.	1,1	19
1857	Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Molecular Cancer, 2010, 9, 140.	7.9	39
1858	Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Molecular Cancer, 2010, 9, 149.	7.9	58
1859	Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Molecular Cancer, 2010, 9, 206.	7.9	51
1860	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. Journal of Translational Medicine, 2010, 8, 8.	1.8	29
1861	An Informatics-assisted Label-free Quantitation Strategy that Depicts Phosphoproteomic Profiles in Lung Cancer Cell Invasion. Journal of Proteome Research, 2010, 9, 5582-5597.	1.8	57
1863	Proteomic Identification of Overexpressed PRDX 1 and Its Clinical Implications in Ovarian Carcinoma. Journal of Proteome Research, 2010, 9, 451-457.	1.8	26
1864	Developmental plasticity of stem cells and diseases. Medical Hypotheses, 2010, 75, 507-510.	0.8	5

#	Article	IF	CITATIONS
1865	Cryopreservation of mammalian oocytes by using sugars: Intra- and extracellular raffinose with small amounts of dimethylsulfoxide yields high cryosurvival, fertilization, and development rates. Cryobiology, 2010, 60, S54-S59.	0.3	28
1866	Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice. Vaccine, 2010, 28, 6333-6337.	1.7	11
1867	p-Carborane-based androgen antagonists active in LNCaP cells with a mutated androgen receptor. MedChemComm, 2011, 2, 877.	3.5	25
1868	A Synthetic Naringenin Derivative, 5-Hydroxy-7,4′-diacetyloxyflavanone- <i>N</i> -phenyl Hydrazone (N101-43), Induces Apoptosis through Up-regulation of Fas/FasL Expression and Inhibition of Pl3K/Akt Signaling Pathways in Non-Small-Cell Lung Cancer Cells. Journal of Agricultural and Food Chemistry, 2011, 59, 10286-10297.	2.4	39
1869	Diffusion MR Imaging: An Important Tool in the Assessment of Brain Tumors. Neuroimaging Clinics of North America, 2011, 21, 27-49.	0.5	22
1870	<i>Retraction:</i> Detection, Characterization, and Spontaneous Differentiation In Vitro of Very Small Embryonic-Like Putative Stem Cells in Adult Mammalian Ovary. Stem Cells and Development, 2011, 20, 1451-1464.	1.1	239
1871	Análisis de la actividadÂde un equipo de soporte de cuidados paliativos. Medicina Paliativa, 2011, 18, 129-134.	0.1	2
1872	Abdominal drainage versus no drainage post gastrectomy for gastric cancer., 2011,, CD008788.		31
1873	Protein Alterations Associated with Pancreatic Cancer and Chronic Pancreatitis Found in Human Plasma using Global Quantitative Proteomics Profiling. Journal of Proteome Research, 2011, 10, 2359-2376.	1.8	98
1874	Malignant glandular lesions and glandular differentiation in invasive/noninvasive urothelial carcinoma of the urinary bladder. Annals of Diagnostic Pathology, 2011, 15, 422-426.	0.6	9
1875	GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. Cancer Letters, 2011, 309, 37-45.	3.2	89
1876	Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. Journal of Clinical Neuroscience, 2011, 18, 1444-1448.	0.8	85
1877	Epidemiology and management of breast carcinoma in Egyptian males: Experience of a single Cancer Institute. Journal of the Egyptian National Cancer Institute, 2011, 23, 115-122.	0.6	9
1878	Colonoscopy and Flexible Sigmoidoscopy in Colorectal Cancer Screening and Surveillance. , 2011, , 83-92.		0
1879	Current Advance in Small Bowel Tumors. Clinical Endoscopy, 2011, 44, 13.	0.6	34
1880	Nomogram to Predict Insignificant Prostate Cancer at Radical Prostatectomy in Korean Men: A Multi-Center Study. Yonsei Medical Journal, 2011, 52, 74.	0.9	8
1881	Non-Invasive Endoscopy Technique - Virtual Colonoscopy. , 0, , .		0
1882	H2S Donor, S-Propargyl-Cysteine, Increases CSE in SGC-7901 and Cancer-Induced Mice: Evidence for a Novel Anti-Cancer Effect of Endogenous H2S?. PLoS ONE, 2011, 6, e20525.	1.1	89

#	Article	IF	CITATIONS
1883	Down-Regulation of Bax-Interacting Factor 1 in Human Pancreatic Ductal Adenocarcinoma. Pancreas, 2011, 40, 433-437.	0.5	17
1884	Long-Term Outcome of High-Intensity Focused Ultrasound in Advanced Pancreatic Cancer. Pancreas, 2011, 40, 1080-1086.	0.5	94
1885	Lymph node ultrasound during melanoma follow-up significantly improves metastasis detection compared with clinical examination alone. Melanoma Research, 2011, 21, 457-463.	0.6	29
1886	Insulin-like growth factor 1 activates methionine adenosyltransferase 2A transcription by multiple pathways in human colon cancer cells. Biochemical Journal, 2011, 436, 507-516.	1.7	29
1887	Patient outcome prediction using multiple biomarkers in human melanoma: A clinicopathological study of 118 cases. Experimental and Therapeutic Medicine, 2011, 2, 131-135.	0.8	15
1888	Bipolar energy for transurethral resection of bladder tumours at lowâ€power settings: initial experience. BJU International, 2011, 108, 553-556.	1.3	38
1889	Functional variant (â^1304T>G) in the <i>MKK4</i> promoter is associated with decreased risk of acute myeloid leukemia in a southern Chinese population. Cancer Science, 2011, 102, 1462-1468.	1.7	13
1890	Expression of RUNX3 in skin cancers. Clinical and Experimental Dermatology, 2011, 36, 769-774.	0.6	20
1891	Breast Cancer and HIV in the Era of Highly Active Antiretroviral Therapy: Two Case Reports and Review of the Literature. Breast Journal, 2011, 17, 87-92.	0.4	15
1892	Chemical-induced cancer incidence and underlying mechanisms in Fen1 mutant mice. Oncogene, 2011, 30, 1072-1081.	2.6	24
1893	Beliefs About Cancer and Diet among Those Considering Genetic Testing for Colon Cancer. Journal of Nutrition Education and Behavior, 2011, 43, 150-156.	0.3	4
1894	Associations Between P53 Arg72Pro and Development of Digestive Tract Cancers: A Meta-analysis. Archives of Medical Research, 2011, 42, 60-69.	1.5	17
1895	Impact of hysterectomy and bilateral oophorectomy prevalence on rates of cervical, uterine, and ovarian cancer among American Indian and Alaska Native women, 1999–2004. Cancer Causes and Control, 2011, 22, 1681-1689.	0.8	12
1896	Cyclooxygenase- and lipoxygenase-mediated DNA damage. Cancer and Metastasis Reviews, 2011, 30, 437-447.	2.7	44
1897	Solitary pulmonary nodules: consequences for patient quality of life. Quality of Life Research, 2011, 20, 101-109.	1.5	21
1898	A cohort study investigating patient expectations and satisfaction outcomes in men undergoing robotic assisted radical prostatectomy. International Urology and Nephrology, 2011, 43, 405-415.	0.6	13
1899	Cryosurgery as primary treatment for localized prostate cancer. International Urology and Nephrology, 2011, 43, 1089-1094.	0.6	17
1900	Down-regulation of TWIST decreases migration and invasion of laryngeal carcinoma Hep-2 cells by regulating the E-cadherin, N-cadherin expression. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1487-1493.	1.2	19

#	Article	IF	CITATIONS
1901	Pretreatment study of P53 overexpression for selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma: a randomized-controlled study. Archives of Gynecology and Obstetrics, 2011, 283, 617-622.	0.8	8
1902	Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin. Cancer Chemotherapy and Pharmacology, 2011, 67, 147-152.	1.1	4
1903	Screening of Prostate Cancer by Analyzing Trace Elements in Hair and Chemometrics. Biological Trace Element Research, 2011, 144, 97-108.	1.9	18
1904	Gastric Cancer: Tumor Markers as Predictive Factors for Preoperative Staging. Journal of Gastrointestinal Cancer, 2011, 42, 127-130.	0.6	15
1905	Re-expression of cell adhesion molecule inhibits growth and induces apoptosis of human pancreatic cancer cell line PANC-1. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 762-767.	1.0	4
1906	In Vitro antimetastatic effect of Changweiqing (è,è ff æ,) through antiinvasion of hypoxic colorectal carcinoma LoVo cells. Chinese Journal of Integrative Medicine, 2011, 17, 517-524.	0.7	7
1907	Application of Weibull model for survival of patients with gastric cancer. BMC Gastroenterology, 2011, 11, 1.	0.8	84
1908	Ethical issues at the interface of clinical care and research practice in pediatric oncology: a narrative review of parents' and physicians' experiences. BMC Medical Ethics, 2011, 12, 18.	1.0	71
1909	JNK suppression is essential for $17\hat{l}^2$ -Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells. Journal of Biomedical Science, 2011, 18, 61.	2.6	24
1910	A replication study examining three common singleâ€nucleotide polymorphisms and the risk of prostate cancer in a Japanese population. Prostate, 2011, 71, 1023-1032.	1.2	19
1911	Naringenin upâ€regulates the expression of death receptor 5 and enhances TRAILâ€induced apoptosis in human lung cancer A549 cells. Molecular Nutrition and Food Research, 2011, 55, 300-309.	1.5	80
1912	Prognostic significance of RUNX3 expression in human melanoma. Cancer, 2011, 117, 2719-2727.	2.0	40
1913	Loss of cell surface TFII-I promotes apoptosis in prostate cancer cells stimulated with activated α2-macroglobulin*. Journal of Cellular Biochemistry, 2011, 112, 1685-1695.	1.2	10
1914	Quantitative structure–activity relationship analysis of a novel series of chemicals antagonizing WT and MT AR. Chemometrics and Intelligent Laboratory Systems, 2011, 107, 283-289.	1.8	0
1915	Crystal structure, docking study and structure–activity relationship of carborane-containing androgen receptor antagonist 3-(12-hydroxymethyl-1,12-dicarba-closo-dodecaboran-1-yl)benzonitrile. Bioorganic and Medicinal Chemistry, 2011, 19, 3540-3548.	1.4	27
1916	Non-viral gene delivery nanoparticles based on Poly(\hat{l}^2 -amino esters) for treatment of glioblastoma. Biomaterials, 2011, 32, 5402-5410.	5.7	133
1917	A statistical and learning based oncogene detection and classification scheme using human cDNA expressions for ovarian carcinoma. Expert Systems With Applications, 2011, 38, 10066-10074.	4.4	7
1918	Synthesis, chemical characterization and preliminary in vitro antitumor activity evaluation of new ruthenium(II) complexes with sugar derivatives. Polyhedron, 2011, 30, 1671-1679.	1.0	5

#	Article	IF	Citations
1919	Ablation for the Management of Pulmonary Malignancies. American Journal of Roentgenology, 2011, 197, W581-W589.	1.0	27
1920	Randomized Phase II Trial of Inhaled Budesonide versus Placebo in High-Risk Individuals with CT Screen–Detected Lung Nodules. Cancer Prevention Research, 2011, 4, 34-42.	0.7	52
1921	Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clinical Chemistry and Laboratory Medicine, 2011, 49, 527-34.	1.4	75
1922	mTOR-RAPTOR and 14-3-3Â immunohistochemical expression in high grade prostatic intraepithelial neoplasia and prostatic adenocarcinomas: a tissue microarray study. Journal of Clinical Pathology, 2011, 64, 683-688.	1.0	15
1923	Cancer-behavior-coping in women with breast cancer: Effect of a cancer self-management program. International Journal of Applied & Basic Medical Research, 2011, 1, 84.	0.2	15
1924	Plasma Leptin, hTERT Gene Expression, and Anthropometric Measures in Obese and Non-Obese Women with Breast Cancer. Breast Cancer: Basic and Clinical Research, 2011, 5, BCBCR.S6734.	0.6	17
1925	Inhibition of Collagen XVI Expression Reduces Glioma Cell Invasiveness. Cellular Physiology and Biochemistry, 2011, 27, 217-226.	1.1	36
1926	Vesicular Stomatitis Virus Has Extensive Oncolytic Activity against Human Sarcomas: Rare Resistance Is Overcome by Blocking Interferon Pathways. Journal of Virology, 2011, 85, 9346-9358.	1.5	48
1927	The National Lung Screening Trial: Overview and Study Design. Radiology, 2011, 258, 243-253.	3.6	992
1928	Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases. Breast Care, 2011, 6, 446-451.	0.8	11
1929	The study of ovarian carcinoma gene regulatory mechanism based on the shortest path algorithm and conditional probabilities. , $2011, \dots$		0
1930	Proteomic Analysis Identified DJ-1 as a Cisplatin Resistant Marker in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2011, 12, 3489-3499.	1.8	61
1931	Inhibition of Hypoxia Inducible Factor Alpha and Astrocyte-Elevated Gene-1 Mediates Cryptotanshinone Exerted Antitumor Activity in Hypoxic PC-3 Cells. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-13.	0.5	24
1932	Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer. Gastroenterology Research and Practice, 2012, 2012, 1-5.	0.7	36
1933	miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma. Cancer Research, 2012, 72, 5576-5587.	0.4	220
1934	Histologic Follow-up in Patients With Papanicolaou Test Findings of Endometrial Cells. American Journal of Clinical Pathology, 2012, 138, 79-84.	0.4	25
1935	Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biology and Therapy, 2012, 13, 756-765.	1.5	51
1936	Effects of chronic nicotine on the autocrine regulation of pancreatic cancer cells and pancreatic duct epithelial cells by stimulatory and inhibitory neurotransmitters. Carcinogenesis, 2012, 33, 1745-1753.	1.3	31

#	Article	IF	CITATIONS
1937	Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma. MAbs, 2012, 4, 256-266.	2.6	8
1938	Hyperbaric oxygen therapy for late radiation tissue injury. , 2012, , CD005005.		64
1940	Myeloid Neoplasias: What Molecular Analyses Are Telling Us. ISRN Oncology, 2012, 2012, 1-7.	2.1	3
1941	Interplay between Menin and K-Ras in Regulating Lung Adenocarcinoma. Journal of Biological Chemistry, 2012, 287, 40003-40011.	1.6	36
1942	Pancreatic Cancer Cells and Normal Pancreatic Duct Epithelial Cells Express an Autocrine Catecholamine Loop that Is Activated by Nicotinic Acetylcholine Receptors α3, α5, and α7. Molecular Cancer Research, 2012, 10, 239-249.	1.5	81
1943	Role of trefoil factor 1 in gastric cancer and relationship between trefoil factor 1 and gastrokine 1. Oncology Reports, 2012, 28, 1257-1262.	1.2	10
1944	The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells. International Journal of Oncology, 2012, 41, 1628-1634.	1.4	24
1945	Association of CASP7 Polymorphisms and Survival of Patients With Non-small Cell Lung Cancer With Platinum-Based Chemotherapy Treatment. Chest, 2012, 142, 680-689.	0.4	8
1946	Cutaneous Metastases From Internal Malignancies. American Journal of Dermatopathology, 2012, 34, 347-393.	0.3	223
1947	In Silico Analysis and Immunohistochemical Characterization of NaPi2b Protein Expression in Ovarian Carcinoma With Monoclonal Antibody Mx35. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 165-172.	0.6	8
1948	A cohort study evaluating paraaortic lymphadenectomy in endometrial cancer. Oncology Letters, 2012, 4, 1361-1365.	0.8	4
1949	14-kDa Phosphohistidine phosphatase plays an important role in hepatocellular carcinoma cell proliferation. Oncology Letters, 2012, 4, 658-664.	0.8	17
1950	Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. The Cochrane Library, 2012, , CD004569.	1.5	18
1951	Aspects Of Morbidity By Cancer For Women In Constanta County In Period 2007 - 2010. ARS Medica Tomitana, 2012, 18, 29-32.	0.0	2
1952	Effect of ascorbic acid and hydrogen peroxide on mouse neuroblastoma cells. Molecular Medicine Reports, 2012, 5, 1449-52.	1.1	17
1953	An Adaptive Window-Setting Scheme for Segmentation of Bladder Tumor Surface via MR Cystography. IEEE Transactions on Information Technology in Biomedicine, 2012, 16, 720-729.	3.6	22
1954	Activities of a novel Schiff Base copper(II) complex on growth inhibition and apoptosis induction toward MCF-7 human breast cancer cells via mitochondrial pathway. Journal of Inorganic Biochemistry, 2012, 117, 1-9.	1.5	66
1955	¿Resulta rentable un estudio selectivo cerebral con 18F-FDG-PET/TAC en los pacientes con cáncer microcÃtico de pulmón?. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 124-129.	0.0	2

#	Article	IF	CITATIONS
1956	$17\hat{l}^2$ hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma. Gynecologic Oncology, 2012, 127, 587-594.	0.6	23
1957	Is a selective brain 18F-FDG PET/CT study profitable in patients with small cell lung cancer?. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 124-129.	0.1	3
1958	K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicology in Vitro, 2012, 26, 429-434.	1.1	22
1959	Early death from papillary thyroid carcinoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2012, 33, 104-108.	0.6	14
1960	Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. Cancer Letters, 2012, 321, 128-136.	3.2	12
1961	Type 2 diabetes mellitus and colorectal cancer: Meta-analysis on sex-specific differences. European Journal of Cancer, 2012, 48, 1269-1282.	1.3	67
1962	PET/CT imaging in different types of lung cancer: An overview. European Journal of Radiology, 2012, 81, 988-1001.	1.2	132
1963	Free flap reconstruction in patients with advanced oral squamous cell carcinoma: Analysis of patient survival and cancer recurrence. Microsurgery, 2012, 32, 598-604.	0.6	22
1964	Hyperbaric oxygenation for tumour sensitisation to radiotherapy. The Cochrane Library, 2012, , CD005007.	1.5	44
1965	KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population. Human Immunology, 2012, 73, 927-931.	1.2	28
1966	A patient with prostate cancer and multiple myelomaâ€"diagnostics and possible association of both diseases. Annals of Diagnostic Pathology, 2012, 16, 515-520.	0.6	5
1967	Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer, 2012, 75, 82-88.	0.9	94
1968	Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy. Lung Cancer, 2012, 77, 578-584.	0.9	28
1969	Gallbladder metastasis of non-small cell lung cancer presenting as acute cholecystitis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 249-252.	0.7	12
1970	Surveillance of resected non-small cell lung cancer. Clinical and Translational Oncology, 2012, 14, 721-725.	1.2	7
1972	Effects of over-expression of ANXA10 gene on proliferation and apoptosis of hepatocellular carcinoma cell line HepG2. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 669-674.	1.0	12
1973	Downregulation of gastrokine-1 in gastric cancer tissues and restoration of its expression induced gastric cancer cells to apoptosis. Journal of Experimental and Clinical Cancer Research, 2012, 31, 49.	3.5	19
1974	Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients. PLoS ONE, 2012, 7, e33200.	1.1	32

#	Article	IF	CITATIONS
1975	Rhein induces apoptosis of human gastric cancer SGC-7901 cells via an intrinsic mitochondrial pathway. Brazilian Journal of Medical and Biological Research, 2012, 45, 1052-1059.	0.7	42
1976	p38α MAPK mediates 17βâ€estradiol inhibition of MMPâ€2 and â€9 expression and cell migration in human lovo colon cancer cells. Journal of Cellular Physiology, 2012, 227, 3648-3660.	2.0	32
1977	Decreased expression of Beclin 1 correlates with a metastatic phenotypic feature and adverse prognosis of gastric carcinomas. Journal of Surgical Oncology, 2012, 105, 542-547.	0.8	41
1978	Cyclostreptin Derivatives Specifically Target Cellular Tubulin and Further Map the Paclitaxel Site. Biochemistry, 2012, 51, 329-341.	1.2	17
1979	Expression and clinical significance of Notch signaling genes in colorectal cancer. Tumor Biology, 2012, 33, 817-824.	0.8	16
1980	Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial. Journal of Gastrointestinal Surgery, 2012, 16, 1531-1538.	0.9	75
1981	Chinese medicine approach in clinical practice for breast cancer survivors. Chinese Journal of Integrative Medicine, 2012, 18, 308-315.	0.7	3
1982	Is there an association between human immunodeficiency virus infection and breast cancer?. Medical Oncology, 2012, 29, 446-447.	1.2	7
1983	Prognostic significance of APE1 cytoplasmic localization in human epithelial ovarian cancer. Medical Oncology, 2012, 29, 1265-1271.	1.2	25
1985	A comparative assessment of $\hat{l}\pm$ -lipoic acid N-phenylamides as non-steroidal androgen receptor antagonists both on and off gold nanoparticles. Bioorganic Chemistry, 2012, 40, 1-5.	2.0	17
1986	1,2,4-Oxadiazoles: A new class of anti-prostate cancer agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1912-1916.	1.0	28
1987	Mitochondrial transcription factor A regulates <i>BCL2L1</i> gene expression and is a prognostic factor in serous ovarian cancer. Cancer Science, 2012, 103, 239-444.	1.7	23
1988	Effect of diallyl trisulfide derivatives on the induction of apoptosis in human prostate cancer PC-3 cells. Molecular and Cellular Biochemistry, 2012, 363, 75-84.	1.4	13
1989	SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma. Journal of Translational Medicine, 2013, 11, 52.	1.8	25
1990	MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. Journal of Ovarian Research, 2013, 6, 18.	1.3	66
1991	Pap Screening Goals and Perceptions of Pain among Black, Latina, and Arab Women: Steps Toward Breaking down Psychological Barriers. Journal of Cancer Education, 2013, 28, 367-374.	0.6	22
1992	Altered expression of \hat{l}^2 -catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma. Tumor Biology, 2013, 34, 2459-2468.	0.8	18
1993	Analysis of blood serum of lung cancer patients using particle induced X-ray emission. Journal of Radioanalytical and Nuclear Chemistry, 2013, 297, 431-436.	0.7	7

#	Article	IF	Citations
1994	KIT Proto-oncogene Exon 8 Deletions at Codon 419 are Highly Frequent in Acute Myeloid Leukaemia with Inv(16) in Indian Population. Molecular Biotechnology, 2013, 54, 461-468.	1.3	6
1995	Cancer Chemoprevention by Polyphenols and Their Potential Application as Nanomedicine. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2013, 31, 67-98.	2.9	55
1996	Equol enhances tamoxifen's anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells. BMC Cancer, 2013, 13, 238.	1.1	60
1997	Colorectal cancer: Comparison of clinicopathologic features between Moroccans patients less than 50 years old and older. Pathologie Et Biologie, 2013, 61, 117-119.	2.2	7
1998	The Value of Expression of M2-PK and VEGF in Patients with Advanced Gastric Cancer. Cell Biochemistry and Biophysics, 2013, 67, 1033-1039.	0.9	16
1999	A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2013, 31, 910-917.	1.2	26
2000	Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemotherapy and Pharmacology, 2013, 71, 671-680.	1,1	18
2001	Isolated renal metastasis from squamous cell lung cancer. Multidisciplinary Respiratory Medicine, 2013, 8, 2.	0.6	12
2002	Prolonged Overall Survival After Pulmonary Metastasectomy in Patients With Breast Cancer. Annals of Thoracic Surgery, 2013, 95, 1170-1180.	0.7	61
2003	Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts. European Journal of Cancer, 2013, 49, 1152-1158.	1.3	26
2004	Data mining models for predicting oral cancer survivability. Network Modeling Analysis in Health Informatics and Bioinformatics, 2013, 2, 285-295.	1.2	28
2005	Chemopreventive effect of cactus (Opuntia humifusa) extracts: radical scavenging activity, pro-apoptosis, and anti-inflammatory effect in human colon (SW480) and breast cancer (MCF7) cells. Food and Function, 2013, 4, 681.	2.1	24
2006	Molecular Origins of Colon and Rectal Cancer: Not a Wnt–Wnt Situation. Current Colorectal Cancer Reports, 2013, 9, 365-371.	1.0	3
2007	Tailoring of a TiO2 nanotube array-integrated portable microdevice for efficient on-chip enrichment and isotope labeling of serum phosphopeptides. Lab on A Chip, 2013, 13, 3853.	3.1	15
2008	Prognostic value of arginaseâ€I expression and regulatory Tâ€cell infiltration in head and neck squamous cell carcinoma. International Journal of Cancer, 2013, 132, E85-93.	2.3	94
2009	The application of Heck reaction in the synthesis of guaianolide sesquiterpene lactones derivatives selectively inhibiting resistant acute leukemic cells. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6087-6092.	1.0	34
2010	A fixed guide flange appliance for patientsÂafter a hemimandibulectomy. Journal of Prosthetic Dentistry, 2013, 110, 429-432.	1.1	6
2011	Acute promyelocytic leukemia, centre, experience, Turkey. Transfusion and Apheresis Science, 2013, 48, 45-49.	0.5	5

#	Article	IF	CITATIONS
2012	Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1820-1825.	0.8	20
2013	Depletion of hepatoma-derived growth factor-related protein-3 induces apoptotic sensitization of radioresistant A549 cells via reactive oxygen species-dependent p53 activation. Biochemical and Biophysical Research Communications, 2013, 439, 333-339.	1.0	15
2014	Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?. Medical Oncology, 2013, 30, 328.	1.2	33
2015	Lung and Pleural Cancers., 2013, , 215-226.		0
2018	Identification of candidate biomarkers using the Experionâ,,¢ automated electrophoresis system in serum samples from ovarian cancer patients. International Journal of Oncology, 2013, 42, 1257-1262.	1.4	8
2019	Altered Expression of Sialylated Glycoproteins in Ovarian Cancer Sera Using Lectin-based ELISA Assay and Quantitative Glycoproteomics Analysis. Journal of Proteome Research, 2013, 12, 3342-3352.	1.8	59
2020	HBV infection increases the risk of pancreatic cancer: a meta-analysis. Cancer Causes and Control, 2013, 24, 529-537.	0.8	40
2021	Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs. Applied Health Economics and Health Policy, 2013, 11, 275-286.	1.0	121
2022	Proposal to utilize simplified Swensen protocol in diagnosis of isolated pulmonary nodule. Acta Radiologica, 2013, 54, 757-764.	0.5	3
2023	Significance of Neuropilin-1 Expression in Acute Myeloid Leukemia. Turkish Journal of Haematology, 2013, 30, 300-306.	0.2	4
2024	Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice. Melanoma Research, 2013, 23, 114-124.	0.6	20
2025	Effect of Endoscopic Stenting of Malignant Bile Duct Obstruction on Quality of Life. Journal of Clinical Gastroenterology, 2013, 47, 526-531.	1.1	48
2026	Can Serum be Used for Analyzing the EGFR Mutation Status in Patients with Advanced Non-small Cell Lung Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 57-63.	0.6	23
2027	XRCC3 Thr241Met Polymorphism and Clinical Outcomes of NSCLC Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e69553.	1.1	14
2028	Green synthesis of silver nanoparticles using Ganoderma neo-japonicum Imazeki: a potential cytotoxic agent against breast cancer cells. International Journal of Nanomedicine, 2013, 8, 4399.	3.3	175
2029	Cytotoxicity of Biologically Synthesized Silver Nanoparticles in MDA-MB-231 Human Breast Cancer Cells. BioMed Research International, 2013, 2013, 1-10.	0.9	272
2030	Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia. Cancer, 2013, 119, 3177-3185.	2.0	31
2031	Psychological factors associated with head and neck cancer treatment and survivorship: Evidence and opportunities for behavioral medicine Journal of Consulting and Clinical Psychology, 2013, 81, 299-317.	1.6	136

#	Article	IF	CITATIONS
2032	The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM). Clinical Nuclear Medicine, 2013, 38, e74-e79.	0.7	65
2033	Etoposide induces apoptosis via the mitochondrial- and caspase-dependent pathways and in non-cancer stem cells in Panc-1 pancreatic cancer cells. Oncology Reports, 2013, 30, 2765-2770.	1.2	10
2034	Fumigaclavine C from a Marine-Derived Fungus Aspergillus Fumigatus Induces Apoptosis in MCF-7 Breast Cancer Cells. Marine Drugs, 2013, 11, 5063-5086.	2.2	61
2035	Knockdown of Coronin-1C disrupts Rac1 activation and impairs tumorigenic potential in hepatocellular carcinoma cells. Oncology Reports, 2013, 29, 1066-1072.	1.2	18
2036	Clinical and surgical-pathological staging in early non-small cell lung cancer. Oncology Reviews, 2013, 7, 7.	0.8	2
2037	Leiomyoma in Retzius' space: An unusual location. Canadian Urological Association Journal, 2013, 7, 612.	0.3	3
2038	MicroRNA-196a Is a Putative Diagnostic Biomarker and Therapeutic Target for Laryngeal Cancer. PLoS ONE, 2013, 8, e71480.	1.1	70
2039	Polymorphisms in XPD Gene Could Predict Clinical Outcome of Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer Patients: A Meta-Analysis of 24 Studies. PLoS ONE, 2013, 8, e79864.	1.1	21
2040	SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901. Archives of Medical Science, 2013, 6, 990-998.	0.4	15
2041	Why does melanoma metastasize into the brain? Genes with pleiotropic effects might be the key. Frontiers in Genetics, 2013, 4, 75.	1.1	4
2042	Mandibular metastasis of adenocarcinoma from prostate cancer: case report according to epidemiology and current therapeutical trends of the advanced prostate cancer. Journal of Applied Oral Science, 2013, 21, 490-495.	0.7	19
2043	Improvement of quality of life in third-line chemotherapy with lapatinib in a case of metastatic breast cancer. Tumori, 2013, 99, e136-e139.	0.6	1
2044	Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 56-61.	0.7	5
2045	Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Genetics and Molecular Research, 2014, 13, 228-236.	0.3	22
2046	Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Genetics and Molecular Research, 2014, 13, 3310-3318.	0.3	12
2047	Clinical Significance of Immunohistochemical Expression of Cancer/Testis Tumor-associated Antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in Patients with Non-small Cell Lung Cancer. Tumori, 2014, 100, 60-68.	0.6	19
2048	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget, 2014, 5, 1576-1594.	0.8	91
2049	Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer. Genetics and Molecular Research, 2014, 13, 5292-5298.	0.3	6

#	ARTICLE	IF	CITATIONS
2050	Overexpression of S100A4 as a biomarker of metastasis and recurrence in oral squamous cell carcinoma. Journal of Applied Oral Science, 2014, 22, 426-433.	0.7	18
2051	Treatment of Acute Myeloid Leukemia. Current Synthetic and Systems Biology, 2014, 02, .	0.3	2
2052	Transforming Growth Factor- \hat{l}^21 rs 1800470 Polymorphism is Associated with Lung CancerRrisk: A Meta-Analysis. Medical Science Monitor, 2014, 20, 2358-2362.	0.5	13
2053	3D ultrasound imaging in image-guided intervention. , 2014, 2014, 6151-4.		11
2054	S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer. Oncogenesis, 2014, 3, e92-e92.	2.1	52
2055	Effect of the LPA-mediated CXCL12-CXCR4 axis in the tumor proliferation, migration and invasion of ovarian cancer cell lines. Oncology Letters, 2014, 7, 1581-1585.	0.8	25
2056	Dialectic Form Finding of Passive and Adaptive Shading Enclosures. Energies, 2014, 7, 5201-5220.	1.6	33
2057	Can CA-125 Predict Lymph Node Metastasis in Epithelial Ovarian Cancers in Turkish Population?. Disease Markers, 2014, 2014, 1-6.	0.6	4
2058	Effect of CDH1 gene methylation on transforming growth factor (TGF- \hat{l}^2)-induced epithelial-mesenchymal transition in alveolar epithelial cell line A549. Genetics and Molecular Research, 2014, 13, 8568-8576.	0.3	8
2059	Safety Study of Photodynamic Therapy Using Talaporfin Sodium in the Pancreas and Surrounding Tissues in the Syrian Golden Hamster. International Journal of Photoenergy, 2014, 2014, 1-7.	1.4	1
2060	Synchronous bladder tumors in a married couple: Effect of treatment options on quality of life. Dicle Medical Journal, 2014, 41, 574-576.	0.2	0
2061	MicroRNA-145 Function as a Cell Growth Repressor by Directly Targeting c-Myc in Human Ovarian Cancer. Technology in Cancer Research and Treatment, 2014, 13, 161-168.	0.8	30
2062	Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma. Future Oncology, 2014, 10, 703-706.	1.1	4
2063	Silencing KRAS Overexpression in Arsenic-Transformed Prostate Epithelial and Stem Cells Partially Mitigates Malignant Phenotype. Toxicological Sciences, 2014, 142, 489-496.	1.4	26
2064	Phospholipase C <i>ε</i> â€1 inhibits p53 expression in lung cancer. Cell Biochemistry and Function, 2014, 32, 294-298.	1.4	23
2065	Cutaneous metastasis: clinicopathological study of 72 patients from a tertiary care center in Lebanon. International Journal of Dermatology, 2014, 53, 147-158.	0.5	36
2066	Retroperitoneal Castleman's disease: advocating a multidisciplinary approach for a rare clinical entity. World Journal of Surgical Oncology, 2014, 12, 30.	0.8	9
2067	Genome-wide analysis associates familial colorectal cancer with increases in copy number variations and a rare structural variation at 12p12.3. Carcinogenesis, 2014, 35, 315-323.	1.3	31

#	Article	IF	CITATIONS
2068	Gestational Lung Adenocarcinoma. International Journal of Surgical Pathology, 2014, 22, 663-666.	0.4	9
2069	Axillary node metastasis from primary ovarian carcinoma. Journal of Cytology, 2014, 31, 202.	0.2	6
2070	Management of Perforated Colon Cancers. Electronic Journal of General Medicine, 2014, 11, .	0.3	4
2071	Fatal cardiac tamponade as the first manifestation of acute myeloid leukemia. American Journal of Emergency Medicine, 2014, 32, 1294.e1-1294.e2.	0.7	9
2072	COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene, 2014, 33, 3432-3440.	2.6	176
2073	Methylation of P16 in exhaled breath condensate for diagnosis of non-small cell lung cancer. Lung Cancer, 2014, 83, 56-60.	0.9	44
2074	CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. Tumor Biology, 2014, 35, 5375-5380.	0.8	171
2075	Significant patterns for oral cancer detection: association rule on clinical examination and history data. Network Modeling Analysis in Health Informatics and Bioinformatics, 2014, 3, 1.	1.2	4
2076	Characterization of CD44 variant expression in head and neck squamous cell carcinomas. Tumor Biology, 2014, 35, 2053-2062.	0.8	28
2077	Using MLP and SVM for predicting survival rate of oral cancer patients. Network Modeling Analysis in Health Informatics and Bioinformatics, 2014, 3, 1.	1.2	4
2078	Evaluation of internal target volume in patients undergoing image-guided intensity modulated adjuvant radiation for gastric cancers. British Journal of Radiology, 2014, 87, 20130583.	1.0	4
2079	A Novel Herbal Formula Induces Cell Cycle Arrest and Apoptosis in Association With Suppressing the PI3K/AKT Pathway in Human Lung Cancer A549 Cells. Integrative Cancer Therapies, 2014, 13, 152-160.	0.8	23
2080	Feature selection for breast cancer detection from ultrasound images. , 2014, , .		11
2081	Minimally Invasive Ablation Treatment for Locally Advanced Pancreatic Adenocarcinoma. CardioVascular and Interventional Radiology, 2014, 37, 586-591.	0.9	14
2082	Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. Journal of Experimental and Clinical Cancer Research, 2014, 33, 42.	3.5	107
2083	Editorial review of ultrasound-guided fine-needle aspiration for solid thyroid nodules larger than 10Âmm: correlation between sonographic characteristics at the needle tip and nondiagnostic results by Wu et al. Sebo review. Endocrine, 2014, 46, 173-174.	1.1	O
2084	Primary Ovarian Serous Adenocarcinoma with Ipsilateral Axillary Lymph Node Metastasis: A Case Report. Indian Journal of Surgical Oncology, 2014, 5, 224-226.	0.3	5
2085	Evaluation and management of small-bowel tumors in the era of deep enteroscopy. Gastrointestinal Endoscopy, 2014, 79, 732-740.	0.5	36

#	ARTICLE	IF	CITATIONS
2086	Post-metastasis survival in extremity soft tissue sarcoma: A recursive partitioning analysis of prognostic factors. European Journal of Cancer, 2014, 50, 1649-1656.	1.3	39
2087	Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines. Protein Engineering, Design and Selection, 2014, 27, 235-243.	1.0	25
2088	Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. International Immunopharmacology, 2014, 21, 439-446.	1.7	41
2089	Chemopreventive effect of Annona muricata on DMBA-induced cell proliferation in the breast tissues of female albino mice. Egyptian Journal of Medical Human Genetics, 2014, 15, 327-334.	0.5	37
2090	SERPINB2 downâ€regulation contributes to chemoresistance in head and neck cancer. Molecular Carcinogenesis, 2014, 53, 777-786.	1.3	25
2091	Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer. Oncology Reports, 2014, 31, 1334-1342.	1.2	57
2092	Pathological stage significantly predicts survival in colorectal cancer patients: a study from two tertiary care centers in India. Colorectal Cancer, 2014, 3, 265-275.	0.8	3
2093	Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma. Oncology Reports, 2014, 32, 189-198.	1.2	33
2094	B-32 * Processing Speed and Executive Function in Pediatric Acute Lymphoblastic Leukemia Survivors. Archives of Clinical Neuropsychology, 2014, 29, 547-548.	0.3	0
2095	HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer. Molecular Medicine Reports, 2015, 12, 2211-2216.	1.1	49
2096	Optimized planning target volume margin in helical tomotherapy for prostate cancer: Is there a preferred method?. Journal of the Korean Physical Society, 2015, 67, 26-32.	0.3	4
2097	Balancing research interests and patient interests: A qualitative study into the intertwinement of care and research in paediatric oncology. Pediatric Blood and Cancer, 2015, 62, 816-822.	0.8	18
2098	Abdominal drainage versus no drainage post-gastrectomy for gastric cancer. The Cochrane Library, 2015, 2015, CD008788.	1.5	61
2099	Male breast carcinoma: radiotherapy contributed to favorable local control in two cases and related literature review. European Journal of Medical Research, 2015, 20, 94.	0.9	3
2100	Oral manifestations as an early clinical sign of acute myeloid leukaemia: a case report. Australian Dental Journal, 2015, 60, 123-127.	0.6	17
2101	Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Molecular Carcinogenesis, 2015, 54, 598-607.	1.3	53
2102	Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AIF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model. Nuclear Medicine Communications, 2015, 36, 914-921.	0.5	8
2103	Parametric Mapping of Contrasted Ovarian Transvaginal Sonography. Ultrasound Quarterly, 2015, 31, 117-123.	0.3	3

#	Article	IF	CITATIONS
2104	A Clinical Analysis of Brain Metastasis in Gynecologic Cancer: A Retrospective Multi-institute Analysis. Journal of Korean Medical Science, 2015, 30, 66.	1.1	27
2105	Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer. Wspolczesna Onkologia, 2015, 6, 441-445.	0.7	4
2106	Lipid from Infective L. donovani Regulates Acute Myeloid Cell Growth via Mitochondria Dependent MAPK Pathway. PLoS ONE, 2015, 10, e0120509.	1.1	12
2107	Reduction of graphene oxide by resveratrol: a novel and simple biological method for the synthesis of an effective anticancer nanotherapeutic molecule. International Journal of Nanomedicine, 2015, 10, 2951.	3.3	136
2108	Nuclear Factor Kappa B, Matrix Metalloproteinase-1, p53, and Ki-67 Expressions in the Primary Tumors and the Lymph Node Metastases of Colorectal Cancer Cases. Gastroenterology Research and Practice, 2015, 2015, 1-9.	0.7	9
2109	Clinical Significance of the Resistance Proteins LRP, Pgp, MRP1, MRP3, and MRP5 in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2015, 25, 236-243.	1.2	26
2110	Comparison of Screened and Nonscreened Breast Cancer Patients in Relation to Age: A 2-Institution Study. Clinical Breast Cancer, 2015, 15, 482-489.	1.1	13
2111	Cyclooxygenase-2 – An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma- An Immunohistochemical Study. Pathology and Oncology Research, 2015, 21, 1123-1131.	0.9	23
2112	BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. Journal of Neuro-Oncology, 2015, 123, 259-266.	1.4	20
2113	Is the exhaled breath temperature in lung cancer influenced by airways neoangiogenesis or by inflammation?. Medical Oncology, 2015, 32, 237.	1.2	5
2114	Treatment plan comparison of linac step and shoot, tomotherapy, rapidarc, and proton therapy for prostate cancer by using the dosimetrical and the biological indices. Journal of the Korean Physical Society, 2015, 67, 7-16.	0.3	5
2115	Integrating GO and KEGG terms to characterize and predict acute myeloid leukemia-related genes. Hematology, 2015, 20, 336-342.	0.7	23
2116	Beneficial effect of T follicular helper cells on antibody class switching of B cells in prostate cancer. Oncology Reports, 2015, 33, 1512-1518.	1.2	16
2117	Pien Tze Huang inhibits liver metastasis by targeting TGF- \hat{l}^2 signaling in an orthotopic model of colorectal cancer. Oncology Reports, 2015, 33, 1922-1928.	1.2	33
2118	Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. Oncology Reports, 2015, 34, 2683-2691.	1.2	19
2119	Antitumor and Antimicrobial Activities of Novel Palladacycles With Abnormal Aliphatic C-H Activation of Schiff Base 2-[(3-phenylallylidene)amino]phenol. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2015, 45, 256-270.	0.6	13
2120	Patient and physician delay in the diagnosis and treatment of non-small cell lung cancer in Turkey. Cancer Epidemiology, 2015, 39, 216-221.	0.8	18
2121	Autophagy is related to the hedgehog signaling pathway in human gastric adenocarcinoma: Prognostic significance of Beclin-1 and Gli2 expression in human gastric adenocarcinoma. Pathology Research and Practice, 2015, 211, 308-315.	1.0	20

#	Article	IF	CITATIONS
2122	Comparison of the KIR3DS1/Bw4 distribution in Chinese healthy and acute myeloid leukemia individuals. Human Immunology, 2015, 76, 79-82.	1.2	6
2123	A bio-inspired computing model for ovarian carcinoma classification and oncogene detection. Bioinformatics, 2015, 31, 1102-1110.	1.8	7
2124	Expression of BAF57 in ovarian cancer cells and drug sensitivity. Cancer Science, 2015, 106, 359-366.	1.7	16
2125	Timosaponin AllI mediates caspase activation and induces apoptosis through JNK1/2 pathway in human promyelocytic leukemia cells. Tumor Biology, 2015, 36, 3489-3497.	0.8	23
2126	Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. Blood, 2015, 126, 640-650.	0.6	28
2127	The use of photodynamic therapy as adjuvant therapy to surgery in recurrent malignant tumors of the paranasal sinuses. Photodiagnosis and Photodynamic Therapy, 2015, 12, 414-421.	1.3	31
2128	Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth. Tumor Biology, 2015, 36, 8887-8893.	0.8	18
2129	Activated α2-Macroglobulin Binding to Human Prostate Cancer Cells Triggers Insulin-like Responses. Journal of Biological Chemistry, 2015, 290, 9571-9587.	1.6	26
2130	Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells. International Journal of Molecular Sciences, 2015, 16, 1266-1292.	1.8	23
2131	Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Scientific Reports, 2015, 5, 11702.	1.6	65
2132	Establishment of a cost-effective method to detect FLT-ITD and D835 mutations in acute myeloid leukemia patients in the Taiwanese population. Tzu Chi Medical Journal, 2015, 27, 18-24.	0.4	3
2133	Effect of cigarette smoking on human health and promising remedy by mangroves. Asian Pacific Journal of Tropical Biomedicine, 2015, 5, 162-167.	0.5	13
2134	Salvage cryosurgery for locally recurrent prostate cancer after primary cryotherapy. International Urology and Nephrology, 2015, 47, 301-305.	0.6	15
2135	Immunotherapy for lung cancer: for whom the bell tolls?. Tumor Biology, 2015, 36, 1411-1422.	0.8	17
2136	The role of deep enteroscopy in the management of small-bowel disorders. Gastrointestinal Endoscopy, 2015, 82, 600-607.	0.5	55
2137	Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: Analysis of the National Cancer Database. Gynecologic Oncology, 2015, 139, 77-83.	0.6	12
2138	The effect of Glutathione-S-transferases in the susceptibility to bladder cancer. Irish Journal of Medical Science, 2015, 184, 851-854.	0.8	6
2139	Multiple Myeloma: 18F-FDG-PET/CT and Diagnostic Imaging. Seminars in Nuclear Medicine, 2015, 45, 16-31.	2.5	21

#	Article	IF	CITATIONS
2140	Synthesis, Characterization, and Anticancer Effect of Trifluoromethylated Aurone Derivatives. Journal of Heterocyclic Chemistry, 2015, 52, 296-301.	1.4	20
2141	Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clinical and Experimental Immunology, 2015, 179, 363-377.	1.1	218
2142	Functional polymorphisms in the <i>CD44</i> gene and acute myeloid leukemia cancer risk in a Chinese population. Molecular Carcinogenesis, 2015, 54, 102-110.	1.3	13
2143	IDENTIFICATION OF NOVEL 5-STYRYL-1,2,4-OXADIAZOLE/TRIAZOLE DERIVATIVES AS THE POTENTIAL ANTI-ANDROGENS THROUGH MOLECULAR DOCKING STUDY. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 8, 72.	0.3	3
2144	Comprehensive analysis of lncRNA expression profiles and identification of functional lncRNAs in lung adenocarcinoma. Oncotarget, 2016, 7, 16012-16022.	0.8	21
2145	Evaluation of skeletal metastatic pattern by 99m Tc- Methylene diphosphonate in prostatic carcinoma patients. Bangladesh Journal of Nuclear Medicine, 2016, 17, 130-133.	0.0	0
2146	Leiomyoma in the Retzius space. Przeglad Menopauzalny, 2016, 4, 220-222.	0.6	0
2147	Overexpressed CISD2 has prognostic value in human gastric cancer and promotes gastric cancer cell proliferation and tumorigenesis <i>via</i> AKT signaling pathway. Oncotarget, 2016, 7, 3791-3805.	0.8	47
2148	Clinical and Hematological Profile of Acute Myeloid Leukemia (AML) Patients of Sindh. Journal of Hematology & Thromboembolic Diseases, 2016, 04, .	0.1	4
2149	Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells. Aging, 2016, 8, 2936-2947.	1.4	15
2150	Changes in the management and survival rates of patients with oral cancer: a 30-year single-institution study. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2016, 42, 31.	0.3	8
2151	The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model. PLoS ONE, 2016, 11, e0168389.	1.1	35
2152	Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study. Oncotarget, 2016, 7, 7952-7959.	0.8	22
2153	Hyperbaric oxygen therapy for late radiation tissue injury. The Cochrane Library, 2018, 2018, CD005005.	1.5	124
2156	Capecitabine for treating head and neck cancer. Expert Opinion on Investigational Drugs, 2016, 25, 851-859.	1.9	11
2157	Prevalence of human papillomavirus infection in squamous cell carcinoma of the oral cavity, oropharynx and larynx. CirugÃa Y Cirujanos (English Edition), 2016, 84, 363-368.	0.0	4
2158	Gastric/GE Junction Cancer., 2016,, 906-933.e5.		3
2159	Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treatment Reviews, 2016, 50, 148-154.	3.4	20

#	ARTICLE	IF	CITATIONS
2160	Potential of hybrid iron oxide–gold nanoparticles as thermal triggers for pancreatic cancer therapy. RSC Advances, 2016, 6, 95044-95054.	1.7	12
2161	The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer. International Journal of Hyperthermia, 2016, 32, 895-899.	1.1	27
2162	Management of Locally Advanced Pancreatic Cancer. Surgical Clinics of North America, 2016, 96, 1371-1389.	0.5	16
2163	MARIA M4: clinical evaluation of a prototype ultrawideband radar scanner for breast cancer detection. Journal of Medical Imaging, 2016, 3, 033502.	0.8	145
2164	Hypermethylation and downregulation of glutathione peroxidase 3 are related to pathogenesis of melanoma. Oncology Reports, 2016, 36, 2737-2744.	1.2	29
2165	Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia. Journal of Hematology and Oncology, 2016, 9, 125.	6.9	16
2166	The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. World Journal of Surgical Oncology, 2016, 14, 60.	0.8	18
2167	Diffusion Magnetic Resonance Imaging in Brain Tumors. , 2016, , 273-300.		0
2168	Metabolic and molecular regulation of dietary polyunsaturated fatty acids on prostate cancer. Proteomics - Clinical Applications, 2016, 10, 267-279.	0.8	8
2170	"The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period― Surgical Oncology, 2016, 25, 49-59.	0.8	6
2171	Risk factors for lymph node metastasis in ovarian cancer: Implications for systematic lymphadenectomy. International Journal of Surgery, 2016, 29, 123-127.	1.1	20
2172	Short- and long-term outcomes of pneumonectomy in a tertiary center. Asian Cardiovascular and Thoracic Annals, 2016, 24, 250-256.	0.2	10
2173	Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 310-314.	1.0	12
2174	The Role of Irreversible Electroporation and Other Ablative Techniques in Patients with Borderline Resectable Pancreatic Cancer., 2016,, 289-306.		0
2175	MT ₁ and MT ₂ Melatonin Receptors: A Therapeutic Perspective. Annual Review of Pharmacology and Toxicology, 2016, 56, 361-383.	4.2	424
2177	Individualised mindfulness-based stress reduction for head and neck cancer patients undergoing radiotherapy of curative intent: a descriptive pilot study. European Journal of Cancer Care, 2017, 26, e12474.	0.7	24
2178	Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers. Journal of Comparative Effectiveness Research, 2017, 6, 15-24.	0.6	1
2179	Associations of killer cell immunoglobulin-like receptors with acute myeloid leukemia in Chinese populations. Human Immunology, 2017, 78, 269-273.	1.2	8

#	Article	IF	Citations
2181	The common parasite <i>Toxoplasma gondii</i> induces prostatic inflammation and microglandular hyperplasia in a mouse model. Prostate, 2017, 77, 1066-1075.	1.2	15
2182	Multiâ€disciplinary management of locally advanced pancreatic cancer with irreversible electroporation. Journal of Surgical Oncology, 2017, 116, 35-45.	0.8	8
2183	Hypofractionation for prostate cancer: an update. Expert Review of Endocrinology and Metabolism, 2017, 12, 199-205.	1.2	1
2184	Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. BMC Medical Genomics, 2017, 10, 16.	0.7	34
2185	Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells. Cancer Cell International, 2017, 17, 35.	1.8	32
2186	Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. Bioorganic and Medicinal Chemistry, 2017, 25, 1235-1241.	1.4	10
2187	Systematic review of hyperbaric oxygen therapy for the treatment of radiation-induced skin necrosis. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2017, 70, 529-538.	0.5	42
2188	Bone and Muscle. Molecular and Integrative Toxicology, 2017, , 281-316.	0.5	2
2189	Evaluation of Safety in Biomarker Driven Multiple Agent Phase IB Trial. , 2017, , 53-64.		0
2190	Genetic, Hematologic and Psychological Aspects of Leukemia. , 2017, , 667-755.		1
2191	Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. Ageing Research Reviews, 2017, 40, 95-119.	5.0	337
2192	Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer. International Journal of Gynecological Cancer, 2017, 27, 1333-1342.	1.2	3
2193	An evaluation of myeloperoxidase-mediated bio-activation of NSAIDs in promyelocytic leukemia (HL-60) cells for potential cytotoxic selectivity. Toxicology Letters, 2017, 280, 48-56.	0.4	3
2194	Thermally triggered theranostics for pancreatic cancer therapy. Nanoscale, 2017, 9, 12735-12745.	2.8	24
2195	Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma. Medicine (United States), 2017, 96, e5903.	0.4	20
2196	Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia. European Journal of Haematology, 2017, 98, 177-183.	1.1	3
2197	Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients. Medicine (United States), 2017, 96, e9247.	0.4	14
2198	Hepatic Metastasis from Colorectal Cancer. Euroasian Journal of Hepato-gastroenterology, 2017, 7, 166-175.	0.1	158

#	Article	IF	CITATIONS
2199	MicroRNA-204-5p inhibits invasion and metastasis of laryngeal squamous cell carcinoma by suppressing forkhead box C1. Journal of Cancer, 2017, 8, 2356-2368.	1.2	46
2200	Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation. World Journal of Gastroenterology, 2017, 23, 1171.	1.4	55
2201	Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 1132.	1.8	47
2202	Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment. International Journal of Nanomedicine, 2017, Volume 12, 6487-6502.	3.3	112
2203	Clinical Impact of microRNAs Associated With Cancer Stem Cells as a Prognostic Factor in Ovarian Carcinoma. Journal of Cancer, 2017, 8, 3538-3547.	1.2	26
2204	Small interfering RNA‑mediated knockdown of Twist attenuates the aggressive phenotypes of human endometrial carcinoma Ishikawa cells. Experimental and Therapeutic Medicine, 2017, 14, 5647-5651.	0.8	1
2205	Anticancer Activity of Pterostilbene in Human Ovarian Cancer Cell Lines. Medical Science Monitor, 2017, 23, 3192-3199.	0.5	9
2206	The cloning and activity of human Hes1 gene promoter. Molecular Medicine Reports, 2018, 17, 3164-3169.	1.1	2
2207	Epidemiology and Carcinogenesis of Rectal Cancer. , 2018, , 19-35.		0
2208	Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields. Nanomedicine, 2018, 13, 423-438.	1.7	36
2209	Hyperbaric oxygenation for tumour sensitisation to radiotherapy. The Cochrane Library, 2018, 4, CD005007.	1.5	29
2210	MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia. Oncology Letters, 2018, 15, 5611-5619.	0.8	34
2211	Cucurmin, anticancer, & Damp; antitumor perspectives: A comprehensive review. Critical Reviews in Food Science and Nutrition, 2018, 58, 1271-1293.	5.4	64
2212	Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro. Toxicology Letters, 2018, 282, 154-165.	0.4	20
2213	New organotin supramolecular complexes based on copper cyanide and auxiliary Nâ€donor ligands as potent inhibitors of cancer cell lines: In vitro and antioxidant experiments. Applied Organometallic Chemistry, 2018, 32, e4053.	1.7	10
2214	Pancreatic enzyme supplementation after gastrectomy for gastric cancer: a randomized controlled trial. Gastric Cancer, 2018, 21, 542-551.	2.7	31
2215	Nutritional implications for quality of life in bladder cancer survivors. Translational Andrology and Urology, 2018, 7, S688-S691.	0.6	1
2216	Overexpression of miR‑21 is involved in acute monocytic leukemia‑associated angiogenesis by targeting IL‑12. Molecular Medicine Reports, 2018, 18, 4122-4128.	1.1	6

#	Article	IF	CITATIONS
2218	Acral Metastasis of the Fingers: Report of 2 Cases. Actas Dermo-sifiliográficas, 2018, 109, e1-e4.	0.2	1
2219	RO resection and reconstruction for a large, rapidly progressive chest wall sarcoma. Journal of Cardiothoracic Surgery, 2018, 13, 127.	0.4	3
2220	Metástasis digital acral: presentación de 2 casos clÃnicos. Actas Dermo-sifiliográficas, 2018, 109, e1-e4.	0.2	1
2221	In Vitro and In Vivo Inhibitory Effect of Gujin Xiaoliu Tang in Non-Small Cell Lung Cancer. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-14.	0.5	3
2222	Targeting apoptosis by 1,2-diazole through regulation of EGFR, Bcl-2 and CDK-2 mediated signaling pathway in human non-small cell lung carcinoma A549 cells. Gene, 2018, 679, 352-359.	1.0	22
2223	Topical inhibition of PUMA signaling mitigates radiation injury. Wound Repair and Regeneration, 2018, 26, 413-425.	1.5	3
2224	Head and Neck Tumors. , 2018, , 1-136.		1
2225	The Value of ¹⁸ F-FDG PET/CT Mathematical Prediction Model in Diagnosis of Solitary Pulmonary Nodules. BioMed Research International, 2018, 2018, 1-10.	0.9	14
2226	Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention. Molecular Nutrition and Food Research, 2018, 62, e1800079.	1.5	105
2227	In Silico Studies on Colon Cancer. , 2018, , 145-158.		O
2228	Applications of Bayesian network models in predicting types of hematological malignancies. Scientific Reports, 2018, 8, 6951.	1.6	48
2229	Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives. International Journal of Molecular Sciences, 2018, 19, 2332.	1.8	63
2230	Trisenox induces cytotoxicity through phosphorylation of mitogenâ€activated protein kinase molecules in acute leukemia cells. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22207.	1.4	2
2231	Maintenance Versus Intermittent Strategies in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis from Another Angle. Advances in Therapy, 2019, 36, 2838-2848.	1.3	1
2232	An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Scientific Reports, 2019, 9, 12070.	1.6	58
2233	Development of a ZHER3â€Affibodyâ€Targeted Nanoâ€Vector for Gene Delivery to HER3â€Overexpressed Breast Cancer Cells. Macromolecular Bioscience, 2019, 19, 1900159.	2.1	6
2234	Head and Neck Tumors. , 2019, , 627-762.		O
2235	A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC. BMC Cancer, 2019, 19, 591.	1.1	13

#	Article	IF	CITATIONS
2236	Are Nanocarriers Effective for the Diagnosis and Treatment of Pancreatic Cancer?., 2019, , 159-174.		2
2237	Maternal folic acid depletion during early pregnancy increases sensitivity to squamous tumor formation in the offspring in mice. Journal of Developmental Origins of Health and Disease, 2019, 10, 683-691.	0.7	5
2238	The value of 18F-FDG PET/CT in the diagnosis of different size of solitary pulmonary nodules. Medicine (United States), 2019, 98, e14813.	0.4	22
2239	Diagnostic and Prognostic Significance of Carboxypeptidase A4 (CPA4) in Breast Cancer. Biomolecules, 2019, 9, 103.	1.8	6
2240	Engineering Multifunctional Gold Decorated Dendritic Mesoporous Silica/Tantalum Oxide Nanoparticles for Intraperitoneal Tumorâ€Specific Delivery. Particle and Particle Systems Characterization, 2019, 36, 1900058.	1.2	6
2241	Selective Internal Radiation Therapy in the Multidisciplinary Management of Liver Metastases From Colorectal Carcinoma. Seminars in Nuclear Medicine, 2019, 49, 182-188.	2.5	7
2242	Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer. Lung Cancer, 2019, 129, 1-7.	0.9	36
2243	Contribution and prognostic value of TSGA10 gene expression in patients with acute myeloid leukemia (AML). Pathology Research and Practice, 2019, 215, 506-511.	1.0	9
2244	Altitude exposure as a training & Derivative and Medicine in Sport, 2020, 23, 75-81.	0.6	2
2245	Genetic and molecular determinants of prostate cancer among Iranian patients: An update. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 37-53.	2.7	3
2246	Therapeutic Efficacy Evaluation of Pegylated Liposome Encapsulated With Vinorelbine Plus $<\!$	1.0	3
2247	Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. Cellular and Molecular Life Sciences, 2020, 77, 3441-3452.	2.4	22
2248	Both endogenous and exogenous miR-139–5p inhibit Fusobacterium nucleatum-related colorectal cancer development. European Journal of Pharmacology, 2020, 888, 173459.	1.7	9
2249	<p>PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells</p> . OncoTargets and Therapy, 2020, Volume 13, 6897-6905.	1.0	11
2250	Restraint stress abates the antioxidant potential of melatonin on dimethyl benz (a) anthracene (DMBA) induced carcinogenesis. Medical Oncology, 2020, 37, 96.	1.2	7
2251	Cisplatin-Induced Giant Cells Formation Is Involved in Chemoresistance of Melanoma Cells. International Journal of Molecular Sciences, 2020, 21, 7892.	1.8	10
2252	SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. Cell Death and Disease, 2020, 11, 956.	2.7	20
2253	Neoplasia of the tubular genital tract in 42 goats. Journal of the American Veterinary Medical Association, 2020, 256, 808-813.	0.2	6

#	Article	IF	CITATIONS
2254	From personalized to precision cancer medicine. Personalized Medicine, 2020, 17, 245-250.	0.8	2
2255	Fabrication of poly(sarcosine), poly (ethylene glycol), and poly (lactic-co-glycolic acid) polymeric nanoparticles for cancer drug delivery. Journal of Drug Delivery Science and Technology, 2021, 61, 102194.	1.4	27
2256	Modeling and Molecular Dynamic Simulation of F(ab $\hat{a} \in \hat{c}$)2 Fragment of Nimotuzumab for Lung Cancer Diagnostics. Bioinformatics and Biology Insights, 2021, 15, 117793222110021.	1.0	3
2257	Role of Ovarian Fertility Sparing Surgery (FSS) in Cases of Early Stage 1 Ovarian Cancer in Patients in Reproductive Age Group. Open Journal of Obstetrics and Gynecology, 2021, 11, 732-741.	0.1	1
2258	Analysis of the P53N a Novel Protein Encoded on Chromosome 22q12.1-12.3 in Glioblastomas and Ependymomas Specimens. Journal of Molecular Neuroscience, 2021, 71, 1714-1722.	1.1	0
2259	DNA methylation analysis improves the prognostication of acute myeloid leukemia. EJHaem, 2021, 2, 211-218.	0.4	5
2260	A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies. Frontiers in Pharmacology, 2021, 12, 639840.	1.6	52
2261	A Systematic Examination of Burden of Childhood Cancers in 183 Countries: Estimates from GLOBOCAN 2018. European Journal of Cancer Care, 2021, 30, e13438.	0.7	12
2262	GPR126 regulates colorectal cancer cell proliferation by mediating HDAC2 and GLI2 expression. Cancer Science, 2021, 112, 1798-1810.	1.7	18
2263	Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection. Journal of Gastrointestinal Oncology, 2021, 12, S91-S98.	0.6	5
2264	Recent Advances in Improved Anticancer Efficacies of Camptothecin Nano-Formulations: A Systematic Review. Biomedicines, 2021, 9, 480.	1.4	40
2265	Aspirin induced long non coding RNA suppresses colon cancer growth. Translational Cancer Research, 2021, 10, 2055-2069.	0.4	4
2266	Viridescent Concoction of Genstein Tendentious silver Nanoparticles for Breast Cancer. Research Journal of Pharmacy and Technology, 2021, , 2867-2872.	0.2	7
2267	CISD2 plays a role in age-related diseases and cancer. Biomedicine and Pharmacotherapy, 2021, 138, 111472.	2.5	9
2268	Comparison of Two Multiple Imputation Procedures in a Cancer Screening Survey. Journal of Data Science, 2003, 1, 293-312.	0.5	14
2269	Pancreatic cancer: A review of epidemiology, trend, and risk factors. World Journal of Gastroenterology, 2021, 27, 4298-4321.	1.4	180
2270	Risk of death due to other causes is lower among octogenarians with non-small cell lung cancer after wedge resection than lobectomy/segmentectomy. Japanese Journal of Clinical Oncology, 2021, 51, 1561-1569.	0.6	5
2271	Anti-proliferative, apoptotic potential of synthesized selenium nanoparticles against breast cancer cell line (MCF7). Nucleosides, Nucleotides and Nucleic Acids, 2021, 40, 926-941.	0.4	7

#	Article	IF	Citations
2272	Preferences of gastric cancer survivors for follow-up careâ€"a multicenter discrete choice experiment study. Supportive Care in Cancer, 2022, 30, 1221-1229.	1.0	2
2273	The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study. Journal of Pharmaceutical Sciences, 2021, 110, 3507-3519.	1.6	6
2274	Synthesis of silver nanoparticles using <i>Ziziphus nummularia</i> leaf extract and evaluation of their antimicrobial, antioxidant, cytotoxic and genotoxic potential (4-in-1 system). Artificial Cells, Nanomedicine and Biotechnology, 2021, 49, 354-366.	1.9	13
2275	Advanced drug delivery systems in prostate cancer. , 2021, , 197-206.		0
2277	Lack of Participation of Older Adolescents and Young Adults with Cancer in Clinical Trials: Impact in the USA., 0,, 32-45.		3
2278	Thermal Ablation in Bone Tumors. , 2006, 167, 135-146.		7
2279	Spatial Dynamics in Cancer., 2006, , 557-572.		5
2280	Hereditary Nonpolyposis Colon Cancer. , 2007, , 525-542.		10
2281	Radioguided Surgery of Solitary Pulmonary Nodules. , 2008, , 262-268.		6
2282	Fertility Management for Women With Cancer. Cancer Treatment and Research, 2007, 138, 15-27.	0.2	30
2283	Surgical Management of the Older Patient with Cancer. , 2009, , 157-200.		3
2284	Impact of Culture, Education and Socio-Economic Status. , 2006, , 313-332.		2
2285	Orthotopic Metastatic Mouse Models of Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2008, , 143-169.	0.1	2
2286	The Basic Biology of Metastasis. Cancer Treatment and Research, 2004, 118, 1-21.	0.2	22
2287	Cancer Cells Homing to Bone: The Significance of Chemotaxis and Cell Adhesion. Cancer Treatment and Research, 2004, 118, 291-309.	0.2	15
2288	Histological, Immunophenotypic and Histomorphometric Characterization of Prostate Cancer Bone Metastases. Cancer Treatment and Research, 2004, 118, 311-339.	0.2	40
2289	Caveolin-1 in Colon Cancer: The Flexible Connection to Wnt Signaling. , 2012, , 17-41.		1
2290	Basic Biology and Clinical Behavior of Renal Cell Carcinoma. Cancer Treatment and Research, 2003, 116, 69-89.	0.2	1

#	Article	IF	CITATIONS
2291	Nonmyeloablative Transplantation. , 2004, , 469-484.		1
2292	Characterization of Natural Product Chemopreventive Agents. , 2005, , 3-37.		26
2293	Lung Cancer Chemoprevention. , 2005, , 305-312.		1
2294	Strategies for Chemoprevention in Pancreatic Cancer. , 2005, , 489-499.		1
2295	COX-2 in cancer. , 2004, , 227-243.		3
2296	Irreversible Electroporation Techniques in the Treatment of Locally Advanced Liver and Pancreatic Cancer., 2017,, 2001-2015.		2
2297	Prostate Cancer Treatment and Quality of Life. Recent Results in Cancer Research, 2007, 175, 251-265.	1.8	8
2298	Epidemiology and Etiology of Cancer in Adolescents and Young Adults. , 2007, , 39-59.		2
2299	Acute Myeloid Leukemia: Epidemiology and Etiology. , 2008, , 47-56.		10
2300	The New Paradigm in Breast Cancer Prevention. , 2004, , 379-438.		2
2301	Radiotherapy of the Pancreas: State of the Art in 2012. Recent Results in Cancer Research, 2012, 196, 89-103.	1.8	1
2302	Chemoprevention of Nonmelanoma Skin Cancer: Experience with a Polyphenol from Green Tea. Recent Results in Cancer Research, 2003, 163, 165-171.	1.8	29
2303	Hodgkin's Lymphoma. , 2003, , 269-281.		1
2304	Timing and Protocols of Endoscopic Follow-Up in Operated Patients After Small Bowel Surgery. , 2014, , 41-48.		1
2305	Pregnancy and Cancer. Advances in Experimental Medicine and Biology, 2012, 732, 89-102.	0.8	2
2306	Gastrointestinal Tumors. , 2006, , 515-523.		2
2307	Cancer of the Stomach. , 2008, , 1431-1464.		3
2308	Ovaries and Fallopian Tubes. , 2008, , 1827-1855.		2

#	Article	IF	CITATIONS
2309	MRI of the Male Pelvis and the Bladder. , 2005, , 371-424.		2
2310	Gynecologic Malignancies., 2005,, 451-456.		1
2311	Neoplasms of the lungs, airways, and pleura. , 2010, , 787-879.		8
2312	Signaling Pathways in Human Breast Cells in Response to Alcohol: Mechanisms for Alcohol-induced Breast Cancer., 2005,, 1017-1025.		4
2313	Communication about palliative care and end-of-life planning. , 2011, , 513-520.		1
2314	Gastric/GE Junction Cancer., 2012,, 903-933.		4
2315	Microvascular flap reconstruction of the mandible: A comparison of bone grafts and bridging plates for restoration of mandibular continuity. Otolaryngology - Head and Neck Surgery, 2003, 129, 48-54.	1.1	11
2317	Gene expression profiling in breast cancer: towards individualising patient management. Pathology, 2005, 37, 271-277.	0.3	41
2318	Proteomics and Bioinformatics Approaches for Identification of Serum Biomarkers to Detect Breast Cancer. Clinical Chemistry, 2002, 48, 1296-1304.	1.5	780
2319	Screening for Prostate Cancer in High Risk Populations. Journal of Urology, 2002, , 1980-1984.	0.2	2
2320	Phase II Trial of Radio Frequency Ablation of Renal Cancer: Evaluation of the Kill Zone. Journal of Urology, 2002, , 2401-2405.	0.2	2
2321	Loss of Fhit Expression in Testicular Germ Cell Tumors and Intratubular Germ Cell Neoplasia. Modern Pathology, 2002, 15, 1068-1072.	2.9	9
2322	Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer?. Journal of Thoracic Oncology, 2006, 1, 564-570.	0.5	6
2323	Phase II Study of Carboplatin Combined with Biweekly Docetaxel for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 979-983.	0.5	6
2324	Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight, 2020, 5, .	2.3	22
2325	Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. Journal of Clinical Investigation, 2007, 117, 2929-2940.	3.9	149
2326	Non-Myeloablative Transplantation. Hematology American Society of Hematology Education Program, 2002, 2002, 392-421.	0.9	45
2327	Carcinogenesis: The more we seek to know the more we need to know - Challenges in the post Genomic Era. Journal of Carcinogenesis, 2003, 2, 1 .	2.5	11

#	Article	IF	CITATIONS
2328	Depression in Internet and Face-to-Face Cancer Support Groups: A Pilot Study. Oncology Nursing Forum, 2002, 29, E45-E51.	0.5	50
2329	The Determinants of Breast Cancer Screening Behavior: A Focus Group Study of Women in the United Arab Emirates. Oncology Nursing Forum, 2002, 29, E91-E98.	0.5	54
2330	Treatment Outcomes and Quality-of-Life Issues for Patients Treated With Prostate Brachytherapy. Clinical Journal of Oncology Nursing, 2003, 7, 48-54.	0.3	4
2331	Self-Reported Reasons Men Decide Not to Participate in Free Prostate Cancer Screening. Oncology Nursing Forum, 2003, 30, E12-E16.	0.5	18
2332	Relationship of Carotenoids to Cancer. Oxidative Stress and Disease, 2004, , 373-407.	0.3	4
2334	High-Utility Patterns Discovery in Data Mining: A Case Study. , 2014, , 274-297.		1
2335	Interdisciplinary Collaboration for Health Professional Education in Cancer Control. Journal of Cancer Education, 2004, 19, 37-44.	0.6	5
2336	Racial and Gender Disparities in Hereditary Colorectal Cancer Risk Assessment: The Role of Family History. Journal of Cancer Education, 2006, 21, S32-S36.	0.6	29
2337	Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer Medical Science Monitor, 2011, 17, BR354-BR363.	0.5	16
2338	The Tyrosine Kinase c-Src Directly Mediates Growth Factor-Induced Notch-1 and Furin Interaction and Notch-1 Activation in Pancreatic Cancer Cells. PLoS ONE, 2012, 7, e33414.	1.1	51
2339	Evidence for a Pro-Proliferative Feedback Loop in Prostate Cancer: The Role of Epac1 and COX-2-Dependent Pathways. PLoS ONE, 2013, 8, e63150.	1.1	26
2340	Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e72251.	1.1	15
2341	Proteasomal Degradation of Mcl-1 by Maritoclax Induces Apoptosis and Enhances the Efficacy of ABT-737 in Melanoma Cells. PLoS ONE, 2013, 8, e78570.	1.1	37
2342	Glabridin Mediate Caspases Activation and Induces Apoptosis through JNK1/2 and p38 MAPK Pathway in Human Promyelocytic Leukemia Cells. PLoS ONE, 2014, 9, e98943.	1.1	46
2343	Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. PLoS ONE, 2016, 11, e0157067.	1.1	17
2344	THORACIC MANIFESTATIONS OF BLAST INJURY: A WALTER REED EXPERIENCE. Chest, 2005, 128, 3507-11.	0.4	55
2345	The antitumor action of cannabinoids on glioma tumorigenesis. Histology and Histopathology, 2015, 30, 629-45.	0.5	7
2346	In vitro Cytotoxicity Effects of 197Au/PAMAMG4 and 198Au/PAMAMG4 Nanocomposites Against MCF7 and 4T1 Breast Cancer Cell Lines. Advanced Pharmaceutical Bulletin, 2017, 7, 87-95.	0.6	7

#	Article	IF	CITATIONS
2347	The Use of Iron Oxide Nanoparticles for Pancreatic Cancer Therapy. Journal of Nanomedicine Research, 2014, 1 , .	1.8	14
2349	Prognostic value of morphologic and clinical parameters in pT2 - pT3 prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2007, 33, 662-672.	0.7	3
2351	Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori, 2014, 100, 60-8.	0.6	16
2352	Traditional Thai Medicines Inhibit <i>Helicobacter pylori</i> In-Vitro and In-Vivo: Support for ethnomedical use. Ethnobotany Research and Applications, 0, 4, 159.	0.3	9
2353	Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, <i>in vitro</i> and <i>in vivo</i> Oncotarget, 2016, 7, 46028-46041.	0.8	20
2354	COX-2 expression in ovarian cancer: an updated meta-analysis. Oncotarget, 2017, 8, 88152-88162.	0.8	21
2355	Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition. Oncotarget, 2016, 7, 21799-21811.	0.8	9
2356	UroSEEK gene panel for bladder cancer surveillance. Translational Andrology and Urology, 2019, 8, S546-S549.	0.6	6
2357	WHAT'S NEW IN MUSCULOSKELETAL ONCOLOGY. Journal of Bone and Joint Surgery - Series A, 2003, 85, 761-767.	1.4	11
2358	What's New in Musculoskeletal Oncology. Journal of Bone and Joint Surgery - Series A, 2005, 87, 1400.	1.4	32
2359	Lower Serum Matrix Metalloproteinaseâ€'9 in Metastatic Patients with Esophageal Squamous Cell Carcinoma After Concurrent Radiotherapy Was Significant for Prognosis /p>. OncoTargets and Therapy, 2020, Volume 13, 12857-12866.	1.0	2
2360	A Review of the Evidence Supporting the Vitamin D-Cancer Prevention Hypothesis in 2017. Anticancer Research, 2018, 38, 1121-1136.	0.5	38
2361	Complications of Radical Cystectomy. , 2007, , 145-162.		8
2362	Membrane Protein Glycanprofiling of Hepatocellular Carcinoma Cell With Different Metastastic Potential by Lectin Microarray*. Progress in Biochemistry and Biophysics, 2009, 36, 1348-1355.	0.3	5
2363	Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World Journal of Gastroenterology, 2008, 14, 3903.	1.4	51
2364	Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World Journal of Gastroenterology, 2004, 10, 1569.	1.4	105
2365	Rectosigmoid findings are not associated with proximal colon cancer: Analysis of 6196 consecutive cases undergoing total colonoscopy. World Journal of Gastroenterology, 2005, 11, 2249.	1.4	8
2366	Effects and possible anti-tumor immunity of electrochemotherapy with bleomycin on human colon cancer xenografts in nude mice. World Journal of Gastroenterology, 2005, 11, 2426.	1.4	12

#	Article	IF	CITATIONS
2367	New tumor-associated antigen SC6 in pancreatic cancer. World Journal of Gastroenterology, 2005, 11, 7671.	1.4	3
2368	Helicobacter pyloriinfection and low serum pepsinogen I level as risk factors for gastric carcinoma. World Journal of Gastroenterology, 2005, 11, 1032.	1.4	22
2369	Integrin-linked kinase in gastric cancer cell attachment, invasion and tumor growth. World Journal of Gastroenterology, 2011, 17, 3487.	1.4	13
2370	Ductal adenocarcinoma of the pancreatic head: A focus on current diagnostic and surgical concepts. World Journal of Gastroenterology, 2012, 18, 3058.	1.4	18
2371	Expression of Fas ligand and Caspase-3 contributes to formation of immune escape in gastric cancer. World Journal of Gastroenterology, 2003, 9, 1415.	1.4	56
2372	Prognostic Factors and Survival in Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. Open Access Macedonian Journal of Medical Sciences, 2015, 3, 75-79.	0.1	12
2373	In vitro Anticancer Agent I-Tissue Culture Study of Human Lung Cancer Cells A549 II-Tissue Culture Study of Mice Leukemia Cells L1210. International Journal of Cancer Research, 2006, 2, 330-344.	0.2	20
2374	Antioxidants: Their Role in Health and Disease. International Journal of Pharmacology, 2005, 1, 226-233.	0.1	33
2375	Pancastatin A and B Have Selective Cytotoxicity on Glucose-Deprived PANC-1 Human Pancreatic Cancer Cells. Journal of Microbiology and Biotechnology, 2020, 30, 733-738.	0.9	3
2376	Prognostic significance of focal neuroendocrine differentiation in prostate cancer: Cases with autopsy-verified cause of death. Indian Journal of Urology, 2010, 26, 41.	0.2	6
2377	Protein Expression Profile using Two-Dimensional Gel Analysis in Squamous Cervical Cancer Patients. Cancer Research and Treatment, 2006, 38, 99.	1.3	18
2378	Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer. Cancer Research and Treatment, 2009, 41, 12.	1.3	29
2379	Tumor-Dependent and -Independent Serum/Plasma Biomarkers for Early Diagnosis of Lung Cancer. Translational Medicine (Sunnyvale, Calif), 2016, 06, .	0.4	5
2380	Update on Epidemiology and Management of Thyroid Cancer. Libyan Journal of Medicine, 2006, 1 , 83-95.	0.8	1
2381	XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy. Genetics and Molecular Research, 2015, 14, 500-506.	0.3	9
2382	Pancreatic cancer and glucose metabolism. Turkish Journal of Gastroenterology, 2009, 20, 257-260.	0.4	12
2383	Public Awareness Level of Oral Cancer in a Group of Dental Patients. Journal of Contemporary Dental Practice, 2010, 11, 49-56.	0.2	18
2384	Assessment of Endometrial Sampling and Histopathological Results: Analysis of 4,247 Cases. Eurasian Journal of Medicine, 2017, 49, 44-47.	0.2	11

#	Article	IF	CITATIONS
2385	Smad4 mediates malignant behaviors of human ovarian carcinoma cell through the effect on expressions of E-cadherin, plasminogen activator inhibitor-1 and VEGF. BMB Reports, 2010, 43, 554-560.	1.1	21
2386	UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. BMB Reports, 2018, 51, 642-647.	1.1	25
2387	PREVENTION OF CIGARETTE SMOKE INDUCED LUNG CANCER BY LOW LET IONIZING RADIATION. Nuclear Engineering and Technology, 2008, 40, 539-550.	1.1	10
2388	Is Mammographic Density a Biomarker to Study the Molecular Causes of Breast Cancer?. , 0, , .		3
2389	Findings to Date From the ASCUS-LSIL Triage Study (ALTS). Archives of Pathology and Laboratory Medicine, 2003, 127, 946-949.	1.2	186
2390	Colon Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 40.	2.3	49
2391	Rectal Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 54.	2.3	17
2392	Factors Associated with Colorectal Cancer Screening Among Cambodians, Vietnamese, Koreans and Chinese Living in the United States. North American Journal of Medicine & Science, 2012, 5, 1.	3.8	40
2393	Oral and Pharyngeal Cancer Among the Arab Population in israel from 1970 to 2006. Asian Pacific Journal of Cancer Prevention, 2012, 13, 585-589.	0.5	10
2394	Overview of Methodological Quality of Systematic Reviews about Gastric Cancer Risk and Protective Factors. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2069-2079.	0.5	28
2395	Current Status of Knowledge, Attitude and Practice (KAP) and Screening for Cervical Cancer in Countries at Different Levels of Development. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4221-4227.	0.5	36
2396	XPG is Predictive Gene of Clinical Outcome in Advanced Non-small-cell Lung Cancer with Platinum Drug Therapy. Asian Pacific Journal of Cancer Prevention, 2013, 14, 701-705.	0.5	18
2397	Survival of Patients with Prostate Cancer in Yazd, Iran. Asian Pacific Journal of Cancer Prevention, 2014, 15, 883-886.	0.5	10
2398	Perspectives of Women during Reproductive Years for Cervical Cancer Scans and Influencing Factors. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7171-7178.	0.5	6
2399	Leukemic Oral Manifestations and their Management. Asian Pacific Journal of Cancer Prevention, 2016, 17, 911-915.	0.5	50
2400	Genetic Predisposition to Prostate Cancer. , 2002, , 279-285.		0
2401	Breast cancer breakthroughs. Nursing Management, 2002, 33, 27-33.	0.2	3
2402	Lung Cancer: Overview. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2003, 46, 7.	0.1	0

#	Article	IF	CITATIONS
2403	Cancers of the large bowel and hepatobiliary tract. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 509-534.	0.5	0
2404	Liver directed therapies for colorectal cancer. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 831-843.	0.5	0
2405	Nerve-sparing Radical Retropubic Prostatectomy. , 2003, , 135-147.		0
2408	Breast cancer. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 585-608.	0.5	0
2409	Analogs of Luteinizing Hormone-releasing Hormone in Benign Prostatic Hyperplasia and Advanced Renal Cell Carcinoma., 2003,, 21-28.		0
2412	Transrectal Ultrasound-Guided Prostate Biopsy. , 2003, , 3-33.		5
2413	Magnetic Resonance Imaging-Guided Interstitial Prostate Brachytherapy. , 2003, , 155-165.		0
2415	Many Cases Need to Be Reviewed to Compare Performance in Surgical Pathology?. American Journal of Clinical Pathology, 2003, 119, 0-0.	0.4	0
2416	Screening for prostate cancer: views from the UK and the rest of the world. , 2003, , 333-342.		0
2418	Diagnosis of systemic melanoma metastases. , 2003, , 459-463.		0
2420	Intensity-Modulated Radiation Therapy for Lymph Node Metastases in Bladder Cancer. Medical Radiology, 2004, , 157-169.	0.0	0
2422	Cancer Management in Older Women. , 2004, , 1171-1185.		0
2423	Genetic Aspects of Urologic Malignancies. , 2004, , 205-240.		0
2424	Prevention of Gynecologic Malignancies. , 2004, , 883-919.		0
2426	The Epidemiology of Lung Cancer. , 2004, , 57-75.		1
2428	Perioperative Care. , 2004, , 630-648.		O
2429	Thoracic Cancer., 2004,, 262-282.		0
2431	Treatment of Recurrent Endometrial Cancer: Chemotherapy, Hormonal Therapy, and Radiotherapy. , 2004, , 289-300.		0

#	Article	IF	Citations
2433	Predicting Outcomes., 2004,, 159-193.		0
2434	Prostacyclin and Lung Cancer Chemoprevention. , 2004, , 177-191.		0
2436	Management of Advanced Stage Endometrial Cancer. , 2004, , 275-288.		0
2437	Novel Alternatives to Chemotherapy in Advanced Disease: Gene Transfer. , 2004, , 99-120.		o
2438	When Is Observation Appropriate?., 2004,, 195-215.		1
2439	Gender and Gastrointestinal Malignancies: Incidence and Response to Treatment. , 2004, , 664-670.		0
2440	Hormonal Treatment of Ovarian Cancer. , 2004, , 491-497.		O
2441	Screening and Early Detection for Genitourinary Cancer. , 2004, , 47-60.		0
2442	Renal Cancer Vaccines., 2004, , 415-423.		0
2443	SENTINEL LYMPH NODE MAPPING IN ENDOMETRIAL CANCER. , 2004, , 181-187.		0
2444	Molecular Genetics of Uterine Malignancies. , 2004, , 1-33.		1
2445	Cancers of the large bowel and hepatobiliary tract. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 443-469.	0.5	0
2446	Small Cell Lung Carcinoma., 2005,, 399-403.		0
2447	Cáncer gástrico, linfoma gástrico y carcinoides del estómago. , 2005, , 179-192.		O
2448	Genitourinary malignancies. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 485-513.	0.5	0
2449	Prostate Cancer Prevention. , 2005, , 185-203.		1
2450	Cancer in Multiracial and Multiethnic Populations. , 2005, , 437-454.		0
2451	Vitamin C Blocks Carcinogenic Tumor Formation. Nutrition and Disease Prevention, 2005, , .	0.1	O

#	Article	IF	CITATIONS
2452	Characterization of the Bystander Effect of Somatostatin Receptor sst2 After In Vivo Gene Transfer into Human Pancreatic Cancer Cells. Human Gene Therapy, 2005, .	1.4	0
2453	The Unmet Clinical Need for New Molecular Genetic Markers in the Prognosis and Therapeutic Management of Breast Cancer. Archives of Pathology and Laboratory Medicine, 2005, 129, 1372-1374.	1.2	1
2454	General tumor factors. , 2005, , 127-137.		0
2455	Current Trend in Metastatic Bone Tumor Treatment. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2006, 49, 1097.	0.1	0
2456	Nuclear Medicine in Nephrourology. , 2006, , 317-324.		0
2457	Evaluation of Twenty Human Adenoviral Types and One Infectivity-Enhanced Adenovirus for the Therapy of Soft Tissue Sarcoma. Human Gene Therapy, 2006, .	1.4	0
2458	Evaluation of Twenty Human Adenoviral Types and One Infectivity-Enhanced Adenovirus for the Therapy of Soft tissue Sarcoma. Human Gene Therapy, 2006, .	1.4	0
2459	Decoy Receptor-2 Small Interfering RNA (siRNA) Strategy Employing Three Different siRNA Constructs in Combination Defeats Adenovirus-Transferred Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Lung Cancer Cells. Human Gene Therapy, 2006, .	1.4	0
2461	Male Patients with the Diagnoses of Synchronous Prostate and Breast Cancer. Korean Journal of Urology, 2007, 48, 348.	0.2	0
2462	Non-Hodgkin's Lymphoma. , 2007, , 1-5.		1
2463	Adjuvant Therapy for Colorectal Cancer. , 2007, , 437-445.		0
2466	Prostatakarzinom. , 2008, , 219-253.		0
2467	Accommodating new technology. , 2008, , 240-249.		0
2471	Mammograms in Cosmetic Breast Surgery. , 2009, , 37-40.		1
2472	Cancer Prevention. Statistics in the Health Sciences, 2009, , 351-392.	0.2	0
2473	Retrospective Analysis of Therapy for Locally Advanced Oral Cancer: Radiotherapy Alone and Thermoradiotherapy. Thermal Medicine, 2009, 25, 59-70.	0.0	0
2474	Bewegung und Krebs. , 2010, , 223-240.		0
2476	Integrated Imaging in Genitourinary Oncology: PET/CT Imaging. , 2010, , 183-189.		0

#	Article	IF	CITATIONS
2477	Patterns of Spread of Gynecologic Disease. , 2010, , 347-361.		0
2480	Cervical Cancer Screening and Prevention. , 2010, , 1212-1216.e2.		1
2481	Tumors of Bone and Soft Tissue. , 2010, , 1324-1358.		0
2482	PET-CT of Ovarian Cancer., 2011, , 329-336.		0
2485	Colorectal Cancer: Adjuvant Therapy. , 2011, , 773-782.		0
2486	Preoperative evaluation of P53 and bcl-2 over expression in clinical stage 1 endometrial carcinoma and their correlation with surgico-pathological data and prognosis of patients. Open Journal of Obstetrics and Gynecology, 2011, 01, 55-63.	0.1	0
2487	Elderly and Early Prostate Cancer. , 0, , .		0
2488	Screening and Early Detection for Genitourinary Cancer. , 2012, , 27-42.		0
2489	Malignant Tumours of the Paranasal Sinuses and Skull Base. Head and Neck Cancer Clinics, 2012, , 41-68.	0.0	0
2490	Retroperitoneal Tumors., 2012, , 1506-1515.e3.		2
2491	Blood Groups and Oral Lesions Diagnostics. , 0, , .		0
2492	Cortical Blindness and Choroidal Metastases Secondary to Metastatic Breast Carcinoma in a Male Patient. Ophthalmic Surgery Lasers and Imaging Retina, 2013, 44, 81-84.	0.4	0
2493	Exploiting Epigenetic Modifiers to Circumvent Melanoma Dual Resistance to TCR-Engineered Immunotherapy- and BRAFV600E-Kinase Inhibitor., 2013,, 203-220.		0
2496	Apoptotic Efect of CGM co-treatment with Cisplatin on G361 Human Melanoma Cell Line. The Korean Journal of Oral Anatomy, 2013, 34, 29-49.	0.0	0
2497	Scalp metastasis in a male breast cancer: A case report. International Journal of Case Reports and Images, 2014, 5, 1.	0.0	0
2498	Cancer of the Stomach and Gastroesophageal Junction. , 2014, , 1240-1270.e7.		1
2499	The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy., 2014,, 99-109.		0
2500	Cytogenetic Investigation in Prenatal Specimecimens for Effective Prognosis of Pregnancy Related Complications. American Journal of Biomedical and Life Sciences, 2014, 2, 46.	0.2	0

#	Article	IF	CITATIONS
2501	Prosthetic Rehabilitation of a Lateral Midfacial Defect Combined with Hemimandibulectomy using Multiple/Sectional Prosthesis. International Journal of Prosthodontics and Restorative Dentistry, 2014, 4, 131-137.	0.1	3
2502	Cutaneous Melanoma., 2014, , 331-487.		0
2503	EVALUATION OF GALL BLADDER CARCINOMA BY ULTRASONOGRAPHY AND COMPUTED TOMOGRAPHY & ITS COMPARISON: A STUDY OF 50 CASES. Journal of Evolution of Medical and Dental Sciences, 2014, 3, 11943-11953.	0.1	0
2504	A 7-Years Retrospective Study of Gastrointestinal Cancers Incidence in the Western Iran. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC01-5.	0.8	2
2505	Retrospective Evaluation of Detection of Minimal Preparedness Multidetector Computed Tomography with Colorectal Neoplasms. Acta Medica Anatolia, 2015, 3, 84.	0.1	0
2506	RADIOLOGICAL PATTERN OF LUNG CANCER – A PROSPECTIVE OBSERVATIONAL STUDY. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 14917-14925.	0.1	0
2507	Hepatic and Extrahepatic Malignancies in Alcoholic Liver Disease. , 2016, , 249-269.		0
2509	Onco-cardiology for Breast Cancer. , 2016, , 889-921.		0
2510	High-grade undifferentiated pleomorphic sarcoma of the pelvis: A case report and review of literature. Urology Annals, 2016, 8, 372.	0.3	1
2511	Photodynamic Therapy of Malignancies of the Nasopharynx, the Nasal Cavity, and the Paranasal Sinuses., 2016,, 415-425.		0
2512	MicroRNA Expression Profiles in Prostate Cancer Cell Lines. MOJ Cell Science & Report, 2016, 3, .	0.1	0
2513	A CASE STUDY ON EPIDEMIOLOGY, CLINICO-PATHOLOGICAL, CLINICO-RADIOLOGICAL CORRELATION, MANAGEMENT AND FOLLOW UP OF CARCINOMA BREAST. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 1475-1477.	0.0	0
2514	Identification of Differentially Expressed Proteins from Prostate Cancer Cell Lines by Fluorescence 2-D Difference Gel Electrophoresis (2-D DIGE). MOJ Cell Science & Report, 2016, 3, .	0.1	0
2515	Your patient has chronic leukemia: Now what?. Cleveland Clinic Journal of Medicine, 2016, 83, 575-581.	0.6	0
2516	ASSESSMENT OF THE RISK OF METASTASIS IN PATIENTS WITH ENDOMETRIAL CARCINOMA. Acta Medica Medianae, 2016, 55, 5-12.	0.0	0
2517	Non-Invasive Characterization of Metabolic Drug Effects on Breast Cancer Cell Spheroids Using Two-Photon Excited Fluorescence Microscopy. , 2017, , .		0
2518	Emerging New Treatment Modalities: Irreversible Electroporation. , 2017, , 453-468.		0
2519	YY1 and KLF4: Their Role in Gastrointestinal Malignancies. , 2017, , 5-17.		0

#	Article	IF	CITATIONS
2520	Irreversible Electroporation Techniques in the Treatment of Locally Advanced Liver and Pancreatic Cancer. , 2017 , , 1 - 16 .		0
2521	The possibility of endovideosurgical interventions for the treatment of the older-age patients presenting with rectal cancer. Russian Journal of Evidence-Based Gastroenterology, 2017, 6, 53.	0.3	0
2523	Introduction: The African Diaspora and Disease-Specific Disparities. , 2017, , 1-14.		0
2524	TRANSVAGINAL DOPPLER SONOGRAPHY OF THE ENDOMETRIUM IN WOMEN WITH POSTMENOPAUSAL BLEEDING FOR PREDICTION OF MALIGNANCY. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 514-518.	0.0	0
2526	Denovo BCR-ABL Positive Acute Myelogenous Leukemia in Adult Saudi Patient-A Case Report. Journal of Cancer Prevention & Current Research, 2017, 8, .	0.1	1
2527	STUDY OF GASTROINTESTINAL CANCERS IN A TERTIARY CARE HOSPITAL. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 5537-5542.	0.0	0
2528	Mechanism underlying Chios gum mastic-induced cell cycle arrest and apoptosis of the G361 human melanoma cell line. The Korean Journal of Oral Anatomy, 2017, 38, 13-30.	0.0	0
2529	CLINICOPATHOLOGICAL STUDY OF CARCINOMA CERVIX IN A TERTIARY CARE CENTRE. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 5680-5683.	0.0	0
2530	Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant). South Asian Journal of Cancer, 2018, 07, 151-155.	0.2	1
2531	Frequency of Malignant Ovarian Germ Cell Tumor and Distribution of Demographic Features in a Main Tertiary Hospital in Iran. Journal of Obstetrics, Gynecology and Cancer Research, 2018, 3, 59-63.	0.0	0
2532	Onco-Cardiology for Breast Cancer. , 2019, , 757-779.		0
2533	Patient Centric Data Integration for Improved Diagnosis and Risk Prediction. Lecture Notes in Computer Science, 2019, , 185-195.	1.0	0
2534	Head and Neck Cancers. , 0, , .		0
2535	Factors associated with self-efficacy self-care of cancer patients undergoing chemotherapy. Iranian Journal of Cancer Care, 2019, 1, 40-47.	0.2	3
2536	A different perspective on the correlation between histopathological type and PET-CT SUVmax in non-small cell lung cancer: A retrospective cohort study. Journal of Surgery and Medicine, 0, , .	0.0	0
2537	Racial/Ethnic Cancer Disparities: A Medicare Policy Challenge. , 2019, , 1-13.		0
2538	DISTRIBUTION PATTERN FOR HLA SPECIFICITIES IN THE PATIENTS WITH ACUTE MYELOID LEUKEMIA. Medical Immunology (Russia), 2019, 21, 965-972.	0.1	0
2540	A novel function of HRPâ€3 in regulating cell cycle progression via the HDAC–E2F1–Cyclin E pathway in lung cancer. Cancer Science, 2022, 113, 145-155.	1.7	5

#	Article	IF	CITATIONS
2541	Clinical, radiological and morphological spectrum of squamous cell carcinoma. IP Journal of Diagnostic Pathology and Oncology, 2020, 5, 392-398.	0.0	0
2542	Effect of Arg399Gln single-nucleotide polymorphism in XRCC1 gene on survival rate of Indian squamous cell head-and-neck cancer patients. Journal of Cancer Research and Therapeutics, 2020, 16, 551-558.	0.3	6
2543	Dendritic Cell-Regulated T Cell Immunity and Tolerance against Acute Myeloid Leukemia. , 2020, , 279-296.		0
2546	La stadiazione endoscopica del parametro N., 2007, , 197-204.		0
2547	Valutazione della terapia ablativa dei tumori renali. , 2007, , 147-153.		0
2548	Toremifene (ACAPODENEâ,,¢) Reduces High Grade Prostatic Intraepithelial Neoplasis in a Phase IIa Clinical Trial., 2005,, 321-328.		O
2550	Colon, Rectal, and Anal Cancer Management. , 2006, , 711-739.		1
2551	CpG Island Hypermethylation and Lung Cancer Invasion and Metastasis. , 2005, , 27-43.		O
2552	Cytokine and Angiogenesis Inhibitors., 2005,, 184-203.		0
2553	Para- und autokrine Aspekte der Pathogenese des duktalen Pankreaskarzinoms: Einfluss von Zytokinen und Wachstumsfaktoren., 2006,, 309-321.		O
2556	Strategies in Lung Cancer Chemoprevention. , 2005, , 297-304.		0
2558	Strategies in Skin Cancer Chemoprevention. , 2005, , 403-419.		0
2559	Chemoprevention in Head and Neck Cancer. , 2005, , 279-303.		0
2564	Proteomics of Human Pancreatic Juice. , 2007, , 377-397.		O
2565	Cytokine and Angiogenesis Inhibitors., 2007,, 124-160.		0
2567	Identification of Marker Genes Discriminating the Pathological Stages in Ovarian Carcinoma by Using Support Vector Machine and Systems Biology. , 2007, , 381-389.		O
2568	Mammograms in Cosmetic Breast Surgery. , 2009, , 69-72.		0
2572	Transarterial 90Yttrium Radioembolisation. Medical Radiology, 2021, , 319-347.	0.0	O

#	Article	IF	CITATIONS
2573	DoÄŸu Karadeniz Subpopulasyonunda Ağız Kanseri Bilgi DÃ⅓zeyi Ve Farkındalığının DeÄŸerlendiriln Osmangazİ Journal of Medicine, 2020, 42, 84-89.	nesi. 0:1	0
2575	Chemoprevention and prostate cancer. Reviews in Urology, 2003, 5, 61-3.	0.9	O
2576	Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Reviews in Urology, 2003, 5 Suppl 2, S3-S13.	0.9	3
2577	Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Reviews in Urology, 2003, 5 Suppl 3, S3-S13.	0.9	1
2578	Selenium and Vitamin E Cancer Prevention Trial-this one's for us. Journal of the National Medical Association, 2002, 94, 856-8.	0.6	5
2579	Immediate breast reconstruction-impact on radiation management. Journal of the National Medical Association, 2003, 95, 286-95.	0.6	13
2580	Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. Journal of the National Medical Association, 2005, 97, 1414-6.	0.6	8
2582	The usefulness of toluidine staining as a diagnostic tool for precancerous and cancerous oropharyngeal and oral cavity lesions. Acta Otorhinolaryngologica Italica, 2009, 29, 187-90.	0.7	34
2583	Tobacco interventions and anaesthesia- a review. Indian Journal of Anaesthesia, 2009, 53, 618-27.	0.3	3
2584	CDH22 expression is reduced in metastatic melanoma. American Journal of Cancer Research, 2011, 1, 233-239.	1.4	10
2586	Diagnosing and managing pancreatic cancer. Practitioner, 2011, 255, 21-5, 2-3.	0.3	5
2587	Extracting and integrating data from entire electronic health records for detecting colorectal cancer cases. AMIA Annual Symposium proceedings, 2011, 2011, 1564-72.	0.2	44
2588	Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. Journal of Thoracic Disease, 2010, 2, 48-51.	0.6	223
2589	Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia. Core Evidence, 2005, 1, 1-12.	4.7	2
2590	Surgical management of colon and rectal cancer. Ochsner Journal, 2002, 4, 156-62.	0.5	4
2591	The case for universal screening colonoscopy. Ochsner Journal, 2002, 4, 139-45.	0.5	1
2592	Hereditary aspects of colon cancer. Ochsner Journal, 2002, 4, 129-38.	0.5	2
2593	Implication of microsatellite instability in human gastric cancers. Indian Journal of Medical Research, 2012, 135, 599-613.	0.4	13

#	Article	IF	CITATIONS
2595	Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced non-small cell lung cancer improve efficacy. International Journal of Biomedical Science, 2012, 8, 28-35.	0.5	7
2596	Cutaneous metastasis of pancreatic adenocarcinoma as a first clinical manifestation: a case report and review of the literature. Gastrointestinal Cancer Research: GCR, 2013, 6, 61-3.	0.8	4
2597	Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. American Journal of Clinical and Experimental Immunology, 2013, 2, 55-74.	0.2	17
2599	Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Research, 2005, 65, 887-97.	0.4	41
2600	Cryosurgery for breast fibroadenomas. Gland Surgery, 2012, 1, 128-31.	0.5	9
2601	Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population. Medical Journal of the Islamic Republic of Iran, 2014, 28, 150.	0.9	11
2602	Spontaneous bilateral pneumothorax in a patient with metastatic synovial sarcoma while under chemotherapy. Translational Lung Cancer Research, 2012, 1, 289-91.	1.3	4
2603	Comparison of Age- Standard Incidence Rate Trends of Gynecologic and Breast Cancer in Iran and Other Countries. Iranian Journal of Public Health, 2014, 43, 1372-9.	0.3	11
2604	Cone beam CT for determining breast cancer margin: an initial experience and its comparison with mammography and specimen radiograph. International Journal of Clinical and Experimental Medicine, 2015, 8, 15206-13.	1.3	5
2605	Impact of PET - CT motion correction in minimizing the gross tumor volume in non-small cell lung cancer. Asia Oceania Journal of Nuclear Medicine and Biology, 2013, 1, 35-46.	0.1	2
2607	Extract Triggers Apoptosis and Down-Regulates Gene Expression in Breast Cancer Cell Lines. Reports of Biochemistry and Molecular Biology, 2019, 8, 119-125.	0.5	3
2608	CAT104 silence behaves as a tumor suppressor in human leukemia cells by down regulating miR-182 expression. International Journal of Clinical and Experimental Pathology, 2017, 10, 11393-11404.	0.5	1
2609	Perineural spread of malignant melanoma of the head and neck: clinical and imaging features. American Journal of Neuroradiology, 2004, 25, 5-11.	1.2	274
2610	Eliciting gastric cancer survivors' preferences for follow-up services: a discrete choice experiment protocol. BMJ Open, 2021, 11, e049742.	0.8	2
2611	miRNA-148b and its role in various cancers. Epigenomics, 2021, 13, 1939-1960.	1.0	15
2612	A Clinic-Based, Comprehensive Care Model for Studying Late Effects in Long-Term Survivors of Pediatric Illnesses. Pediatrics, 2004, 113, 1141-1145.	1.0	36
2613	Cancer survival status among male population of Northeast India: A hospital based study., 2021, 1, 28.		0
2614	Disparities in Supportive Care Needs Over Time Between Racial and Ethnic Minority and Non-Minority Patients With Advanced Lung Cancer. Journal of Pain and Symptom Management, 2022, 63, 563-571.	0.6	8

#	Article	IF	CITATIONS
2615	The effect of <i>Paraoxonase</i> gene polymorphisms and paraoxonase enzyme activity on Non-Hodgkin lymphoma. Nucleosides, Nucleotides and Nucleic Acids, 2022, , 1-14.	0.4	0
2616	Differentiation Between Malignant and Benign Pulmonary Nodules by Using Automated Three-Dimensional High-Resolution Representation Learning With Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography. Frontiers in Medicine, 2022, 9, 773041.	1.2	3
2617	The thyroid gland. , 2015, , 2899-2950.		1
2621	Allogeneic Transplantation for Acute Myeloid Leukemia in Children. , 0, , 1040-1054.		0
2622	Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma., 0,, 1096-1104.		0
2623	Autologous and Allogeneic Hematopoietic Cell Transplantation for Hodgkin's Disease. , 0, , 1189-1206.		0
2624	Hematopoietic Cell Transplantation for Breast Cancer., 0,, 1298-1307.		1
2625	Hematopoietic Cell Transplantation in Ovarian Carcinoma. , 0, , 1320-1332.		0
2626	Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. Journal of Urology, 2002, 168, 2401-5.	0.2	48
2627	Descriptive Analysis of Patients with Gastric Tumors Referred to the Largest Emergency Hospital in Oltenia Region-Romania, Between 2015-2020. Current Health Sciences Journal, 2021, 47, 290-297.	0.2	0
2628	Screen-detected adenocarcinoma of the lung. Practical points for surgical pathologists. American Journal of Clinical Pathology, 2003, 119 Suppl, S39-57.	0.4	5
2629	Expression of claudin-1, -3, -4, -5 and -7 proteins in low grade colorectal carcinoma of canines. Histology and Histopathology, 2010, 25, 55-62.	0.5	15
2630	Emerging drugs in pancreatic cancer. Expert Opinion on Emerging Drugs, 2004, 9, 73-89.	1.0	0
2631	Improvement of quality of life in third-line chemotherapy with lapatinib in a case of metastatic breast cancer. Tumori, 2013, 99, e136-9.	0.6	1
2635	Preclinical research in treatment of pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 384-7.	1.5	2
2636	Synthesis of naphthalimide derivatives bearing benzothiazole and thiazole moieties: In vitro anticancer and in silico ADMET study. Journal of Molecular Structure, 2022, 1263, 133173.	1.8	3
2637	Use of combined PET/CT imaging in evaluation of the solitary pulmonary nodule: Principles, techniques, and pitfalls., 0,, 24-43.		0
2638	Primary pancreatic adenocarcinoma. , 0, , 26-34.		1

#	Article	IF	CITATIONS
2639	Role of PAP smear N cervical biopsy in unhealthy cervix. Journal of Scientific and Innovative Research, 2015, 4, 4-9.	0.3	6
2640	p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Molecular Cancer Therapeutics, 2004, 3, 895-902.	1.9	107
2641	Deep Clustering via Center-Oriented Margin Free-Triplet Loss for Skin Lesion Detection in Highly Imbalanced Datasets. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 4679-4690.	3.9	23
2642	Folate Transport Gene Inactivation in Mice Increases Sensitivity to Colon Carcinogenesis. Cancer Research, 2005, 65, 887-897.	0.4	45
2643	Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Molecular Cancer Therapeutics, 2004, 3, 137-147.	1.9	18
2644	A Prospective Study of Smoking and Risk of Breast Cancer in Young Adult Women. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 398-404.	1.1	57
2645	Elevated Prostate-Specific Antigen Levels Up to 25 Years Prior to Death from Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 373-377.	1.1	23
2646	Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-κB dependent. Molecular Cancer Therapeutics, 2004, 3, 727-736.	1.9	46
2647	Matrix Metalloproteinase-12 Expression Correlates with Local Recurrence and Metastatic Disease in Nonâ€"Small Cell Lung Cancer Patients. Clinical Cancer Research, 2005, 11, 1086-1092.	3.2	101
2648	Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter. Molecular Cancer Therapeutics, 2004, 3, 687-691.	1.9	23
2649	XPD Polymorphism and Risk of Subsequent Cancer in Individuals with Nonmelanoma Skin Cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1271-1275.	1.1	31
2650	Our Endometrial Biopsy Results Received in Our Clinic in the Last 1 Year. Muğla Sıtkı Koçman üniversitesi Tıp Dergisi, 2022, 9, 174-177.	0.2	0
2651	Guided imagery for treatment (GIFT): protocol of a pilot trial of guided imagery versus treatment as usual to address radiotherapy-related distress in head and neck cancer. Pilot and Feasibility Studies, 2022, 8, .	0.5	0
2652	Toluidine blue: As an adjuvant screening tool. Journal of Oral Medicine Oral Surgery Oral Pathology and Oral Radiology, 2022, 8, 125-129.	0.0	0
2653	Microwave Irradiation-Assisted Extraction and Synthesis of Silver Nanoparticles Using Tree Tomato Fruit Pulp (Solanum betaceum Sendt.) and Determination of In Vitro Cytotoxic Effect on MCF-7 Cells. Springer Protocols, 2023, , 395-412.	0.1	0
2656	Alcohol as a Non-UV Social-Environmental Risk Factor for Melanoma. Cancers, 2022, 14, 5010.	1.7	2
2657	Peritoneal Cytology in Patients with Potentially Resectable Adenocarcinoma of the Pancreas. American Surgeon, 2004, 70, 208-214.	0.4	40
2658	Combination synergy between \hat{l}^2 -carotene and lupeol against breast adenocarcinoma in vitro and in vivo using combination index. Phytomedicine Plus, 2023, 3, 100392.	0.9	0

#	Article	IF	CITATIONS
2659	Multimodality Management of Locally Advanced Rectal Cancer. American Surgeon, 2003, 69, 612-619.	0.4	7
2660	Advances in the Treatment of Non-Small Cell Lung Cancer with Anlotinib and Adverse Re-action Management. Advances in Clinical Medicine, 2022, 12, 11844-11851.	0.0	0
2661	A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling. Journal of Pharmaceutical and Biomedical Analysis, 2023, 225, 115232.	1.4	3
2662	Machine learning approach for classification of prostate cancer based on clinical biomarkers. The Journal of Cognitive Systems, 2022, 7, 17-20.	0.6	1
2663	Unusual case of a leiomyoma in the space of Retzius mimicking broad ligament fibroid. BMJ Case Reports, 2023, 16, e253050.	0.2	0
2664	An Explainable Brain Tumor Detection Framework for MRI Analysis. Applied Sciences (Switzerland), 2023, 13, 3438.	1.3	1
2665	Colorectal carcinoma in a tertiary hospital in North-western Nigeria: a histopathologic retrospective review. Pyramid Journal of Medicine, 2023, 6, .	0.1	0
2668	Towards Reliable Colorectal Cancer Polyps Classification via Vision Based Tactile Sensing and Confidence-Calibrated Neural Networks. , 2023, , .		3
2675	15.ÂRecruiting Participants and Sustaining Partnerships Through Institutional Change Research: Methods and Lessons From the Accountability for Cancer Care Through Undoing Racism and Equity (ACCURE) Study., 2023,,.		0